Molecular characterization of phosphonate biosynthesis in nature by Yu, Xiaomin
  
 
BY 
XIAOMIN YU 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements  
for the degree of Doctor of Philosophy in Microbiology  
in the Graduate College of the  
University of Illinois at Urbana-Champaign, 2014 
Urbana, Illinois 
Doctoral Committee:  
 
Professor William W. Metcalf, Chair 
Associate Professor Rachel J. Whitaker 
Professor John E. Cronan 
Professor Gary J. Olsen 
MOLECULAR CHARACTERIZATION OF PHOSPHONATE BIOSYNTHESIS IN 
NATURE 
ii 
 
ABSTRACT 
 
Phosphonates, compounds characterized by direct C-P bonds, comprise a structurally 
diverse class of natural products demonstrating an impressive range of biological activities. 
Although the first biologically produced phosphonate was described more than 50 years ago, the 
range and diversity of phosphonate production in nature is still not well understood. The 
biosynthetic pathways of almost all known phosphonates share the same initial step, in which 
phosphoenolpyruvate (PEP) is isomerized to phosphonopyruvate (PnPy) by PEP mutase (PepM). 
By using the pepM gene as a molecular marker for phosphonate biosynthetic capacity, I showed 
that phosphonate biosynthesis is both common and diverse across a wide range of environments, 
with pepM homologs detected in ~5% of sequenced microbial genomes and 7% of genome 
equivalents in metagenomic datasets. In addition, PEP mutase sequence conservation was found 
to be strongly correlated with conservation of other nearby genes, suggesting the diversity of 
phosphonate biosynthetic pathways could be inferred by examining PEP mutase diversity. By 
extrapolation, hundreds of unique phosphonate biosynthetic pathways were predicted to exist in 
nature.   
As part of a large screening program to uncover new phosphonate-containing natural 
products, two related phosphonate producers were identified by screening for the pepM gene: 
Glycomyces sp. NRRL B-16210 and Stackebrandtia nassauensis NRRL B-16338. These two 
actinomycetes produced high amounts of novel phosphonate-containing compounds, which were 
determined to be 2-hydroxyethylphosphonate (2-HEP) containing polysaccharides (also called 
phosphonoglycans). The phosphonoglycans were purified by sequential organic solvent 
extractions, methanol precipitation and ultrafiltration. Sugar component analyses indicated the 
presence of various O-methylated galactoses in both phosphonoglycans; the O-methyl groups 
were shown to derive from S-adenosylmethionine. Partial acid hydrolysis of the purified 
phosphonoglycans from Glycomyces yielded 2-HEP in ester linkage to the O-5 or O-6 position of 
a hexose (presumably galactose) and a 2-HEP mono(2,3-dihydroxypropyl) ester. Partial acid 
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hydrolysis of Stackebrandtia EPS also revealed the presence of 2-HEP mono(2,3-
dihydroxypropyl) ester. Examination of the genome sequences of the two strains revealed similar 
pepM-containing gene clusters that are likely to be required for phosphonoglycan synthesis. 
Like other classes of natural products, most of the phosphonate biosynthetic pathways 
remain silent under standard laboratory culture conditions. To elicit cryptic phosphonate gene 
clusters from actinomycetes, two strategies were employed: co-culturing with other 
microorganisms and selecting for antibiotic-resistant mutants. Although none of the methods 
successfully turned on phosphonate production, potential avenues for further exploration in terms 
of inducing the production of unknown phosphonates and increasing the yields of known 
phosphonates remain possible.  
To explore the possibility of using the industrial workhorse Corynebacterium glutamicum as a 
heterologous host to produce phosphonates, a synthetic biology approach was described. A 
synthetic pathway for the synthesis of 2-HEP was assembled and reconstituted in C. glutamicum, 
which afforded the production of 2-HEP.  However, further modifications are required to improve 
the stability of the construct and optimize the product yield.  
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CHAPTER 1: INTRODUCTION 
 
1.1 The Biological Importance of Phosphorus  
Phosphorus (P) is essential to all living organisms as a primary constituent of DNA, RNA and 
ATP. It is also a key structural component of phospholipids, phosphoproteins, phosphorylated 
exopolysaccharides and numerous metabolites. In addition, P provides buffering capacity, 
impacts the solubility of organic molecules and can provide a high concentration of negative 
charge within a given molecular dimension (39).  
Phosphorus predominantly exists in the most oxidized state (+5 valence) in the form of 
inorganic phosphate, phosphate esters and phosphoanhydrides. One exception to this is the 
natural occurrence of the carbon to phosphorus (C-P) bond in the so-called phosphonate (+3 
valence) and phosphinate (+1 valence) class of organophosphates. In recent years, there has 
been a growing body of literature on this group of less-studied phosphorus compounds (54, 79, 
82, 94, 130).   
1.2 Chemical Properties and Natural Occurrence of Phosphonates 
One of the significant features of phosphonates and phosphinates is the thermal and 
chemical stability of C-P bonds (43, 82). Some known phosphonates and phosphinates act as 
potent enzyme inhibitors because they are structural mimics of phosphate esters, carboxylic 
acids and tetrahedral intermediates, and can compete with the latter for binding to enzyme active 
sites (82). Given the ubiquitous roles of phosphorylated intermediates and carboxylates in cellular 
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biology, C-P bond containing compounds could potentially target a wide variety of cellular 
pathways (82).  
Since the discovery of the first naturally occurring phosphonate, 2-aminoethylphosphonic 
acid (AEP, Figure 1.1) in the acid hydrolysate of rumen protozoa in 1959, C-P compounds have 
been identified in a number of bacteria, archaea and eukaryotes (44, 46, 81). Phosphonates are 
most commonly found as components in structural macromolecules, such as lipids or glycans 
(82). A growing number of small-molecule phosphonates has also been described, many of which 
are antimetabolites (54, 82). Besides, biogenic phosphonate compounds are suggested to have 
an important role in the marine P cycle (10, 15, 64). The roles of phosphonates as structural 
components, bioactive molecules and bioavailable P will be individually discussed as below.  
1.3 Phosphonates as Structural Components of Macromolecules 
 
Figure 1.1. Common phosphonate-containing head groups in phosphonolipids and 
phosphonoglycans.  
Natural compounds with a C-P bond were first discovered in living systems in 1959 when 
Horiguchi and Kandatsu isolated 2-AEP from the acid hydrolysates of a proteolipid prepared from 
ciliate protozoa of sheep rumen (46). Shortly after, Kittredge and coworkers found the same 
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compound in the phosphonolipids from sea anemone Anthopleura elegantissima (63). 
Subsequent studies by several research groups showed that 2-AEP and derivatives (Figure 1.1) 
were common constituents in lipids in a number of ciliated protozoa, anemones, corals and 
mollusks (40, 62). The lipid backbone, where 2-AEP or derivatives is bound, is usually either a 
ceramide as in sphingophosphonolipids, or a diacylglycerol as in glycerolphosphonolipids (40). 
Baer showed that besides phosphatidyl-AEP, plasmalogen-AEP (where AEP is attached to a 
unique class of glycerophospholipids containing one vinyl-ester linked long chain alcohol group) 
is also present in phosphonolipids extracted from a mixed sheep rumen protozoa sample (19). 
Other phosphonate head groups have also been reported, such as 1-hydroxy-2-AEP found in a 
sphingophosphonolipid from Bdellovibrio stolpii and N-acyl-AEP and N,N-acylmethyl-AEP found 
in a sphingophosphonolipid from Corbicula sandai (Figure 1.1) (41, 128).  
Whereas phosphate is a common modification of polysaccharides, there are only a few 
examples of polysaccharides containing phosphonate moieties. A phosphonate-containing 
polysaccharide (also referred to as phosphonoglycan) was initially isolated from the plasma 
membrane of the soil amoeba Acanthamoeba castellanii and was shown to be a 
lipophosphonoglycan (65, 66). The composition of the A. castellanii lipophosphonoglycan 
consists of neutral sugars (26%), amino sugars (3%), acid-hydrolyzable phosphate (3%), long 
chain fatty acids (14%), inositol (8%), phytosphingosines (13%) and aminophosphonates (10%), 
which are 2-AEP and 1-hydroxy-2-AEP in 1:1 ratio (21, 65). The aminophosphonates were 
proposed to be involved in the linkage of the lipids, perhaps through the inositol moieties (21). In 
the albumin glands of the snail Megalobulimus paranaguensis, 2-AEP was found to be a 
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component of a branched β-D-galactopyranan, where 2-AEP is esterified to D-galactose at O-6 
(27). Previato and coworkers subsequently discovered that in a lipopeptidophosphonoglycan 
isolated from epimastigote forms of Trypanosoma cruzi, the structure of the carbohydrate-
containing part contains two end units of galactose linked to a mannotetraose main-chain, which 
is linked (1→4) to a glucosaminyl unit substituted at O-6 by ester-linked 2-AEP (97). A similar 
result was observed in the O-glycan of Q-mucin from jellyfish. The O-glycans are mainly 
composed of three monosaccharides: N-acetylgalactosamine (GalNAc), AEP-(O→6)-GalNAc and 
P-6-GalNAc (123).  
Among bacteria, Bacteroides fragilis NCTC 9343 produces a capsular polysaccharide 
complex (CPC), which is directly involved in abscess formation in animal models (89). CPC 
comprises at least three distinct polysaccharides, PS A, PS B and PS C, in which a 2-AEP 
substituent is located at O-4 of the N-acetyl-β-D-glucopyranosyl residue in PS B (2, 18). A 
capsular polysaccharide has also been isolated from the outer membrane of the ruminal 
bacterium Fibrobacter succinogenes S85 and contains N-(2-hydroxyethyl)-2-AEP (125) (Figure 
1.1). Interestingly, F. succinogenes S85 lacks typical lipopolysaccharide and a possible function 
for the phosphonic acids was proposed to stabilize membranes in the presence of phosphatases 
and lipases (125).  
Perhaps the most striking example of phosphonoglycan occurrence is in the freshly laid egg 
masses of the freshwater snail Helisoma, where almost 85% of the phosphorus is in the form of 
AEP and another unknown phosphonate linked to high molecular weight molecules consisting of 
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mainly of carbohydrate (83). In each of the known phosphonoglycans described above, similar to 
observations in phosphonolipids, the phosphonate moiety is either AEP or AEP derivatives. 
Finally, AEP- or N-methyl-AEP-containing phosphonoproteins have been identified from 
various organisms, such as sea anemone species Metridium dianthus (98) and Anthopleura 
xanthogrammica (61) and the ciliated protozoan Tetrahymena pyriformis (102). Although the 
structure of linkage has not been fully established, covalent attachment of phosphonates to 
proteins does not seem to occur. Phosphonoproteins that have been characterized so far are 
invariably phosphonoglycoproteins, in which phosphonates appear to be attached to the 
oligosaccharide side chain (40).  
Most naturally-occurring phosphonate-containing macromolecules have been discovered 
because of scientist’s curiosity about C-P bond itself. However, no experiments have been 
conducted to directly address their physiological functions in any organism. Nevertheless, based 
on their structural resemblance to natural phosphate esters and carboxylic acids, chemical 
stabilities and wide distributions, various roles have been proposed. It has been speculated that 
the presence of phosphonates in the biomembrane can impart resistance against hydrolytic 
enzymes (e.g. phospholipases, phosphodiesterases and phosphatases) (45). Substitutions of the 
phosphono group for the carboxylic, sulfonic or phosphoric group may increase the buffering 
capacity of the molecule under physiological conditions (43). Other potential roles of structural 
phosphonates include cell-cell signaling or as phosphorus reservoirs in the environments of low 
phosphate concentration (40, 45). One such example was observed in the oyster Crassostrea 
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virginica, which was shown to conserve phosphonolipids at the expense of phosphodiester bonds 
in starved conditions (117).   
1.4 Phosphonates as Antimetabolites  
 
Figure 1.2. Structures of bioactive small molecule phosphonates. 
As structural analogs of phosphate esters and carboxylic acids, phosphonates (both natural 
and man-made) have shown a wide range of bioactivities with medicinal and agricultural 
applications (Figure 1.2). For example, the synthetic phosphonate glyphosate (N-
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phosphonomethylglycine), under an assortment of trade names such as Roundup
®
, Glyphomax
®
, 
Rodeo
®
, Accord
®
 and Shackle
®
, is one of the most widely used herbicides. It is a potent inhibitor 
of 5-enolpyruvylshikimic acid 3-phosphate synthase (ESPS), which is essential for aromatic 
amino acid biosynthesis in plants (116). Similar to glyphosate, the herbicide phosphinothricin (PT), 
the only known naturally-occurring phosphinate, is the active component of phosphinothricin 
tripeptide (PTT or bialaphos) produced by Streptomyces viridochromogenes and S. 
hygroscopicus (3, 48), phosalacine produced by Kitasatospora phosalacina (88) and trialaphos 
produced by S. hygroscopicus KSB-1285 (56). PT is a structural analog of glutamate, hence a 
potent inhibitor of glutamine synthetase (71). PT-containing herbicides are also commercially 
available, sold under the trade names Basta
®
, Buster
®
 and Liberty
®
. Other examples of synthetic 
phosphonates include alendronate (with trade name Fosamax
®
), a common prescription for 
osteoporosis (90); adefovir (with trade names Preveon
®
 and Hepsera
®
), used for treatment of 
hepatitis B and herpes simplex virus infections (16, 78); and tenofovir (with trade name Viread
®
), 
used for treatment of HIV infection (20).  
Fosfomycin, isolated from S. fradiae, S. wedmorensis and Pseudomonas syringae, is an 
epoxide-containing phosphonate (34, 113). Fosfomycin inactivates UDP-N-acetylglucosamine 
enolpyruvyl transferase (MurA), which catalyzes the first committed step of bacterial cell wall 
biosynthesis; hence it exhibits broad spectrum activity against several Gram-positive and Gram-
negative microorganisms, including methicillin- and vancomycin-resistant Staphylococcus aureus 
and enterococci (100, 113, 114). Fosfomycin tromethamine, sold under the name Monurol
® 
in the 
United States, is an FDA-approved drug to treat bladder infections in women.  
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Two structurally related phosphonate antibiotics, FR-900098 and fosmidomycin, originally 
isolated from S. rubellomurinus and S. lavendulae, respectively, inhibit deoxyxylulose phosphate 
reductoisomerase (DXR), an enzyme of the nonmevalonate pathway of isoprenoid biosynthesis, 
which is present in Plasmodium falciparum but absent in humans (47, 87, 112). Hence, both 
compounds show promise as effective and attractive antimalarial drugs (49, 53, 73).   
Other important bioactive phosphonates include rhizocticins, antifungal compounds produced 
by Bacillus subtilis ATCC6633 (99); plumbemycins, antibacterial compounds produced by S. 
plumbeus (91); dehydrophos, a broad-spectrum antibiotic produced by S. luridus (52); 
fosfazinomycins, antifungal compounds produced by S. lavendofoliae (30); K-26, a strong 
inhibitor of angiotensin-converting enzyme produced by Astrosporangium hypotensionis (85, 133); 
and phosphonothrixin, a herbicidal compound produced by Saccharothrix sp. ST-888 (118).  
1.5 Phosphonates as Bioavailable P 
Despite the ubiquitous role of P in metabolism, P limitation is prevalent in many terrestrial 
and aquatic ecosystems (24, 26). For example, phosphates are considered to be a limiting 
nutrient in oligotrophic regions of the ocean, such as the Mediterranean Sea, the Sargasso Sea 
and the Pacific Ocean gyres (93). Likewise, in terrestrial environments, P availability is found to 
decline over time due to mineralogical transformations and the effect of leaching and erosion, 
affecting primary production in many natural ecological systems (126).  
Increasing evidence has shown that biogenic phosphonates comprise a significant portion of 
bioavailable P source in the oceans (79). By using tangential-flow ultrafiltration to concentrate 
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high-molecular-weight (HMW) dissolved material from seawater collected at various depths and 
geographic regions of the Pacific and Atlantic Oceans followed by 
31
P NMR analyses, Clark and 
coworkers found that phosphonates constituted 25% of HMW dissolved organic P (DOP) in all 
samples (15). Extending the same analyses to 16 additional samples collected from the Pacific 
Ocean, the Atlantic Ocean and the North Sea has found the same proportion of phosphonates in 
HMW DOP regardless of sampling sites and water depths (64). With a new technique to recover 
dissolved organic matter across a size spectrum, Young and Ingall revealed the presence of 5-10% 
of phosphonates in the DOP pool from a broad range of marine environments (134). In addition, 
Benitez-Nelson and coworkers provided in situ evidence for preferential remineralization of 
phosphonates over phosphate esters in the anoxic Cariaco Basin during periods of low-particle-
flux events implying phosphonates as an active source of bioavailable P in the water column 
under anoxic conditions (4).  
Besides, phosphonate catabolic genes have been found to be widely distributed in marine 
microbes. About 40% of bacterial genomes and 30% of GOS marine metagenomes are predicted 
to encode one or more pathways for phosphonate catabolism, underscoring the likely importance 
of phosphonates in marine biogeochemical P cycling and by extension their roles in primary 
productivity and in C and N turnover (79, 124).  
The quantitative importance of biogenic phosphonates as a P source in the terrestrial 
biosphere has yet to be established. However, studies show that phosphonates also occur in a 
variety of soils, suggesting phosphonates may also be important in those environments (119, 122, 
136).  
 10 
1.6 Biosynthesis of Phosphonates 
Recent renewed interest in the biosynthetic pathways of phosphonates and phosphinates 
has uncovered a wealth of novel biochemistry as well as revealing common trends in 
phosphonate biosynthesis. The collective knowledge of this class of compounds will provide 
useful information to understand the metabolic range for phosphonate biosynthesis and aid in the 
discovery of new phosphonate biosynthetic pathways. Therefore, the biosynthetic pathways for 
known phosphonate compounds are reviewed as follows.  
1.6.1 Biosynthesis of 2-AEP 
 
Figure 1.3. Proposed pathway for the biosynthesis of 2-AEP. Abbreviations used: PEP, 
phosphoenolpyruvate; PnPy, phosphonopyruvate; PnAA, phosphonoacetaldehyde; 2-AEP, 2-
aminoethylphosphonate; PepM, phosphoenolpyruvate mutase; Ppd, phosphonopyruvate 
decarboxylase. 
Based on the radiolabeling patterns observed in 2-AEP arising from reactions of 
14
C- or 
32
P-
labelled metabolites in T. pyriformis, phosphoenolpyruvate (PEP) was shown to be the most likely 
precursor (42, 74, 121, 127). Despite those isotopic labeling studies, the stoichiometric 
transformation of PEP to phosphonopyruvate (PnPy) was not demonstrated until twenty years 
later when PEP mutase (PepM), the critical enzyme responsible for this transformation, was 
isolated and characterized for the first time from T. pyriformis (107). The equilibrium of the 
reaction was shown to favor PEP by more than 500 fold (9). As a result, a strong exergonic 
ensuing reaction should follow to drive the net synthesis of phosphonates.  
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In the 2-AEP biosynthetic pathway, the subsequent step is catalyzed by PnPy decarboxylase, 
converting PnPy to phosphonoacetaldehyde (PnAA) (1). This enzyme belongs to the family of 
thiamine pyrophosphate (TPP) and divalent metal-dependent decarboxylases, which catalyze the 
decarboxylation of α-keto carboxylates (51, 135). The last step involves transamination of PnAA 
to 2-AEP, performed by AEP transaminase (Figure 1.3). Though AEP transaminase has not been 
biochemically characterized in any phosphonate metabolic pathways, the catabolic reaction has 
been studied in some soil-dwelling bacteria which utilize 2-AEP as a source of nitrogen, carbon 
and phosphorus (11, 23, 57). Like many other aminotransferases, this enzyme uses pyridoxal 5-
phosphate (PLP) as cofactor and pyruvate as ammonium acceptor (11, 57).  
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1.6.2 Biosynthesis of phosphinothricin  
 
Figure 1.4. Proposed pathway for the biosynthesis of phosphinothricin tripeptide. This figure is 
adapted from (82). Abbreviations used: PEP, phosphoenolpyruvate; PnPy, phosphonopyruvate; 
PnAA, phosphonoacetaldehyde; 2-HEP, 2-hydroxyethylphosphonate; HMP, 
hydroxymethylphosphonate; PF, phosphonoformate; PF-CMP, phosphonoformyl-CMP; CPEP, 
carboxyphosphoenolpyruvate; CPnPy, carboxyphosphonopyruvate; PPA, phosphinopyruvate; 
PMM, phosphinomethylmalate; DKDPT, deamino-α-ketodemethylphosphinothricin; DMPT, 
demethylphosphinothricin; AcDMPT, N-acetyldemethylphosphinothricin; AcDM-PTT, N-acetyl 
demethylphosphinothricin tripeptide; AcPTT, N-acetyl phosphinothricin tripeptide; PTT, 
phosphinothricin tripeptide; PepM, phosphoenolpyruvate mutase; Ppd, phosphonopyruvate 
decarboxylase; HEPD, 2-HEP dioxygenase. 
Phosphinothricin (PT), the only known phosphinate-containing natural product, is a 
nonproteinogenic amino acid found in a number of peptide antibiotics (3, 48, 56, 88). PT-
containing compounds are Trojan horse antibiotics (meaning they possess structural features in 
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disguise that facilitate uptake by the target cells and once inside the cell, the disguise is removed 
and the toxic part is released to target a specific cellular function), which are taken up by non-
specific peptide permeases and activated by intracellular peptidases to release the active 
component PT as an inhibitor of glutamine synthetase (71). Seto and Kuzuyama, by chemical 
and biochemical analyses of a series of blocked mutants of S. hygroscopicus defective in 
phosphinothricin tripeptide (PTT) production, identified most biosynthetic intermediates in the PTT 
pathway (110). The complete PTT gene cluster, comprising 24 ORFs, was recently cloned and 
sequenced from S. viridochromogenes; characterization of the PTT cluster from this strain 
revealed a number of unusual transformations and led to a revision of the previously proposed 
pathway (5, 6, 104) (Figure 1.4).  
The first two steps in the PTT pathway are identical to the biosynthesis of 2-AEP. In the third 
step, PnAA is converted to the common intermediate 2-hydroxyethylphosphonate (2-HEP) by 
PhpC, a metal-dependent alcohol dehydrogenase (111). Next, 2-HEP dioxygenase (HEPD) 
catalyzes the unusual scission of the unactivated C-C bond in 2-HEP to afford the production of 
hydroxymethylphosphonate (HMP) and formate (12). HEPD is a member of the non-heme iron 
(II)-dependent dioxygenases; in contrast to most members of this family, oxidative consumption 
of 2-HEP does not require additional cofactors or input of external electron sources (12).  
Subsequent reactions performed by PhpE and PhpJ, an alcohol dehydrogenase and an 
aldehyde dehydrogenase, respectively, successively oxidize HMP to phosphonoformate (PF). In 
vitro experiments with PhpF suggested that this enzyme catalyzes the displacement of the β- and 
γ-phosphates of CTP by PF to produce CMP-5′-PF, which can be viewed as an activated 
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intermediate for transferring the PF group to an appropriate acceptor (5). In reactions analogous 
to those catalyzed by phosphoglycerate mutase and enolase in glycolysis, PhpG and PhpH are 
proposed to work in concert to produce carboxyphosphoenolpyruvate (CPEP), though mutational 
analyses to support this hypothesis were not conclusive (5).  
PhpI, a CPEP mutase, first discovered by Hidaka and Seto (36), is shown to catalyze the 
formation of phosphinopyruvate (PPA) from CPEP. By analogy with PEP mutase, the first step of 
the CPEP mutase reaction generates a new C-P bond by carboxyphospho group migration to 
produce carboxyphosphonopyruvate (CPnPy), which is then decarboxylated to form PPA (28, 96). 
Unlike PEP mutase catalyzed reaction which requires a second enzyme, such as PnPy 
decarboxylase, to overcome the highly endergonic conversion, decarboxylation of CPnPy is 
performed by the same enzyme (96).  
Transformation of C3 intermediate PPA to C4 intermediate demethylphosphinothricin (DMPT) 
involves three reactions analogous to those catalyzed by citrate synthase, aconitase and 
isocitrate dehydrogenase in the TCA cycle. Condensation of PPA and acetyl-CoA to afford 2-
phosphinomethylmalate (PMM), catalyzed by phosphinomethylmalate synthase (Pms), proceeds 
in a manner similar to the production of citric acid (37, 109). By stereochemical studies, Pms is 
shown to be closely related to (R)-citrate synthase whereas the mostly commonly found citrate 
synthase is in the (S) configuration (37). Next, Pmi catalyzes the isomerization of PMM to 
isophosphinomethylmalate, resembling the isomerization of citrate to isocitrate. It was speculated 
that the TCA aconitase AcnA catalyzed this step as an acnA mutant was not able to produce PTT 
(106). However, the isolation and characterization of the pmi gene from the S. viridochromogenes 
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cluster, which encodes a PTT biosynthesis-specific aconitase-like enzyme, casts doubt on this 
hypothesis (33, 103). The final transamination to form DMPT is believed to be catalyzed by 
endogenous enzymes due to the observation that this reaction could occur in microorganisms not 
known to have PTT biosynthetic genes (120).  
DMPT undergoes N-acetylation to form acetyl-DMPT as a way to confer self-resistance to 
PTT of the producing organism since the free amino acid DMPT is quite toxic to the producer 
(110). The enzyme for this reaction is phosphinothricin acetyltransferase, encoded by the pat 
gene in S. viridochromogenes and the bar gene in S. hygroscopicus (82). Following acetylation, 
the final steps in PTT biosynthesis involve peptide bond formation, P-methylation and 
deacetylation. The tripeptdie backbone of PPT is assembled by three stand-alone nonribosomal 
peptide synthetase modules (29, 105). PhsA recruits the PT-precursor AcDMPT whereas PhsB 
and PhsC assemble the two alanine residues of PTT (105). Upon peptide bond formation, P-
methyltransferase (PhpK) is shown to catalyze the methyl group transfer from methylcobalamin to 
N-acetyl demethylphosphinothricin tripeptide (AcDM-PTT), producing N-acetyl phosphinothricin 
tripeptide (AcPTT) (129). This enzyme belongs to the class of radical S-adenosyl-L-methionine 
(SAM) superfamily (129). A similar enzyme, Fom3, is found in the fosfomycin biosynthetic 
pathway (132).  
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1.6.3 Biosynthesis of fosfomycin    
 
Figure 1.5. Proposed pathway for the biosynthesis of fosfomycin in streptomycetes. 
Abbreviations used: PEP, phosphoenolpyruvate; PnPy, phosphonopyruvate; PnAA, 
phosphonoacetaldehyde; 2-HEP, 2-hydroxyethylphosphonate; (S)-2-HPP, (S)-2-
hydroxypropylphosphonate; PepM, phosphoenolpyruvate mutase; Ppd, phosphonopyruvate 
decarboxylase; HppE, HPP epoxidase. 
An early biosynthetic study using isotope-labeled precursors indicated that carbons 1 and 2 
of fosfomycin produced by S. fradiae may originate from PEP and carbon 3 is derived from the 
methyl of methionine (101). However, the detailed mechanism of C-P bond formation of 
fosfomycin has remained unknown for more than a decade. The entire biosynthetic gene cluster 
of fosfomycin was later cloned from S. wedmorensis and S. fradiae; the minimal fosfomycin gene 
cluster of S. fradiae was determined and heterologous production of fosfomycin was achieved in 
S. lividans (35, 132). Based on gene cluster analyses and feeding experiments, a minimum of five 
enzymatic steps have been proposed for the biogenesis of fosfomycin in streptomycetes (Figure 
1.5).  
As with phosphinothricin, the initial biosynthetic steps of fosfomycin are identical up to the 
formation of 2-HEP. It has been proposed that a methyl group is incorporated into a C-H bond at 
C2 of 2-HEP to form (S)-2-hydroxypropylphosphonate (2-HPP) by Fom3 (110). Fom3, a member 
of the radical SAM family which contain a [Fe-S] cluster and require methylcobalamin, has 
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homology with the aforementioned PhpK, but its activity has yet to be reconstituted in vitro due to 
difficulties with functional expression and purification (95). In the final step, 2-HPP is oxidized to 
the epoxide-containing fosfomycin by HppE, completing the biosynthesis of fosfomycin (108). In 
vivo labeling studies indicate that the epoxide oxygen is not derived from molecular oxygen but 
from the dehydrogenation of the secondary alcohol of 2-HPP (31, 32). The unusual epoxidation 
by HppE, which represents a new subfamily of non-heme mononuclear iron enzymes, has been 
characterized in great detail; though mechanistic details for epoxide formation is still under debate, 
they all agree that the conversion of 2-HPP to fosfomycin proceeds in a stereospecific manner 
(38, 68, 75-77, 80, 137).  
Interestingly, a distinct fosfomycin biosynthetic pathway has recently been reported in P. 
syringae PB-5123, another fosfomycin producer (58). Although the pathway from this strain 
shares the first and last steps with fosfomycin pathways of S. wedmorensis and S. fradiae, 
enzymes converting PnPy to 2-HPP are different. Surprisingly, searching the whole genome of P. 
syringae did not identify a recognizable ppd homolog. Instead, a citrate synthase-like enzyme is 
present, which likely catalyzes the addition of an acetate anion equivalent to PnPy to generate 2-
phosphonomethylmalate (58, 95). Homologous proteins, Pms and FrbC, are found in the 
biosynthetic gene clusters of phosphinothricin and FR-900098 (6, 25). The details of the pathway 
are still unclear. Based on sequence homology of some of the genes in the Pseudomonas 
fosfomycin cluster, a longer pathway to convert PnPy to 2-HPP was proposed (58).  
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1.6.4 Biosynthesis of dehydrophos    
 
Figure 1.6. Proposed pathway for the biosynthesis of dehydrophos. This figure is adapted from 
(8). Abbreviations used: PEP, phosphoenolpyruvate; PnPy, phosphonopyruvate; PnAA, 
phosphonoacetaldehyde; 2-HEP, 2-hydroxyethylphosphonate; DHEP, 1, 2-
dihydroxyethylphosphonate; HP-EP, 1-hydroxy-2-phosphorylethyl phosphonate; OP-EP, 1-oxo-2-
phosphorylethyl phosphonate; pSer(P), 1-amino-2-phosphorylethyl phosphonate; AP, 
acetylphosphonate; L-Ala(P), L-1-aminoethylphosphonate, L-Ala(POMe), L-1-
aminoethylphosphonate O-monomethylester; ΔAla(POMe), 1-aminovinylphosphonate O-
monomethylester. 
Dehydrophos (formerly A53858), isolated from S. luridus, was first described by scientists at 
Eli Lilly to have broad-spectrum activity against both Gram-positive and Gram-negative bacteria 
(52). The chemical structure of dehydrophos has been revised multiple times with the most recent 
revision revealing a unique O-methylated vinylphosphonate connected to a glycine-leucine 
dipeptide by an amide bond (131). Dehydrophos is another example of Trojan horse compounds, 
where upon cellular uptake via non-specific oligopeptide permeases it is digested by 
aminopeptidase to unmask 1-aminovinylphosphonate (ΔAla(P)), a phosphonate analogue of 
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dehydroalanine (14). Then, ΔAla(P) undergoes tautomerization and hydrolysis to afford methyl 
acetylphosphonate (MAP), which is a potent inhibitor of pyruvate dehydrogenase and bacterial 1-
deoxy-D-xylulose 5-phosphate synthase (14, 86, 115).  
Cloning, sequencing, heterologous expression and mutant analysis of the dehydrophos 
biosynthetic gene cluster identified the minimal cluster of 16 genes and delineated the order of 
the first four biosynthetic steps (13) (Figure 1.6). The first three steps mirror those of 
phosphinothricin and fosfomycin pathways, consisting of C-P formation, decarboxylation and 
reduction of PnAA to 2-HEP. Following that, DhpA, a 2-oxoglutarate-dependent dioxygenase, 
catalyzes the conversion of 2-HEP to 1, 2-dihydroxyethylphosphonate (DHEP). The role of DhpA 
was determined both by analysis of accumulated intermediates in blocked mutants and by in vitro 
biochemical characterization of the protein in E. coli (13).  
Next, the consecutive actions of DhpB and DhpC afford 1-oxo-2-phosphorylethyl 
phosphonate (OP-EP). Since a dhpC mutant accumulates both DHEP and a phosphate ester of 
DHEP, whereas a dhpB mutant only accumulates DHEP, it suggests that the DhpB reaction 
occurs before the DhpC reaction; based on homologous proteins of known function, DhpB, a 
glycerate kinase homolog, may be responsible for phosphorylation of DHEP, while DhpC, which 
shares high sequence similarity with malate dehydrogenase, may oxidize the phosphorylated 
DHEP to OP-EP (13). OP-EP subsequently undergoes transamination to form 1-amino-2-
phosphorylethyl phosphonate (pSer(P)) (8). The candidate for this reaction appears to be missing 
in the dehydrophos cluster and the conversion may be attributed to endogenous enzymes, as 
observed in the biosynthesis of phosphinothricin (5).  
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DhpH consists of two domains, the N-terminal pyridoxal 5′-phosphate (PLP) domain and the 
C-terminal GCN5-related N-acetyltransferase (GNAT) domain. DhpD is another PLP-dependent 
enzyme in the dehydrophos cluster. By in vitro reconstituting the activity of DhpH and DhpD, van 
der Donk group demonstrated that the N-terminal PLP domain of DhpH catalyzes β-elimination of 
the phosphate group followed by tautomerization to afford acetylphosphonate (AP), which is 
transaminated to L-1-aminoethylphosphonate (L-Ala(P)) by DhpD (8). The C-terminal domain of 
DhpH forms the dipeptide L-Leu-L-Ala(P) in a Leu-tRNA
Leu
-dependent manner. Subsequent 
monomethylation by DhpI, introduction of the C-C double bond by DhpJ and attachment of 
glycine by DhpK complete the biosynthetic pathway of dehydrophos (8, 72).  
1.6.5 Biosynthesis of rhizocticins and plumbemycins  
 
Figure 1.7. Proposed pathway for the biosynthesis of rhizocticins and plumbemycins. This figure 
is adapted from (7). Abbreviations used: PEP, phosphoenolpyruvate; PnPy, phosphonopyruvate; 
PnAA, phosphonoacetaldehyde; OAA, oxaloacetate; APPA, 2-amino-5-phosphono-3-cis-
pentenoic acid. 
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Both rhizocticins and plumbemycins are (Z)-2-amino-5-phosphono-3-pentenoic acid (APPA)-
containing oligopeptide antibiotics (84, 92). Like PTT and dehydrophos, oligopeptide transport 
system is required for rhizocticin and plumbemycin uptake by target cells. The liberation of the 
warhead APPA within cells by host peptidases acts as an inhibitor of threonine synthase, an 
enzyme catalyzing the PLP-dependent conversion of phosphohomoserine to L-threonine (22, 67, 
69, 70). Whereas rhizocticins exert antifungal activity, plumbemycins are antibacterials. Both 
compounds rely on APPA for direct toxicity; as a result, target selectivity may be determined by 
the specificity of oligopeptide transport and hydrolysis systems within a target organism (7).  
The rhizocticin biosynthetic gene cluster has been cloned from B. subtilis ATCC6633 (7). The 
early steps in rhizocticin biosynthesis up to PnAA formation are common in many phosphonate 
biosynthetic pathways (Figure 1.7). The subsequent step is an aldol reaction between PnAA and 
oxaloacetate catalyzed by the aldolase homolog RhiG to yield 2-oxo-4-hydroxy-5-
phosphonopentanoic acid (7). The RhiG product is then further converted to APPA by 
dehydration and transamination. RhiI (a kinase homolog) and RhiJ (an aminotransferase homolog) 
are proposed to be responsible for the dehydration and transamination reaction, respectively, but 
the order in which these two reactions occur is still under investigation (7). In the final step, the 
APPA product is decorated stepwise at the N-terminus with Arg and Val by the action of L-
aminoacid ligases RhiC and RhiM in an ATP-dependent manner (59, 60).  
The plumbemycin biosynthetic gene cluster, recently identified from S. plumbeus, looks 
largely the same as that for rhizocticins; however, the regulation and self-resistance mechanisms 
are shown to be different (Svetlana Borisova, personal communication).  
 22 
1.6.6 Biosynthesis of FR-900098 
 
Figure 1.8. Proposed pathway for the biosynthesis of FR-900098. This figure is adapted from 
(50). Abbreviations used: PEP, phosphoenolpyruvate; PnPy, phosphonopyruvate. 
The FR-900098 biosynthetic gene cluster was identified from the fosmid library of S. 
rubellomurinus using degenerate primers designed to amplify the conserved catalytic portion of 
the pepM gene (25). When one such pepM-containing fosmid was transferred to the heterologous 
host S. lividans, it conferred FR-900098 production. Therefore, this fosmid contains all genes 
required for the biosynthesis of FR-900098. Like the fosfomycin gene cluster from P. syringae, 
this cluster lacks an identifiable homolog of PnPy decarboxylase. An alternative mechanism was 
thus proposed where FrbC, a homolog of homocitrate synthase, catalyzes the exergonic 
condensation of acetyl-CoA and PnPy to afford 2-phosphonomethylmalate (25) (Figure 1.8). The 
activity of FrbC has been demonstrated in vitro using the purified enzyme (25). The subsequent 
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steps parallel the TCA cycle, leading to the formation of 2-oxo-4-phosphonobutyrate as FrbA is a 
homolog of aconitate hydratase and FrbB (and FrbE) is a homolog of isocitrate dehydrogenase.  
The late steps of the FR-900098 pathway were elucidated by reconstructing the entire 
pathway in E. coli, whole-cell feeding assays and in vitro enzymatic activity assays (50). 2-oxo-4-
phosphonobutyrate is transaminated to 2-amino-4-phosphonobutyrate (2APn), most likely by a 
ubiquitous cellular transaminase. Bifunctional FrbH, which contains nucleotidyl transferase and 
PLP-dependent aminotransferase/decarboxylase domains, has been shown to catalyze CMP 
attachment of 2APn followed by decarboxylation, yielding CMP-5′-3-aminopropylphosphonate 
(CMP-5′-3APn). CMP-5′-3APn subsequently undergoes N-hydroxylation catalyzed by FrbG and 
N-acetylation catalyzed by FrbF to form CMP-5′-FR-900098, although the identity of FrbG 
reaction product has never been confirmed in vitro (50). Finally, nucleotide hydrolase FrbI 
hydrolyzes CMP-5′-FR-900098 to produce the final product FR-900098. The gene frbI seems to 
be dispensable for FR-900098 biosynthesis; endogenous nucleotide hydrolases may fulfill the 
same function (50).  
1.6.7 Biosynthesis of methylphosphonate  
 
Figure 1.9. Proposed pathway for the biosynthesis of methylphosphonate. Abbreviations used: 
PEP, phosphoenolpyruvate; PnPy, phosphonopyruvate; PnAA, phosphonoacetaldehyde; 2-HEP, 
2-hydroxyethylphosphonate; MPn, methylphosphonate; PepM, phosphoenolpyruvate mutase; 
Ppd, phosphonopyruvate decarboxylase; AD, alcohol dehydrogenase; MPnS, 
methylphosphonate synthase. 
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Much of the aerobic ocean is supersaturated with methane but the origin of the methane 
remains unclear. Karl et al. provided evidence that methylphosphonate (MPn) may be 
decomposed via C-P lyase to produce methane under aerobic conditions (55). However, biogenic 
production of MPn was not known. The recent finding that marine archaeon Nitrosopumilus 
maritimus produces cell-associated MPn esters may provide an explanation for this oceanic 
methane paradox (81).  
N. maritimus harbors genes for the formation of 2-HEP (Figure 1.9). One other gene in the 
phosphonate gene cluster encodes a protein of the cupin superfamily, which has weak homology 
to HppE and HEPD, two enzymes in fosfomycin and PTT pathways (81). When this enzyme was 
reconstituted in vitro with Fe(II), it converted 2-HEP to MPn, thus it was assigned the name 
methylphosphonate synthase (MPnS) (Figure 1.9). Like HEPD, MPnS is non-heme iron-
dependent oxygenase that cleaves the unactivated C-C bond in 2-HEP. Despite the low 
sequence identity between HEPD and MPnS, critical residues responsible for Fe(II) and substrate 
binding are conserved (17). It has been proposed that MPnS and HEPD share a consensus 
mechanism that differs only in the final step of catalysis (95). In N. maritimus, MPn is thought to 
be further ester-linked to an exopolysaccharide (81).  
1.7 Outline of Work Presented in the Thesis  
As stated above, almost all known phosphonate biosynthetic pathways, with the single 
exception of K-26 (85), share a common first step, namely the rearrangement of PEP to PnPy 
catalyzed by PEP mutase. Thus, pepM gene screening is a viable tool to identify organisms with 
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the genetic capacity to produce phosphonate natural products. Two key questions are central to 
this effort: (1) how common is phosphonate production in nature and (2) how diverse are 
phosphonate natural products?  
Chapter 2 provides evidence for the broad range and scope of the metabolic diversity of 
phosphonate biosynthetic genes among microbes through an in-depth analysis of pepM gene 
distribution over a diverse set of environments/datasets. Moreover, by analyzing the pepM gene 
neighborhoods we provide insight into the nature of the phosphonate molecules being produced, 
suggesting the likely importance of phosphonate natural products in the environment and the 
biology of many different microbes.  
Encouraged by the analysis shown in Chapter 2 that hundreds of unique phosphonate 
molecules may remain to be discovered in nature, our lab embarked on a large-scale screening 
program dedicated to discovering new phosphonate-containing compounds from actinomycetes, 
since this group of organisms are known to be the most prolific producers of diverse natural 
products. As part of a team effort, I screened 973 strains from the USDA-ARS actinobacteria 
collection with pepM degenerate primers designed in lab and found that 40 of those strains 
contain pepM. Subsequent culturing of all pepM
+
 strains under a single culture condition at a 
single time point identified 6  potential phosphonate producers. Two such strains, from the genera 
of Glycomyces and Stackebrandtia, were shown to produce novel phosphonoglycans. Chapter 3 
details the isolation and structural characterizations of phosphonoglycans from these two strains.  
At present, 85% of pepM
+
 strains in our collection fail to produce detectable levels of 
phosphonates. Chapter 4 discusses some attempts such as co-culturing with other 
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microorganisms and selection of antibiotic resistant mutants to induce phosphonate production 
from cryptic clusters. Chapter 5 describes my effort to test Corynebacterium glutamicum, an 
important industrial microorganism, as an alternative heterologous host for phosphonate 
production. Finally, Chapter 6 is a brief summary of the results from previous chapters and points 
out possible future work.  
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CHAPTER 2: DIVERSITY AND ABUNDANCE OF PHOSPHONATE BIOSYNTHETIC  
GENES IN NATURE
1
 
 
2.1 Introduction 
As described in Chapter 1, there is increasing evidence to support a significant role for C-P 
compounds in the biological phosphorus cycle (4, 10, 23, 31, 32, 44, 47). However, relatively little 
is known about the source of phosphonates in nature. Previous studies suggested that bacteria 
could be the major contributors to marine phosphonates (4, 9, 23), yet a significant microbial 
source remains to be identified.  
Early studies of the source of environmental phosphonates relied heavily on chemical 
analyses, which in many cases were not sensitive enough to detect phosphorus compounds in 
low abundance. At the same time, investigations into the biosynthesis of phosphonates and 
phosphinates have revealed the genetic basis for the synthesis of C-P compounds, which in turn 
opens the door to gene-based methods for assessing the abundance and diversity of 
phosphonate producers. With the single exception of K-26, PepM has been shown to catalyze the 
first step in all known phosphonate biosynthetic pathways (34). Since genes encoding 
                                                          
1
See published manuscript (Yu X, Doroghazi JR, Janga SC, Zhang JK, Circello BT, Griffin BM, Labeda DP and Metcalf 
WW. 2013. Diversity and abundance of phosphonate biosynthetic genes in nature. Proc Natl Acad Sci USA. 110(51): 
20759-20764). X Yu performed the major part of the experiments and analyzed the data described herein. JR Doroghazi 
analyzed the phosphonate gene cluster similarity as a function of PepM identity and generated Figure 2.28B. SC Janga 
performed statistical analyses. JK Zhang was involved in PCR screening of actinomycete isolates and constructing fosmid 
libraries. He also constructed a pepM clone library. BT Circello was involved in isolation of local actinomycete isolates and 
PCR screening. BM Griffin provided insights for research design and DP Labeda contributed culturing methods for 
actinomycetes.  
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subsequent steps of phosphonate biosynthesis are usually clustered with the pepM gene (34), 
this trait has greatly simplified genetic and biochemical studies of phosphonate biosynthesis. 
Initial studies identified Ppd as the enzyme providing the driving force to overcome the 
thermodynamically unfavorable nature of PepM-catalyzed reaction; however, recent data show 
that other driving reactions (e.g. in the biosynthetic pathways of FR-900098 from S. 
rubellomurinus and fosfomycin from P. syringae) exist (14, 22). Subsequent steps diverge in 
different phosphonate biosynthetic pathways. Based on the abundance of ppd homologs, 
Villarreal-Chiu and his coworkers predicted that 10% of sequenced genomes and genome 
equivalents in metagenomic datasets encode phosphonate biosynthesis (44). A similar approach 
found that pepM homologs occur in ~16% of genome equivalents in the Global Ocean Survey 
(GOS) data (33). Because PepM is a member of the isocitrate lyase family, whereas Ppd is a 
member of the TPP-dependent enzyme family, analyses relying solely on homology-based 
searches (as in the above two examples) are likely to overestimate the occurrence of 
phosphonate production, even when fairly stringent cut-off values are used.  
In this chapter, we revisit the use of PepM as a proxy to estimate the distribution and 
abundance of phosphonate production in diverse enviroments. By filtering sequences with the 
catalytically important amino acid motif (EDKXXXXXNS) of PepM, we are able to distinguish 
PepM from other members of the isocitrate lyase superfamily. Our results reveal that 
phosphonate biosynthesis is both abundant and diverse. Further, by analyzing the pepM gene 
neighborhoods, we show that there is a strong correlation between PepM phylogeny and pepM 
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gene neighborhood similarity, and by extrapolation that hundreds of novel phosphonate metabolic 
pathways await discovery in nature.  
2.2 Materials and Methods 
Bacterial strains, plasmids and culture conditions. The bacterial strains and plasmids 
used in this study are listed in Table 2.1. E. coli strains were grown at 37°C on Luria-Bertani agar 
or broth supplemented with antibiotics where appropriate. Antibiotics were used for plasmid 
maintenance at the following concentrations: chloramphenicol 12.5 µg/ml, ampicillin 100 µg/ml 
and kanamycin 50 µg/ml. Streptomyces strains were grown at 30°C on ISP2 or ISP4 agar (Difco) 
or in liquid malt-yeast extract–glucose (MYG) medium (pH 7.0) containing 1% malt, 0.4% yeast 
extract and 1% glucose. Other actinomycete strains were grown at 30°C on ATCC medium 172 
agar or broth (11).  
Table 2.1. Bacterial strains, plasmids and oligonucleotides 
Strain Relevant characteristics Source/Reference 
Escherichia coli 
WM4489 E. coli DH10B derivative; mcrA Δ(mrr-hsdRMS-
mcrBC) ϕ80(ΔlacM15) ΔlacX74 endA1 recA1 deoR 
Δ(ara leu)7697araD139 galU galK nupG 
rpsLλattB::pAE12(PrhaB::trfA33 ΔoriR6K-cat::frt5) 
(8) 
Top10 Host used for construction of soil pepM gene clone 
library; F
–
mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara leu)7697 galU galK 
rpsL (Str
R
) endA1 nupG 
Invitrogen, 
Carlsbad, CA 
MMG107 Derivative of WM4489 containing fosmid 6368-6F4 This chapter  
MMG117 Derivative of WM4489 containing fosmid 6349-6C11 This chapter  
MMG127 Derivative of WM4489 containing fosmid 6391-9F4 This chapter  
MMG131 Derivative of WM4489 containing fosmid 6373-13G9 This chapter  
MMG133 Derivative of WM4489 containing fosmid 6386-3A1 This chapter  
MMG140 Derivative of WM4489 containing fosmid 6352-7H7 This chapter  
MMG151 Derivative of WM4489 containing fosmid 4235-7G11 This chapter  
MMG160 Derivative of WM4489 containing fosmid 6372-7H12 This chapter  
MMG557 Derivative of WM4489 containing fosmid 6378 This chapter  
MMG303 Derivative of WM4489 containing fosmid 1533-1A9 This chapter  
MMG304 Derivative of WM4489 containing fosmid 1533-3C9 This chapter  
MMG305 Derivative of WM4489 containing fosmid 1533-2B10 This chapter  
MMG306 Derivative of WM4489 containing fosmid 1533-3G11 This chapter  
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Table 2.1. (cont.)   
MMG307 Derivative of WM4489 containing fosmid 1533-5B10 This chapter  
MMG309 Derivative of WM4489 containing fosmid 1533-4E1 This chapter  
MMG310 Derivative of WM4489 containing fosmid 1533-2F1 This chapter  
MMG311 Derivative of WM4489 containing fosmid 1533-2E4 This chapter  
MMG316 Derivative of WM4489 containing fosmid 66-15G9 This chapter  
MMG394 Derivative of WM4489 containing fosmid 66-20D7 This chapter  
MMG395 Derivative of WM4489 containing fosmid 66-18H9 This chapter  
MMG323 Derivative of WM4489 containing fosmid 431-13G6 This chapter  
MMG324 Derivative of WM4489 containing fosmid 431-21C7 This chapter  
MMG325 Derivative of WM4489 containing fosmid 431-63E4 This chapter  
MMG326 Derivative of WM4489 containing fosmid 431-71C2 This chapter  
MMG328 Derivative of WM4489 containing fosmid 431-74C11 This chapter  
MMG330 Derivative of WM4489 containing fosmid 431-82B6 This chapter  
MMG331 Derivative of WM4489 containing fosmid 431-52H5 This chapter  
MMG336 Derivative of WM4489 containing fosmid 31A4-12B1 This chapter  
MMG337 Derivative of WM4489 containing fosmid 31A4-12C8 This chapter  
MMG338 Derivative of WM4489 containing fosmid 31A4-24G1 This chapter  
MMG339 Derivative of WM4489 containing fosmid 31A4-43H11 This chapter  
MMG340 Derivative of WM4489 containing fosmid 31A4-54C11 This chapter  
MMG341 Derivative of WM4489 containing fosmid 31A4-71B4 This chapter  
MMG342 Derivative of WM4489 containing fosmid 31A4-71E4 This chapter  
MMG343 Derivative of WM4489 containing fosmid 31A4-74C12 This chapter  
MMG345 Derivative of WM4489 containing fosmid 1522-42G8 This chapter  
MMG346 Derivative of WM4489 containing fosmid 1522-44D6 This chapter  
MMG347 Derivative of WM4489 containing fosmid 1522-44F9 This chapter  
MMG348 Derivative of WM4489 containing fosmid 1522-44G10 This chapter  
MMG349 Derivative of WM4489 containing fosmid 1522-51A2 This chapter  
MMG355 Derivative of WM4489 containing fosmid 1522-62B5 This chapter  
MMG358 Derivative of WM4489 containing fosmid 332-33G12 This chapter  
MMG359 Derivative of WM4489 containing fosmid 332-34H12 This chapter  
MMG360 Derivative of WM4489 containing fosmid 332-42H2 This chapter  
MMG361 Derivative of WM4489 containing fosmid 332-43A2 This chapter  
MMG362 Derivative of WM4489 containing fosmid 332-51B4 This chapter  
MMG363 Derivative of WM4489 containing fosmid 332-54A6 This chapter  
MMG364 Derivative of WM4489 containing fosmid 332-64D10 This chapter  
MMG365 Derivative of WM4489 containing fosmid 332-74D12 This chapter  
MMG369 Derivative of WM4489 containing fosmid 152-23E9 This chapter  
MMG370 Derivative of WM4489 containing fosmid 152-34E7 This chapter  
MMG371 Derivative of WM4489 containing fosmid 152-42G9 This chapter  
MMG372 Derivative of WM4489 containing fosmid 152-42H8 This chapter  
MMG373 Derivative of WM4489 containing fosmid 152-44H10 This chapter  
MMG374 Derivative of WM4489 containing fosmid 152-52F7 This chapter  
MMG375 Derivative of WM4489 containing fosmid 152-61G9 This chapter  
MMG376 Derivative of WM4489 containing fosmid 152-74F8 This chapter  
MMG378 Derivative of WM4489 containing fosmid 1612-42B5 This chapter  
MMG379 Derivative of WM4489 containing fosmid 1612-14B5 This chapter  
MMG380 Derivative of WM4489 containing fosmid 1612-14C12 This chapter  
MMG385 Derivative of WM4489 containing fosmid 1662-24B10 This chapter  
MMG386 Derivative of WM4489 containing fosmid 1662-32B2 This chapter  
MMG387 Derivative of WM4489 containing fosmid 1662-43A4 This chapter  
MMG388 Derivative of WM4489 containing fosmid 1662-44E1 This chapter  
MMG389 Derivative of WM4489 containing fosmid 1662-44H12 This chapter  
MMG390 Derivative of WM4489 containing fosmid 1662-62F12 This chapter  
MMG391 Derivative of WM4489 containing fosmid 1662-71C7 This chapter  
MMG392 Derivative of WM4489 containing fosmid 1662-71D11 This chapter  
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MMG393 Derivative of WM4489 containing fosmid 1662-83E6 This chapter  
MMG406 Derivative of WM4489 containing fosmid 1121-72C2 This chapter  
MMG407 Derivative of WM4489 containing fosmid 1121-72B5 This chapter  
MMG408 Derivative of WM4489 containing fosmid 1121-63E12 This chapter  
MMG409 Derivative of WM4489 containing fosmid 1121-44D3 This chapter  
MMG410 Derivative of WM4489 containing fosmid 1121-31H1 This chapter  
MMG412 Derivative of WM4489 containing fosmid 1121-31F8 This chapter  
MMG536 Derivative of WM4489 containing fosmid 6133-2310D This chapter  
MMG538 Derivative of WM4489 containing fosmid 6133-49C This chapter  
MMG537 Derivative of WM4489 containing fosmid 836-333F This chapter  
MMG539 Derivative of WM4489 containing fosmid 836-112C This chapter  
MMG540 Derivative of WM4489 containing fosmid 1140-234E This chapter  
MMG541 Derivative of WM4489 containing fosmid 1140-2410E This chapter  
MMG542 Derivative of WM4489 containing fosmid 1140-3210F This chapter  
MMG543 Derivative of WM4489 containing fosmid 16215-
1312F 
This chapter  
MMG544 Derivative of WM4489 containing fosmid 16215-214G This chapter  
MMG545 Derivative of WM4489 containing fosmid 16802-
1411B 
This chapter  
MMG546 Derivative of WM4489 containing fosmid 16802-241G This chapter  
MMG547 Derivative of WM4489 containing fosmid 16802-349G This chapter  
MMG548 Derivative of WM4489 containing fosmid 16348-413C This chapter  
MMG549 Derivative of WM4489 containing fosmid 16348-85G This chapter  
Streptomyces 
NRRL B-1140 pepM positive  ARS Culture 
Collection 
NRRL B-16215 pepM positive  ARS Culture 
Collection 
31A4 Louisiana soil isolate, pepM positive This chapter  
MMG1121 Illinois soil isolate, pepM positive This chapter  
MMG1522 Illinois soil isolate, pepM positive This chapter  
MMG1533 Illinois soil isolate, pepM positive This chapter  
MMG1612 Illinois soil isolate, pepM positive This chapter  
MMG1662 Illinois soil isolate, pepM positive This chapter  
WM4235 Alaskan soil isolate, pepM positive This chapter  
WM6349 Illinois soil isolate, pepM positive This chapter  
WM6352 Illinois soil isolate, pepM positive This chapter  
WM6368 Illinois soil isolate, pepM positive This chapter  
WM6372 Illinois soil isolate, pepM positive This chapter  
WM6373 Illinois soil isolate, pepM positive This chapter  
WM6378 Illinois soil isolate, pepM positive This chapter  
WM6386 Illinois soil isolate, pepM positive This chapter  
WM6391 Illinois soil isolate, pepM positive This chapter  
XY66 Illinois soil isolate, pepM positive This chapter  
XY152 Illinois soil isolate, pepM positive This chapter  
XY332 Illinois soil isolate, pepM positive This chapter  
XY431 Illinois soil isolate, pepM positive This chapter  
Kitasatospora 
NRRL F-6133 pepM positive  ARS Culture 
Collection 
Lechevalieria 
NRRL S-836 pepM positive  ARS Culture 
Collection 
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Table 2.1. (cont.) 
Micromonospora 
NRRL B-16802 pepM positive  ARS Culture 
Collection 
Saccharothrix 
NRRL B-16348 pepM positive  ARS Culture 
Collection 
Plasmid Relevant characteristics  Source/Reference 
pJK050 Double-cos fosmid vector; oriV, λattB, loxP, FRT, 
Cm
R
 
(14) 
pAE5 Souce of mini-Mu transposon (14) 
pCR2.1-TOPO 3.9-kb vector used for subcloning in E. coli; Amp
R
, 
Kan
R
 
Invitrogen, 
Carlsbad, CA 
Fosmid 6368-6F4
a
 WM6368 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 6349-6C11
a
 WM6349 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 6391-9F4
a
 WM6391 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 6373-13G9
a
 WM6373 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 6386-3A1
a
 WM6386 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 6352-7H7
a
 WM6352 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 4235-7G11
a
 WM4235 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 6372-7H12
a
 WM6372 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 6378
a
 WM6378 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1533-1A9
b
 MMG1533 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1533-3C9
b
 MMG1533 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1533-2B10
b
 MMG1533 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1533-3G11
b
 MMG1533 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1533-5B10
b
 MMG1533 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1533-4E1
b
 MMG1533 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1533-2F1
b
 MMG1533 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1533-2E4
b
 MMG1533 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 66-15G9
b
 XY66 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 66-20D7
b
 XY66 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 66-18H9
b
 XY66 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 431-13G6
b
 XY431 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
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Fosmid 431-21C7
b
 XY431 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 431-63E4
b
 XY431 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 431-71C2
b
 XY431 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 431-74C11
b
 XY431 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 431-82B6
b
 XY431 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 431-52H5
b
 XY431 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 31A4-12B1
b
 31A4 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 31A4-12C8
b
 31A4 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 31A4-24G1
b
 31A4 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 31A4-
43H11
b
 
31A4 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 31A4-
54C11
b
 
31A4 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 31A4-71B4
b
 31A4 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 31A4-71E4
b
 31A4 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 31A4-
74C12
b
 
31A4 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 1522-42G8
b
 MMG1522 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1522-44D6
b
 MMG1522 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1522-44F9
b
 MMG1522 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1522-
44G10
b
 
MMG1522 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1522-51A2
b
 MMG1522 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1522-62B5
b
 MMG1522 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 332-33G12
b
 XY332 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 332-34H12
b
 XY332 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 332-42H2
b
 XY332 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 332-43A2
b
 XY332 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 332-51B4
b
 XY332 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 332-54A6
b
 XY332 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 332-64D10
b
 XY332 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
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Fosmid 332-74D12
b
 XY332 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 152-23E9
b
 XY152 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 152-34E7
b
 XY152 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 152-42G9
b
 XY152 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 152-42H8
b
 XY152 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 152-44H10
b
 XY152 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 152-52F7
b
 XY152 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 152-61G9
b
 XY152 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 152-74F8
b
 XY152 genomic DNA cloned into pJK050; contains 
pepM gene 
This chapter  
Fosmid 1612-42B5
b
 MMG1612 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1612-14B5
b
 MMG1612 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1612-
14C12
b
 
MMG1612 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-
24B10
b
 
MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-32B2
b
 MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-43A4
b
 MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-44E1
b
 MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-
44H12
b
 
MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-62F12
b
 MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-71C7
b
 MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-
71D11
b
 
MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1662-83E6
b
 MMG1662 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1121-72C2
b
 MMG1121 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1121-72B5
b
 MMG1121 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1121-
63E12
b
 
MMG1121 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1121-44D3
b
 MMG1121 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1121-31H1
b
 MMG1121 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1121-31F8
b
 MMG1121 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
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Fosmid 6133-
2310D
c
 
NRRL F-6133 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 6133-49C
c
 NRRL F-6133 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 836-333F
c
 NRRL S-836 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 836-112C
c
 NRRL S-836 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1140-234E
c
 NRRL B-1140 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1140-2410E
c
 NRRL B-1140 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 1140-3210F
c
 NRRL B-1140 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 16215-
1312F
c
 
NRRL B-16215 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 16215-
214G
c
 
NRRL B-16215 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 16802-
1411B
c
 
NRRL B-16802 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 16802-
241G
c
 
NRRL B-16802 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 16802-
349G
c
 
NRRL B-16802 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 16348-
413C
c
 
NRRL B-16348 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Fosmid 16348-85G
c
 NRRL B-16348 genomic DNA cloned into pJK050; 
contains pepM gene 
This chapter  
Primer Sequence (5'-3')
d
 
pepMF-for CGCCGGCGTCTGCNTNGARGAYAA 
pepMA-for CGCCGGCGTCTGCATNGAHGAYAA 
pepMB-for CGCCGGCGTCTGCYTNGARGAYAA 
pepMC-for CGCCGGCGTCTGCTTYGARGAYAA 
pepMD-for CGCCGGCGTCTGCGTNGARGAYAA 
pepMR-rev GGCGCGCATCATGTGRTTNGCVYA 
pepMW-rev GCGCGCATCATGTGGTTNGCRTADAT 
pepMX-rev GCGCGCATCATGTGGTTNGCCCADAT 
pepMY-rev GCGCGCATCATGTGGTTNGCRTANAT 
pepMZ-rev GCGCGCATCATGTGGTTNCCCCADAT 
M13F(-21) TGTAAAACGACGGCCAGT 
Barcode adapter
e
 Sequence (5'-3') 
31A4_adapter CATCAGCTATTTAAATAGCTGATG 
XY66_adapter CAGTATGAATTTAAATTCATACTG 
XY152_adapter GTAGTGATATTTAAATATCACTAC 
XY332_adapter GATCACGAATTTAAATTCGTGATC 
XY431_adapter CGTCTCGTATTTAAATACGAGACG 
MMG1121_adapter GTGCATCTATTTAAATAGATGCAC  
MMG1522_adapter CTCTGATAATTTAAATTATCAGAG 
MMG1533_adapter CGAGTAGAATTTAAATTCTACTCG 
MMG1612_adapter GCATGTGAATTTAAATTCACATGC 
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MMG1662_adapter GTCTATGAATTTAAATTCATAGAC 
a 
Refers to fosmids which were sequenced by a transposon-based strategy as described in (14). 
b 
Refers to fosmids which were barcoded, pooled and pyrosequenced as described in (35).  
c 
Refers to fosmids which were pooled, fragmented, tagged by in vitro transposition with Nextera 
DNA Sample Prep Kits and pyrosequenced.  
d 
Standard abbreviations are used: N=A/C/G/T, V=A/C/G, D=A/G/T, H=A/C/T, R=A/G, Y=C/T.  
e 
Adapter sequences were used to sort reads after sequencing. Barcoding adapters contain a 
sequence tag, a SwaI restriction site (underscored) and the reverse complement of a sequence 
tag. See reference (35) for details of sequence tag design. 
Identification and sequence analysis of PEP mutase genes in databases. PEP mutase 
sequences from S. viridochromogenes DSM 40736 (AAU00071) (5), S. wedmorensis (BAA32495) 
(46) and S. rubellomurinus (ABB90393) (14) were used as queries for a BLASTP search 
(searches performed in November, 2012) with an E-value threshold of 10
-20 
against all sequenced 
genomes (including genomes of 4362 Bacteria, 176 Archaea and 187 Eukarya) in the IMG 
database (28), the GOS peptides at the CAMERA database (‘GOS: all ORF peptides (p)’) 
(including 79 sampling sites, from GS000a-GS149) (40) and all microbiomes (including 43 
engineered, 395 environmental and 843 host-associated microbiomes) in the IMG/M database 
(30), respectively. BLASTP hits were aligned using Muscle (12) with known PEP mutase 
sequences using the default settings. Sequences without the conserved active site motif of PEP 
mutase (EDKXXXXXNS) (7) were removed. After removing 82 sequences without the motif and 
18 duplicate sequences, 296 potential PEP mutase homologs (including 287 from bacterial 
genomes, 2 from archaeal genomes and 7 from eukaryotic genomes) were identified from the 
IMG database.  
BLASTP search for pepM homologs in GOS metagenomes resulted in 1067 total hits. Four 
hundred and thirty-five potential PEP mutase homologs remained after removing 304 replicate 
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sequences and 328 sequences without the EDKXXXXXNS motif. The poorer hits (with higher E-
values) of duplicate sequences, which were derived from paired-end reads, were deleted, leaving 
392 unique PEP mutase homologues. Similar BLASTP searches against 1281 IMG/M 
microbiomes retrieved 2384 pepM homologs. Genome equivalents and the frequency of pepM-
containing genomes in each sampling site of GOS metagenomes and IMG/M microbiomes were 
determined using the method from Howard et al. (18). PepM sequences from different sources 
were aligned and a pairwise distance matrix for each dataset was generated in ARB (26) as input 
for mothur (39) for OTU clustering with furthest neighbor as the clustering method. Rarefaction 
analysis and richness estimates (Chao1 and ACE) were performed in mothur at the cutoff level of 
0.16. 
Construction, sequencing and analysis of soil-derived pepM clone libraries. Total DNA 
was extracted from a soil sample collected at Parkland College (Champaign, Illinois) using the 
PowerMax Soil DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA) as directed by the 
manufacturer. This DNA was used as a template for PCR amplification of a 406 bp internal 
fragment of the pepM gene as described previously (14) using a set of five forward and five 
reverse degenerate primers in all possible pairwise combinations (Table 2.1). PCR amplicons 
were pooled, gel-purified and cloned with TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA) 
following the manufacturer’s protocol. Seven hundred and sixty-eight clones were randomly 
picked into 250 μL LB broth supplemented with 50 µg/ml kanamycin in eight 96-well plates and 
incubated overnight at 37°C. Plasmid DNA was isolated and sequenced with the standard M13 
forward primer at the Roy J. Carver Biotechnology Center at the University of Illinois Urbana-
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Champaign. Vector-based sequences and chimeric sequences (as identified using Uchime 
command implemented in Mothur) were excluded from further analysis. The primer sequences 
were trimmed from remaining 713 sequences. After translation into their corresponding amino 
acid sequences, an additional 118 sequences were removed, either for being too short or for not 
containing the EDKXXXXXNS motif. A pairwise distance matrix was generated in ARB as input 
for Mothur for OTU clustering with furthest neighbor as the clustering method. Rarefaction 
analysis and richness estimates (Chao1 and ACE) were performed at the cutoff level of 0.16.  
Strain isolation, PEP mutase gene screening, sequencing and sequence annotations 
of phosphonate biosynthetic gene clusters from actinomycetes. Soil samples were obtained 
from geochemically diverse areas, such as Kickapoo State Park (Illinois) (sandy trail soil, iron rich 
bluff soil, rich old forest soil, streambed soil and dark trail soil), Shawnee National Forest (Illinois) 
(campfire soil and moss-associated soil), Champaign-Urbana local area (Illinois) (compost, sod 
and garden) and exotic (Louisianan soil and Alaskan soil). Three soil pre-treatment methods were 
employed to enrich for actinomycetes, all of which have been described previously (15, 17, 42). 
Treated soil samples were diluted 1000-fold and 100 μL of the dilution was spread onto four 
isolation media, Arginine-Glycerol-Salt, Low Tryptone Yeast, Starch-Glucose and Humic Acid-
Vitamin agar, all previously used for the enrichment of actinomycetes (15, 21). Alternatively, a 
starch-glycerol-nitrate-based isolation medium (0.2% starch, 11 mM glycerol, 5 mM KNO3, 17 mM 
NaCl, 3 mM K2HPO4, 8 mM MgSO4, 5 mM CaCO3, 10 mM MOPS (pH=7.4), 0.1% trace element 
solution, 16% Bacto agar) was used for strain isolation. All plates were incubated at 30°C for 14 
days. Three to four distinct actinomycete colonies, which were identified by morphological criteria 
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(24) (e.g. filamentous growth, aerial mycelium, tough, dusty and often pigmented colonies, etc.) 
and microscopic observation (e.g. rod-shaped cells, branching hyphae, etc.) were picked from 
each isolation plate and restreaked twice on ISP4 agar (Difco) to generate clonal isolates. To 
generate spore stocks of these isolates, a single colony was grown in MYG broth for 72 h 
incubation at 30°C. 100 μL of this culture was then spread onto ISP4 agar. Following incubation 
at 30°C for 7 days, spores were collected and stored in 7% DMSO at -80°C; in total, spores from 
1649 putative actinomycete isolates were collected. An additional 973 actinomycete strains, 
comprising 21 different genera from dispersed geographical locations, were obtained from ARS 
(NRRL) Culture Collection (http://nrrl.ncaur.usda.gov). All putative actinomycete strains, including 
those isolated locally and those obtained from ARS, were revived in MYG or ATCC 172 broth for 
genomic DNA extractions using UltraClean Microbial DNA Isolation Kit (MO BIO Laboratories, 
Carlsbad, CA). The genomic DNA was used as the template for pepM screening by PCR with 
degenerate primers listed in Table 2.1. The 16S rRNA gene was amplified from each strain as a 
positive control. Amplicons of the appropriate size were sequenced to verify that they were 
derived from the pepM gene. In total, PCR screening yielded 120 pepM
+
 actinomycetes, twenty-
five of which were chosen for further characterization.  
Fosmid clones carrying the phosphonate biosynthetic gene clusters from each of the twenty-
five chosen strains were isolated as described in (14), except that E. coli WM4489 was used as 
the cloning host. Clones from nine of these strains were sequenced using a transposon-based 
strategy as previously described (14) (Table 2.1). To facilitate parallel high throughput 
sequencing, clones from an additional ten strains were barcoded with ten different sequence-
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specific adapters and pooled using the protocol described by Meyer et al. (35) except the SwaI 
restriction site (ATTTAAAT) was used in place of the SrfI restriction site (GCCCGGGC) to 
construct barcoding adapters (Table 2.1). The pooled DNA sample was then pyrosequenced on 
four 16
th
 regions of a full plate using the GS FLX system. Clones from the remaining six strains 
were pooled, fragmented and tagged by in vitro transposition using Nextera DNA Sample Prep 
Kits (Roche Titanium-compatible) (EPICENTRE Biotechnologies, Madison, WI) and then 
pyrosequenced using the GS FLX sequencing (Table 2.1). Sequence assembly of Sanger reads 
and 454 reads was accomplished using Sequencher (Gene Codes Corp., Ann Arbor, MI) and 
Newbler (27), respectively. Additional sequence-specific primers were designed to fill in 
remaining gaps, as needed, by traditional Sanger sequencing using the Applied Biosystems 
3730xl DNA Analyzer. All sequencing was performed at the Roy J. Carver Biotechnology Center 
at the University of Illinois at Urbana-Champaign. Potential open reading frames were initially 
identified using RAST (2) and Blast analysis (1). Start sites and additional ORFs were corrected 
after visual inspection of the translated sequence.   
Phylogenetic analysis of PEP mutase sequences. PepM homologs were identified from 
NCBI by a BLASTP search with an E-value threshold of 10
-20
 using above queries on Feb. 11, 
2013. Deduced amino acid sequences of pepM from NCBI sequenced genomes and from 25 
actinomycete isolates from this study were aligned in Muscle (12). A maximum-likelihood tree 
was constructed with default settings (JTT+CAT model) in FastTree (36) using the 
methylisocitrate lyase (MICL) sequence from E. coli as the outgroup. Unique PEP mutase 
sequences from the local soil clone libraries were identified and aligned with sequences from IMG, 
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IMG/M, GOS datasets and 25 actinomycete isolates in Muscle (12). GOS and IMG/M reads that 
were not fully aligned with soil PEP mutase reads were removed from the alignment, leaving a 
total of 2166 sequences. A second maximum-likelihood tree including these sequences was 
inferred with FastTree (36) with the following settings (JTT+CAT model, -pseudo, -mlacc 2 -
slownni) to account for the fragmentary nature of metagenomic data.  
Phosphonate biosynthetic gene cluster analysis. Phosphonate gene clusters from 
complete and draft genomes, were downloaded from GenBank on January 30 and February 11, 
2013, respectively. Phosphonate biosynthetic gene clusters were identified by performing a 
BLASTP search for pepM and a custom Perl script to search for existence of the EDKXXXXXNS 
motif. Twenty-five actinomycete phosphonate gene clusters identified from this study were 
included for comparisons. Gene cluster boundaries were drawn six genes to either side of the 
pepM gene. The six-gene window was empirically chosen after manually examining the 
congruence between gene cluster similarity and the automated distance measurement for a large 
number of examples. Smaller gene windows under-represented diversity, while larger windows 
over-represented diversity. Predicted amino acid sequences found within all phosphonate 
biosynthetic gene clusters were used as input for the OrthoMCL pipeline (25). OrthoMCL 
similarity group membership for each gene and pepM amino acid similarity assessed using uclust 
(13) were used for grouping similar gene clusters. The gene cluster groups shown are required to 
have 60% pepM similarity and half of their genes in the same similarity groups for a linkage to be 
made. Nearest neighbor clustering was used; a new gene cluster was added to a group if it met 
the criteria to be grouped with any members of the group. All bioinformatics work, except where 
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indicated, was performed with in-house Perl scripts interfaced with MySQL. The plot comparing 
phosphonate gene cluster similarity versus PEP mutase similarity was created using two 
measures. PEP mutase similarity was calculated using full length amino acid sequences aligned 
with Muscle (12). Similarity of aligned sequences was calculated based on identity using pairwise 
deletion of sites. Gene cluster similarity was calculated using OrthoMCL similarity groups (25). 
The number of similarity groups in common was divided by the average gene cluster size for 
each pairwise comparison. Only clusters exceeding ten genes were used for the comparison. The 
plot was created using R (http://www.R-project.org/). Density plot was created using the package 
aqfig. Linear regression was performed only over the PepM range (0.6, 1.0). Note, this part was 
performed by Dr. James Doroghazi of Metcalf lab.   
Nucleotide accession numbers. Twenty-five actinomycete phosphonate biosynthetic gene 
cluster sequences have been deposited in GenBank under accession numbers KF386859-
KF386883. Partial soil PEP mutase gene sequences have been deposited in GenBank under 
accession numbers KF386884-KF387474. 
2.3 Results 
The ability to synthesize phosphonates is relatively common and widespread in nature. 
We searched for pepM homologs in IMG microbial genomes (28), GOS marine metagenomes (37, 
43) and IMG/M microbiomes (29), using the sequences of biochemically validated PepM 
sequences as queries (5, 14, 46). All potential hits were screened for the highly conserved 
 53 
catalytic motif EDKXXXXXNS, which distinguishes PEP mutase from other members of the 
isocitrate lyase superfamily (7). 
Two hundred and forty-seven bacterial genomes (5.7%) in the IMG genomes database 
encode pepM homologs. PEP mutase-encoding bacteria include 9 of 33 bacterial phyla, 
predominantly from Proteobacteria, Bacteroidetes, Firmicutes, Actinobacteria and Spirochaetes 
(Figure 2.1). The ability to produce phosphonates is not phylogenetically coherent except among 
Burkholderia, Selenomonas and Nitrosococcus. Seventy-seven out of eighty-two sequenced 
Burkholderia genomes (accounting for 31% of the pepM-positive genomes) encode at least one 
pepM gene, with some strains carrying as many as four, while eight of nine sequenced 
Selenomonas genomes and all four sequenced Nitrosococcus genomes contain pepM. Two 
archaeal genomes (1.1%), Nitrosoarchaeum limnia SFB1 and Nitrosopumilus maritimus SCM1, 
encode pepM. Seven pepM homologs were discovered in six eukaryotic genomes (3.2%), 
including sea snail (Lottia gigantean), sea anemone (Nematostella vectensis) and several 
protozoa (Paramecium tetraurelia, Perkinsus marinus, Tetrahymena thermophila and 
Trypanosoma cruzi).  
  
Figure 2.1. Distribution of pepM homologs within IMG bacterial genomes. Phyla which account 
for < 1% are grouped in ‘Others’, including Fibrobacteres, Nitrospirae and Synergistetes. 
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Analysis of the GOS metagenomes, which encompass near-surface marine environments 
from around the world, revealed pepM homologs from 59 out of 79 sampling sites (Table 2.2). 
The IMG/M microbiomes (29), which include metagenomic data from a variety of ecosystems, 
contain pepM homologs in 558 of the 1281 datasets in the collection. To quantify the relative 
occurrence of phosphonate biosynthetic genes in these datasets, we compared the abundance of 
pepM to that of typical single copy genes as described (18). By this measure, pepM genes occur 
in ca. 7.6% of microbial genomes in the GOS and IMG/M metagenomes (assuming only one copy 
of pepM per genome). The abundance of pepM is essentially the same in all GOS sites (between 
4.4%-8.7%), with a mangrove site and a hypersaline site (both in Ecuador) having the highest 
(20.7%) and the lowest (0.3%) abundance, respectively (Figure 2.2A). In contrast, there are 
significant differences in between the various IMG/M metagenomes based on a large set of 
metagenomic data analyzed, with mammalian- and molluscan-associated microbiomes having 
the highest median pepM abundances (17.4% and 29.9%, respectively) (Figure 2.2B).  
Table 2.2. pepM homologs per 100,000 reads in the GOS data by sampling site 
Sample 
dataset 
Description Sample Location Total reads pepM homologs per 
100,000 reads 
GS000a Open Ocean Sargasso Station 11, 13 644551 5 
GS000b Open Ocean Sargasso Station 11, 13 317180 5 
GS000c Open Ocean Sargasso Station 3 368835 10 
GS000d Open Ocean Sargasso Station 13 332240 8 
GS001c Open Ocean Hydrostation S 92351 1 
GS002 Coastal  Gulf of Maine 121590 2 
GS003 Coastal Browns Bank, Gulf of 
Maine 
61605 3 
GS004 Coastal Outside Halifax, Nova 
Scotia 
52959 8 
GS005 Embayment Bedford Basin, Nova 
Scotia 
61131 2 
GS006 Estuary Bay of Fundy, Nova Scotia 59679 7 
GS008 Coastal Newport Harbor, Rhode 
Island 
129655 2 
GS009 Coastal Block Island, New York 79303 5 
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Table 2.2. (cont.) 
GS010 Coastal Cape May, New Jersey 78304 3 
GS011 Estuary Delaware Bay, New 
Jersey 
124435 3 
GS013 Coastal Off Nags Head, North 
Carolina 
138033 3 
GS014 Coastal South of Charleston, 
South Carolina 
128885 5 
GS015 Coastal Off Key West, Florida 127362 3 
GS016 Coastal Sea Gulf of Mexico 127122 3 
GS017 Open Ocean Yucatan Channel 257581 4 
GS018 Open Ocean Rosario Bank 142743 3 
GS019 Coastal Northeast of Colon 135325 5 
GS020 Fresh Water Lake Gatun 296355 3 
GS021 Coastal Gulf of Panama 131798 5 
GS022 Open Ocean 250 miles from Panama 
City 
121662 2 
GS023 Open Ocean 30 miles from Cocos 
Island 
133051 8 
GS025 Fringing Reef Dirty Rock, Cocos Island 120671 1 
GS026 Open Ocean 134 miles Northeast of 
Galapagos 
102708 5 
GS027 Coastal Devil’s Crown, Floreana 
Island 
222080 7 
GS028 Coastal Coastal Floreana 189052 6 
GS029 Coastal North James Bay, Santigo 
Island 
131529 5 
GS030 Warm Seep Warm Seep, Roca 
Redonda 
359152 2 
GS031 Coastal 
Upwelling 
Upwelling, Fernandina 
Island 
436401 4 
GS032 Mangrove Mangrove on Isabella 
Island 
148018 8 
GS033 Hypersaline Punta Cormorant, 
Hypersaline Lagoon, 
Floreana Island 
692255 0
a
 
GS034 Coastal North Seamore Island 134347 3 
GS035 Coastal Wolf Island 140814 3 
GS036 Coastal Cabo Marshall, Isabella 
Island 
77538 3 
GS037 Open Ocean Equatorial Pacific TAO 
Buoy 
65670 2 
GS046 Open Ocean 300 miles from French 
Polynesia 
626 160
b
 
GS047 Open Ocean 201 miles from French 
Polynesia 
66023 2 
GS048a Coral Reef Moorea, Cooks Bay 90515 4 
GS048b Coral Reef Inside Cooks Bay, 
Moorea, French Polynesia 
47691 2 
GS049 Coral Reef Moorea, Outside Cooks 
Bay 
92501 8 
GS051 Coral Atoll Rangirora Atoll 128982 5 
GS109 Open Ocean Indian Ocean 59812 8 
GS110a Open Ocean Indian Ocean 99288 5 
GS111 Open Ocean Indian Ocean 59079 2 
GS112a Open Ocean Indian Ocean 99781 4 
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Table 2.2. (cont.) 
GS112b Open Ocean Indian Ocean 52118 2 
GS113 Open Ocean Indian Ocean 109700 2 
GS114 Open Ocean 500 miles west of the 
Seychelles in the Indian 
Ocean 
348823 5 
GS116 Open Ocean Outside Seychelles, Indian 
Ocean 
60932 2 
GS117a Coastal 
sample 
St. Anne Island, 
Seychelles 
346952 4 
GS119 Open Ocean International water outside 
of Reunion Island 
60987 7 
GS121 Open Ocean International water 
between Madagascar and 
South Africa 
110720 6 
GS122a Open Ocean International water 
between Madagascar and 
South Africa 
101558 4 
GS123 Open Ocean International water 
between Madagascar and 
South Africa 
107966 7 
GS148 Fringing Reef East coast Zanzibar 
(Tanzania), offshore Paje 
lagoon 
107741 1 
GS149 Harbor West coast Zanzibar 
(Tanzania), harbor region 
110984 5 
 total 9346749 4.2 
a 
indicates values > 0 but < 0.5. 
b
 not statistically representative due to small sample size.
 
 
Figure 2.2. The pepM gene abundance in GOS metagenomes and IMG/M microbiomes. (A) 
Boxplot of prokaryotic genome equivalents for pepM occurrence by habitat type in GOS. No 
significant difference was found in the relative pepM abundance across GOS habitats (p=0.9328,  
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Figure 2.2. (cont.) 
Kruskal Wallis test applied to habitats with more than one sampling site). (B) Boxplot of 
percentage of prokaryotic genome equivalents for pepM occurrence by ecosystem type in IMG/M 
microbiomes. Relative pepM abundance across various ecosystems differed significantly (p < 3.3 
x 10
-5
, Kruskal Wallis test applied to categories with more than one sampling site). (C) Distribution 
of predicted prokaryotic phyla for pepM homologs identified in GOS metagenomes. Phyla which 
account for < 1% are grouped in ‘Others’, including in the descending order Actinobacteria, 
Tenericutes, Chlamydiae, Thermotogae, Deinococcus-Thermus, Deferribacteres and 
Crenarchaeota. (D) Distribution of predicted prokaryotic phyla for pepM homologs identified in 
IMG/M microbiomes. Phyla which account for < 1% are grouped in ‘Others’, including in the 
descending order Chlamydiae, Thermotogae, Synergistetes, Chlorobi, Tenericutes, 
Verrucomicrobia, Ignavibacteria, Acidobacteria, Nitrospirae, Chrysiogenetes, Chloroflexi, 
Deferribacteres, Planctomycetes, Aquificae, Caldiserica, Elusimicrobia, Fibrobacteres, 
Fusobacteria, Gemmatimonadetes, and Thermodesulfobacteria. In (A) and (B), the number of 
sampling sites for each type is shown in the parenthesis. 
To gain insight into which taxa are associated with phosphonate biosynthesis in the 
metagenomic data, we used PhymmBL: a bioinformatics tool that allows strong inference 
regarding the phylogeny of organisms from which individual sequence reads are derived (6). This 
analysis predicts that Proteobacteria, followed by Firmicutes, Cyanobacteria and Spirochaetes 
are the most abundant pepM-associated phyla in the marine environments represented in the 
GOS data, with ten other phyla represented at lower abundances (Figure 2.2C). At the genus 
level, 40% of pepM reads seem to be derived from Prochlorococcus (17.9%), Candidatus 
Pelagibacter (11.8%) and Borrelia (10.8%), whereas remaining reads were predicted to belong to 
the other 62 genera. In the IMG/M metagenomes, at least 28 different prokaryotic groups were 
predicted at the phylum level, primarily from Firmicutes, Proteobacteria and Bacteroidetes (Figure 
2.2D), with the top five pepM-containing genera being Bacteroides (7.0%), Clostridium (6.8%), 
Bacillus (6.6%), Nitrosopumilus (6.5%) and Streptococcus (4.3%). PhymBL analysis of a pepM 
PCR clone library from local soils (see below) assigned 97% of the reads to Proteobacteria, with 
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only minor fractions assigned to Actinobacteria (1.5%), Nitrospirae (1.2%) and Acidobacteria 
(0.2%). The two most abundant subgroups in this library were the proteobacterial orders 
Burkholderiales (73.6%) and Rhizobiales (19.2%).  
Lastly, we assessed the prevalence of phosphonate biosynthesis in cultivable bacteria by 
screening using degenerate PCR primers designed from conserved PepM amino acids motifs. 
Due to our interest in bioactive phosphonic acids, we focused our efforts on actinomycetes, which 
are known to be prolific producers of diverse natural products. We examined 1649 strains isolated 
from local soils using protocols that are selective for spore-forming actinobacteria and an 
additional 973 strains from the USDA-ARS actinobacteria collection: of these, 120 strains (4.6%) 
gave PCR products that were verified to be authentic pepM amplicons by DNA sequencing.  
The pepM gene neighborhoods suggest considerable diversity in phosphonate 
biosynthetic pathways. Because the genes encoding phosphonate biosynthetic pathways are 
typically clustered together with the pepM gene (5, 8, 46), examination of the pepM gene 
neighborhood provides insight into the diversity of their phosphonic acid products. Accordingly, 
we examined the pepM gene neighborhoods in all known phosphonate producers, as well as 
those encoded in sequenced microbial genomes and in twenty-five of the pepM-positive 
actinobacteria, which were cloned and sequenced as described. Putative gene functions were 
assigned based on genome annotations and homology of the protein products to enzymes of 
known function. Annotated diagrams of all gene clusters are shown in http://file-
server.igb.illinois.edu/~xyu9/Dataset_S4._Phosphonate_gene_clusters.html and Figures 2.3-2.27.  
 59 
 
Figure 2.3. Organization of the Streptomyces sp. XY332 phosphonate biosynthetic gene cluster. 
1, AfsR-like transcriptional regulator (714 aa); 2, hypothetical protein (205 aa); 3, asparagine 
synthetase (728 aa); 4, SAM-dependent methyltransferase, type 11 (234 aa); 5, PEP mutase 
(285 aa); 6, phosphonopyruvate decarboxylase (371 aa); 7, 3', 5'-cyclic nucleotide 
phosphodiesterase (254 aa); 8, carbamoyl-phosphate synthase L chain, ATP-binding (370 aa); 9, 
taurine catabolism dioxygenase TauD, TfdA family (304 aa); 10, N-methyltransferase (199 aa); 11, 
hypothetical protein (400 aa); 12, transporter, MFS superfamily (408 aa); 13, dTMP kinase (225 
aa); 14, 3-carboxymuconate cycloisomerase (506 aa); 15, nitrogen regulatory protein (217 aa); 16, 
nitrogen regulatory protein (302 aa); 17, glutamine synthetase family protein (524 aa); 18, 
amidase, Asp-tRNAsn/Glu-tRNAGln amidotransferase A subunit (486 aa); 19, hypothetical 
protein (590 aa); 20, GCN5-related N-acetyltransferase (135 aa); 21, adenylosuccinate lyase 
(436 aa); 22, AfsR-like transcriptional regulator (124 aa). 
 
Figure 2.4. Organization of the Streptomyces sp. WM6372 phosphonate biosynthetic gene 
cluster. 1, secreted protein (313 aa); 2, asparagine synthetase (728 aa); 3, SAM-dependent 
methyltransferase, type 11 (234 aa); 4, PEP mutase (285 aa); 5, phosphonopyruvate 
decarboxylase (379 aa); 6, 3', 5'-cyclic nucleotide phosphodiesterase (254 aa); 7, carbamoyl-
phosphate synthase L chain, ATP-binding (466 aa); 8, taurine catabolism dioxygenase TauD, 
TfdA family (318 aa); 9, N-methyltransferase (350 aa); 10, hypothetical protein (427 aa); 11, 
transporter, MFS superfamily (412 aa); 12, dTMP kinase (232 aa); 13, 3-carboxymuconate 
cycloisomerase (493 aa); 14, nitrogen regulatory protein (656 aa); 15, glutamine synthetase 
family protein (520 aa); 16, amidase, Asp-tRNAsn/Glu-tRNAGln amidotransferase A subunit (501 
aa); 17, hypothetical protein (576 aa); 18, GCN5-related N-acetyltransferase (135 aa); 19, 
adenylosuccinate lyase (436 aa); 20, AfsR-like transcriptional regulator (342 aa). 
 
Figure 2.5. Organization of the Streptomyces sp. XY152 phosphonate biosynthetic gene cluster. 
1, dimodular NRPS (1324 aa); 2, NRPS condensation domain (459 aa); 3, ABC-type multidrug 
transport system, permease (271 aa); 4, ABC-type multidrug transport system, permease (267 
aa); 5, ABC-type multidrug transport system, ATPase (338 aa); 6, PEP mutase (289 aa); 7, 
cysteine synthase (341 aa); 8, hypothetical protein (393 aa); 9, phosphonopyruvate 
decarboxylase (388 aa); 10, radical SAM family protein (561 aa); 11, sugar 
nucleotidyltransferases (275 aa); 12, monooxygenase (394 aa); 13, IS1647-like transposase (115 
aa); 14, XRE family transcriptional regulator (161 aa); 15, phytanoyl-CoA dioxygenase  
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Figure 2.5. (cont.) 
superfamily (280 aa); 16, condensation domain protein (437 aa); 17, dihydrodipicolinate 
reductase (254 aa); 18, acyl-CoA dehydrogenase, short-chain specific (383 aa); 19, NRPS 
condensation domain (443 aa); 20, hypothetical protein (476 aa); 21, AMP-dependent synthetase 
and ligase (556 aa); 22, hypothetical protein (69 aa); 23, class II aldolase/adducin family protein 
(160 aa); 24, transporter, MFS superfamily (415 aa); 25, transposase IS3/IS911 family protein (93 
aa). 
 
Figure 2.6. Organization of the Streptomyces sp. XY66 phosphonate biosynthetic gene cluster. 1, 
beta-ketoacyl synthase (406 aa); 2, modular polyketide synthase (2151 aa); 3, acyl carrier protein 
(132 aa); 4, NRPS accessory protein (176 aa); 5, cytochrome P450 hydroxylase (388 aa); 6, 
taurine catabolism dioxygenase TauD/TfdA (297 aa); 7, 1-acyl-sn-glycerol-3-phosphate 
acyltransferase (236 aa); 8, acyl carrier protein (84 aa); 9, polyketide synthase (590 aa); 10, 
polyketide synthase (2078 aa); 11, 3-oxoacyl-(acyl-carrier-protein) synthase, KASII (378 aa); 12, 
3-oxoacyl-(acyl-carrier-protein) synthase, KASII (292 aa); 13, hypothetical protein (110 aa); 14, 3-
oxoacyl-(acyl-carrier-protein) reductase (249 aa); 15, acyl carrier protein (89 aa); 16, 3-oxoacyl-
(acyl-carrier-protein) reductase (265 aa); 17, 3-oxoacyl-(acyl-carrier-protein) synthase I (319 aa); 
18, 3-oxoacyl-(acyl-carrier-protein) synthase, KASII (403 aa); 19, hydrolase or acyltransferase of 
alpha/beta superfamily (268 aa); 20, membrane-bound C-5 sterol desaturase (318 aa); 21, 
tetracenomycin C efflux protein (550 aa); 22, phosphopantetheinyl transferase (225 aa); 23, PEP 
mutase (532 aa); 24, phosphonopyruvate decarboxylase fragment (187 aa); 25, 
phosphonopyruvate decarboxylase fragment (188 aa); 26, 2-aminoethylphosphonate:pyruvate 
aminotransferase (306 aa); 27, hypothetical protein (650 aa). 
 
Figure 2.7. Organization of the Streptomyces sp. WM6368 phosphonate biosynthetic gene 
cluster. 1, transcriptional  regulator, SARP family (227 aa); 2, 3-oxoacyl-(acyl-carrier-protein) 
synthase (259 aa); 3, thioesterase (98 aa); 4, 1-acyl-sn-glycerol-3-phosphate acyltransferase 
(237 aa); 5, acyl carrier protein (70 aa); 6, polyketide synthase (589 aa); 7, polyketide synthase 
(2085 aa); 8, 3-oxoacyl-(acyl-carrier-protein) synthase, KASII (352 aa); 9, 3-oxoacyl-(acyl-carrier-
protein) synthase, KASII (419 aa); 10, 3-oxoacyl-(acyl-carrier-protein) reductase (249 aa); 11, 
acyl carrier protein (90 aa); 12, 3-oxoacyl-(acyl-carrier-protein) reductase (274 aa); 13, 3-oxoacyl-
(acyl-carrier-protein) synthase I (328 aa); 14, 3-oxoacyl-(acyl-carrier-protein) synthase, KASII 
(398 aa); 15, hydrolase or acyltransferase of alpha/beta superfamily (263 aa); 16, membrane-
bound C-5 sterol desaturase (312 aa); 17, tetracenomycin C efflux protein (512 aa); 18, 
phosphopantetheinyl transferase (227 aa); 19, PEP mutase (546 aa); 20, phosphonopyruvate  
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Figure 2.7. (cont.) 
decarboxylase (391 aa); 21, 2-aminoethylphosphonate:pyruvate aminotransferase (372 aa); 22, 
hypothetical protein (731 aa). 
 
Figure 2.8. Organization of the Streptomyces sp. WM6373 phosphonate biosynthetic gene 
cluster. 1, phosphopantetheinyl transferase (104 aa); 2, PEP mutase (532 aa); 3, 
phosphonopyruvate decarboxylase (375 aa); 4, 2-aminoethylphosphonate:pyruvate 
aminotransferase (372 aa); 5, hypothetical protein (733 aa); 6, hypothetical protein (153 aa); 7, 
hypothetical protein (1375 aa); 8, hypothetical protein (180 aa); 9, secreted protein (429 aa); 10, 
TetR-family transcriptional regulator (243 aa); 11, transmembrane efflux protein (513 aa); 12, 
extradiol ring-cleavage dioxygenase III subunit B (273 aa); 13, RNA polymerase principal sigma 
factor (309 aa). 
 
Figure 2.9. Organization of the Streptomyces sp. WM6349 phosphonate biosynthetic gene 
cluster. 1, membrane-bound C-5 sterol desaturase (317 aa); 2, tetracenomycin C efflux protein 
(550 aa); 3, phosphopantetheinyl transferase (225 aa); 4, PEP mutase (532 aa); 5, 
phosphonopyruvate decarboxylase (375 aa); 6, 2-aminoethylphosphonate:pyruvate 
aminotransferase (372 aa); 7, hypothetical protein (733 aa); 8, hypothetical protein (153 aa); 9, 
hypothetical protein (1375 aa); 10, hypothetical protein (180 aa); 11, secreted protein (429 aa); 12, 
TetR-family transcriptional regulator (243 aa); 13, transmembrane efflux protein (485 aa); 14, 
extradiol ring-cleavage dioxygenase III subunit B (273 aa); 15, hypothetical protein (216 aa); 16, 
RNA polymerase principal sigma factor (309 aa). 
Figure 2.10. Organization of the Streptomyces sp. NRRL B-1140 phosphonate biosynthetic gene 
cluster. 1, transmembrane acyltransferase (430 aa); 2, flavin-containing monooxygenase (414 aa); 
3, 3-oxoacyl-(acyl-carrier-protein) synthase, KASIII (327 aa); 4, cytochrome P450 hydroxylase 
(411 aa); 5, aldo/keto reductase family oxidoreductase (276 aa); 6, 1-acyl-sn-glycerol-3-
phosphate acyltransferase (224 aa); 7, 3-oxoacyl-ACP reductase (249 aa); 8, acyl carrier protein 
(86 aa); 9, 3-oxoacyl-(acyl-carrier-protein) synthase II (328 aa); 10, 3-oxoacyl-(acyl-carrier-protein] 
synthase, KASII (115 aa); 11, 1-acyl-sn-glycerol-3-phosphate acyltransferase (230 aa); 12, 
membrane-bound C-5 sterol desaturase (305 aa); 13, PEP mutase (329 aa); 14, 
phosphonopyruvate decarboxylase (375 aa); 15, 2-aminoethylphosphonate:pyruvate 
aminotransferase (389 aa); 16, hypothetical protein (761 aa). 
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Figure 2.11. Organization of the Streptomyces sp. XY431 phosphonate biosynthetic gene cluster. 
1, hypothetical protein (418 aa); 2, major facilitator superfamily protein (424 aa); 3, PEP mutase 
(289 aa); 4, transketolase, N-terminal section (269 aa); 5, transketolase, C-terminal section (311 
aa); 6, thiamine pyrophosphate protein TPP binding domain protein (591 aa); 7, non-ribosomal 
peptide synthetase (435 aa); 8, phytanoyl-CoA dioxygenase (324 aa); 9, putative modular 
polyketide synthase (565 aa); 10, esterase/lipase (366 aa); 11, multidrug resistance transporter, 
MFS superfamily (487 aa); 12, iron-containing alcohol dehydrogenase (385 aa); 13, 
phosphoglycerate kinase/triose-phosphate isomerase (396 aa); 14, N-acetyl-gamma-glutamyl-
phosphate reductase (360 aa); 15, zinc-binding alcohol dehydrogenase (342 aa); 16, amino acid 
adenylation domain-containing protein (709 aa). 
 
Figure 2.12. Organization of the Streptomyces sp. WM4235 phosphonate biosynthetic gene 
cluster. 1, FomD (191 aa); 2, amino acid adenylation domain protein (75 aa); 3, major facilitator 
superfamily protein (433 aa); 4, PEP mutase (287 aa); 5, transketolase, N-terminal section (274 
aa); 6, transketolase, C-terminal section (308 aa); 7, thiamine pyrophosphate protein TPP binding 
domain protein (578 aa); 8, non-ribosomal peptide synthetase (434 aa); 9, phytanoyl-CoA 
dioxygenase (304 aa); 10, putative modular polyketide synthase (836 aa); 11, zinc-binding 
alcohol dehydrogenase (337 aa); 12, N-acetyl-gamma-glutamyl-phosphate reductase (360 aa); 
13, phosphoglycerate kinase/triose-phosphate isomerase (389 aa); 14, iron-containing alcohol 
dehydrogenase (376 aa); 15, assimilatory nitrate reductase large subunit (1395 aa); 16, 
oxidoreductase (345 aa); 17, TetR family transcriptional regulator (238 aa). 
 
Figure 2.13. Organization of the Streptomyces sp. 31A4 phosphonate biosynthetic gene cluster. 
1, NUDIX hydrolase (151 aa); 2, erythropoiesis-stimulating protein (339 aa); 3, hypothetical 
protein (271 aa); 4, CoA ligase (415 aa); 5, histidinol-phosphate aminotransferase (338 aa); 6, 
prolyl oligopeptidase family protein(649 aa); 7, TPR domain-containing protein (419 aa); 8, 
hypothetical protein (291 aa); 9, hypothetical protein (75 aa); 10, aspartate carbamoyltransferase 
(349 aa); 11, permease of the major facilitator superfamily (423 aa); 12, inositol 
monophosphatase family protein (673 aa); 13, adenylylsulfate kinase (196 aa); 14, sulfate 
adenylyltransferase subunit 2 (307 aa); 15, sulfate adenylyltransferase subunit 1 (436 aa); 16, 
sodium/hydrogen exchanger (450 aa); 17, adenylylsulfate kinase (158 aa); 18, hypothetical 
protein (286 aa); 19, hypothetical protein (355 aa); 20, hypothetical protein (441 aa); 21, 
phosphonopyruvate decarboxylase, alpha subunit (175 aa); 22, phosphonopyruvate  
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decarboxylase, beta subunit (200 aa); 23, PEP mutase (298 aa); 24, aldehyde dehydrogenase 
(492 aa); 25, regulatory protein (233 aa); 26, peptidyl-prolyl cis-trans isomerase (177 aa); 27, 
putative membrane protein (298 aa). 
 
Figure 2.14. Organization of the Streptomyces sp. MMG1121 phosphonate biosynthetic gene 
cluster. 1, NUDIX hydrolase (157 aa); 2, erythropoiesis-stimulating protein (343 aa); 3, 
hypothetical protein (277 aa); 4, CoA ligase (415 aa); 5, histidinol-phosphate aminotransferase 
(341 aa); 6, prolyl oligopeptidase family protein(615 aa); 7, TPR domain-containing protein (419 
aa); 8, hypothetical protein (291 aa); 9, hypothetical protein (75 aa); 10, aspartate 
carbamoyltransferase (349 aa); 11, permease of the major facilitator superfamily (426 aa); 12, 
inositol monophosphatase family protein (672 aa); 13, adenylylsulfate kinase (194 aa); 14, sulfate 
adenylyltransferase subunit 2 (307 aa); 15, sulfate adenylyltransferase subunit 1 (435 aa); 16, 
sodium/hydrogen exchanger (450 aa); 17, adenylylsulfate kinase (148 aa); 18, hypothetical 
protein (286 aa); 19, hypothetical protein (344 aa); 20, hypothetical protein (441 aa); 21, 
phosphonopyruvate decarboxylase, alpha subunit (175 aa); 22, phosphonopyruvate 
decarboxylase, beta subunit (202 aa); 23, PEP mutase (298 aa); 24, aldehyde dehydrogenase 
(192 aa); 25, aldehyde dehydrogenase (269 aa); 26, 4-oxalocrotonate tautomerase (95 aa); 27, 
fumarate reductase flavoprotein subunit (477 aa); 28, Bcr/CflA subfamily drug resistance 
transporter (428 aa); 29, LysR family transcriptional regulator (301 aa); 30, hypothetical protein 
(80 aa); 31, putative aldolase (234 aa); 32, hypothetical protein (286 aa); 33, 3-isopropylmalate 
dehydrogenase (740 aa); 34, dimethylmenaquinone methyltransferase (233 aa); 35, hypothetical 
protein (107 aa); 36, hypothetical protein (205 aa); 37, regulatory protein (234 aa); 38, peptidyl-
prolyl cis-trans isomerase (177 aa); 39, putative membrane protein (298 aa). 
 
Figure 2.15. Organization of the Streptomyces sp. MMG1522 phosphonate biosynthetic gene 
cluster. 1, hypothetical protein (383 aa); 2, phosphohydrolase (217 aa); 3, biotin carboxylase (413 
aa); 4, argininosuccinate lyase domain protein (402 aa); 5, non-ribosomal peptide synthetase 
(252 aa); 6, amino acid adenylation domain (220 aa); 7, putative fusion protein 
(ligase/carboxylase and argininosuccinate lyase (427 aa); 8, major facilitator superfamily protein 
(421 aa); 9, TldE/PmbA protein, part of proposed TldE/TldD proteolytic complex (258 aa); 10, 
TldD protein, part of proposed TldE/TldD proteolytic complex (449 aa); 11, taurine catabolism 
dioxygenase TauD, TfdA family (324 aa); 12, PEP mutase (267 aa); 13, cysteine synthase (325 
aa); 14, ornithine cyclodeaminase (357 aa); 15, non-ribosomal peptide synthetase adenylation 
domain protein (579 aa); 16, hypothetical protein (386 aa); 17, isopentenyl phosphate kinase (312 
aa); 18, 2-aminoethylphosphonate:pyruvate aminotransferase (375 aa); 19, nitrogen regulatory  
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protein (773 aa); 20, hypothetical protein (248 aa); 21, phosphonopyruvate decarboxylase, alpha 
subunit (184 aa); 22, phosphonopyruvate decarboxylase, beta subunit (183 aa); 23, acyl carrier 
protein (90 aa); 24, FomB (214 aa); 25, FomB (121 aa); 26, putative integral membrane protein 
(284 aa); 27, adenylate cyclase (154 aa); 28, D-3-phosphoglycerate dehydrogenase (362 aa); 29, 
ABC transporter permease protein (284 aa); 30, ABC transporter permease protein (315 aa); 31, 
ABC transporter solute-binding lipoprotein (448 aa). 
 
Figure 2.16. Organization of the Streptomyces sp. MMG1533 phosphonate biosynthetic gene 
cluster. 1, integral membrane protein (130 aa); 2, arabinose efflux permease family protein (474 
aa); 3, AraC family transcription regulator (332 aa); 4, luciferase-like monooxygenase (364 aa); 5,  
NAD(P)H-dependent FMN reductase (197 aa); 6, two-component system response regulator (164 
aa); 7, two-component system sensor kinase (471 aa); 8, hypothetical protein (229 aa); 9, Fe-S 
protein, homolog of D-lactate dehydrogenase (cytochrome) (974 aa); 10, fumarylacetoacetate 
hydrolase family protein (258 aa); 11, protein of unknown function DUF81 (242 aa); 12, L-
aspartate aminotransferase (399 aa); 13, carboxylase (419 aa); 14, argininosuccinate lyase 
domain protein (413 aa); 15, PEP mutase (293 aa); 16, transporter, MFS family (232 aa); 17, 
transporter, MFS family (175 aa); 18, LuxR family transcriptional regulator (377 aa). 
 
Figure 2.17. Organization of the Streptomyces sp. WM6378 phosphonate biosynthetic gene 
cluster. 1, anti sigma factor antagonist (107 aa); 2, hypothetical protein (202 aa); 3, hypothetical 
protein (205 aa); 4, homocitrate synthase (382 aa); 5, aconitase (892 aa); 6, NADPH-dependant 
flavin reductase (149 aa); 7, PEP mutase (278 aa); 8, monooxygenase-like protein (461 aa); 9, 
SAM-dependent methyltransferase (264 aa); 10, acetyltransferase (163 aa); 11, hypothetical 
protein (390 aa); 12, probable nikkomycin biosynthesis protein, carboxylase (388 aa); 13, 
hypothetical protein (429 aa); 14, hypothetical protein (346 aa); 15, LuxR family transcriptional 
regulator (193 aa); 16, nikkomycin regulatory protein (1040 aa); 17, two-component system 
sensor kinase (860 aa); 18, two-component system response regulator (228 aa); 19, potassium-
transporting ATPase C chain (215 aa); 20, potassium-transporting ATPase B chain (709 aa); 21, 
potassium-transporting ATPase A chain (548 aa). 
 
Figure 2.18. Organization of the Streptomyces sp. WM6391 phosphonate biosynthetic gene 
cluster. 1, anti sigma factor antagonist (107 aa); 2, hypothetical protein (202 aa); 3, homocitrate 
synthase (382 aa); 4, aconitase (892 aa); 5, NADPH-dependant flavin reductase (192 aa); 6, PEP 
mutase (278 aa); 7, monooxygenase-like protein (461 aa); 8, SAM-dependent methyltransferase  
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 (264 aa); 9, acetyltransferase (163 aa); 10, hypothetical protein (390 aa); 11, probable 
nikkomycin biosynthesis protein, carboxylase (388 aa); 12, hypothetical protein (429 aa); 13, 
hypothetical protein (346 aa); 14, LuxR family transcriptional regulator (193 aa); 15, nikkomycin 
regulatory protein (1050 aa); 16, two-component system sensor kinase (860 aa); 17, two-
component system response regulator (228 aa); 18, potassium-transporting ATPase C chain (215 
aa); 19, potassium-transporting ATPase B chain (713 aa); 20, potassium-transporting ATPase A 
chain (548 aa). 
 
Figure 2.19. Organization of the Streptomyces sp. WM6352 phosphonate biosynthetic gene 
cluster. 1, hypothetical protein (1125 aa); 2, dTDP-4-keto-6-deoxyglucose 3,5 epimerase (193 aa); 
3, dTDP-glucose 4,6-dehydratase (323 aa); 4, dTDP-4-dehydrorhamnose reductase (283 aa); 5, 
glucose-1-phosphate thymidylyltransferase (303 aa); 6, cyclic nucleotide-binding protein (322 aa); 
7, hypothetical protein (254 aa); 8, PEP mutase (559 aa); 9, phosphonopyruvate decarboxylase 
(394 aa); 10, integral membrane protein (418 aa); 11, predicted sugar nucleotidyltransferase (260 
aa); 12, 2-aminoethylphosphonate:pyruvate aminotransferase (355 aa); 13, hypothetical protein 
(355 aa); 14, glycosyltransferase (243 aa); 15, response regulator receiver protein (214 aa). 
 
Figure 2.20. Organization of the Streptomyces sp. WM6386 phosphonate biosynthetic gene 
cluster. 1, NADH:flavin oxidoreductase/NADH oxidase (278 aa); 2, LysR family transcriptional 
regulator (307 aa); 3, multidrug ABC transporter, ATP-binding protein (330 aa); 4, ABC-2 type 
transporter (261 aa); 5, D-3-phosphoglycerate dehydrogenase (373 aa); 6, phosphopantetheinyl 
transferase (229 aa); 7, acyl carrier protein (90 aa); 8, AMP-dependent synthetase and ligase 
(553 aa); 9, NRAMP family Mn
2+
/Fe
2+
 transporters (484 aa); 10, PEP mutase (289 aa); 11, rieske 
[2Fe-2S] domain protein (127 aa); 12, amidohydrolase 2 (362 aa); 13, short-chain 
dehydrogenase/reductase SDR (285 aa); 14, glutamate-1-semialdehyde aminotransferase (469 
aa); 15, 2-amino-3-ketobutyrate CoA ligase (404 aa); 16, iron-containing alcohol dehydrogenase 
(383 aa); 17, putative sensor histidine kinase (439 aa); 18, D-3-phosphoglycerate dehydrogenase 
(339 aa); 19, phosphonopyruvate decarboxylase (383 aa); 20, nicotinamide-nucleotide 
adenylyltransferase (185 aa); 21, phosphoglycerate mutase (428 aa); 22, 
carboxyphosphonoenolpyruvate synthase (417 aa); 23, carboxyphosphonoenolpyruvate mutase 
(297 aa); 24, phosphonoacetaldehyde dehydrogenase (463 aa); 25, beta-lactamase domain 
protein (253 aa); 26, TetR family transcriptional regulatory protein (182 aa). 
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Figure 2.21. Organization of the Streptomyces sp. MMG1612 phosphonate biosynthetic gene 
cluster. 1, ABC transporter, ATP binding protein (329 aa); 2, ABC transporter, permease (259 aa); 
3, ABC transporter, permease (268 aa); 4, hypothetical protein (228 aa); 5, amine oxidase (455 
aa); 6, hypothetical protein (380 aa); 7, hypothetical protein (310 aa); 8, PEP mutase (302 aa); 9, 
D-3-phosphoglycerate dehydrogenase (347 aa); 10, phosphoglycerate kinase (408 aa); 11, 
hypothetical protein (114 aa); 12, carbamoyltransferase (528 aa); 13, hypothetical protein (45 aa); 
14, O-methyltransferase (354 aa); 15, FkbM family methyltransferase (256 aa); 16, 
serine/threonine protein kinase (277 aa). 
 
Figure 2.22. Organization of the Streptomyces sp. MMG1662 phosphonate biosynthetic gene 
cluster. 1, hypothetical protein (370 aa); 2, sensor histidine kinase (453 aa); 3, NAD-dependent 
aldehyde dehydrogenase (466 aa); 4, D-3-phosphoglycerate dehydrogenase (341 aa); 5, PEP 
mutase (315 aa); 6, phosphonopyruvate decarboxylase (378 aa); 7, ArsR family transcriptional 
regulator (76 aa); 8, 3-methyl-2-oxobutanoate hydroxymethyltransferase (272 aa); 9, zinc-binding 
alcohol dehydrogenase (358 aa); 10, penicillin binding protein/ beta-lactamase (377 aa); 11, 
dTMP kinase (207 aa); 12, pantoate/beta-alanine ligase (289 aa); 13, aminotransferase, class III 
(450 aa); 14, hypothetical protein (253 aa); 15, FrbJ (346 aa); 16, D-isomer specific 2-
hydroxyacid dehydrogenase, NAD-binding (310 aa); 17, GCN5-related N-acetyltranferase (139 
aa); 18, transposase, IS4 family (257 aa); 19, asparagine synthetase (622 aa); 20, transposase, 
IS66 (129 aa); 21, transporter, MFS family (192 aa); 22, hypothetical protein (263 aa); 23, non-
ribosomal peptide synthetase (1534 aa). 
 
Figure 2.23. Organization of the Streptomyces sp. NRRL B-16215 phosphonate biosynthetic 
gene cluster. 1, membrane-associated oxidoreductase (488 aa); 2, 6-phosphogluconate 
dehydrogenase, decarboxylating (294 aa); 3, glucose-6-phosphate isomerase (562 aa); 4, 
glucose-6-phosphate dehydrogenase assembly protein OpcA (314 aa); 5, glucose-6-phosphate 
1-dehydrogenase (606 aa); 6, transaldolase (366 aa); 7, transketolase (695 aa); 8, transcriptional 
regulator, AraC family (361 aa); 9, peptidyl carrier protein type II (98 aa); 10, streptomycin 
biosynthesis operon regulator (358 aa); 11, PEP mutase (308 aa); 12, polyketide 
cyclase/dehydrase superfamily (157 aa); 13, hypothetical protein (452 aa); 14, aminotransferase, 
class III (434 aa); 15, dTMP kinase (212 aa); 16, LmbE family protein (244 aa). 
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Figure 2.24. Organization of the Kitasatosporasp. NRRL F-6133 phosphonate biosynthetic gene 
cluster. 1, sugar nucleotidyltransferases-like protein (274 aa); 2, radical SAM family Fe-S protein 
(562 aa); 3, 2-aminoethylphosphonate:pyruvate aminotransferase (384 aa); 4, 
phosphonopyruvate decarboxylase (377 aa); 5, hypothetical protein (228 aa); 6, hypothetical 
protein (402 aa); 7, dTMP kinase (221 aa); 8, hypothetical protein (529 aa); 9, PEP mutase (325 
aa); 10, hypothetical protein (746 aa); 11, SAM-dependent methyltransferase (214 aa); 12, 
phosphatase (220 aa); 13, ABC transporter permease and ATP-binding protein (629 aa); 14, ABC 
transporter ATP-binding protein (596 aa); 15, sulfatase (494 aa). 
 
Figure 2.25. Organization of the Micromonospora sp. NRRL B-16802 phosphonate biosynthetic 
gene cluster. 1, aspartate carbamoyltransferase (348 aa); 2, carboxylase (411 aa); 3, PEP 
mutase (317 aa); 4, CoA ligase (411 aa); 5, histidinol-phosphate aminotransferase (355 aa); 6, 
peptidase S9, prolyl oligopeptidase active site domain protein (645 aa); 7, phosphonopyruvate 
decarboxylase (386 aa); 8, hypothetical protein (414 aa); 9, hypothetical protein (292 aa); 10, 
hypothetical protein (373 aa); 11, hypothetical protein (244 aa); 12, NAD-dependent aldehyde 
dehydrogenase (486 aa); 13, biotin carboxylase (419 aa); 14, NUDIX hydrolase (153 aa); 15, 
dihydrofolate reductase (204 aa); 16, hypothetical protein (221 aa). 
 
Figure 2.26. Organization of the Lechevalieria sp. NRRLS-836 phosphonate biosynthetic gene 
cluster. 1, FAD-binding monooxygenase (417 aa); 2, hydrolase or acyltransferase of alpha/beta 
superfamily (294 aa); 3, malonyl CoA-ACP protein transacylase (305 aa); 4, hypothetical protein 
(148 aa); 5, hypothetical protein (287 aa); 6, hydrolase/acyltransferase (258 aa); 7, 4'-
phosphopantetheinyl transferase (172 aa); 8, secreted protein (343 aa); 9, ABC-type multidrug 
transport system, ATPase component (313 aa); 10, ABC-type multidrug transport system, 
permease component (393 aa); 11, ABC-type multidrug transport system, permease component 
(383 aa); 12, dTMP kinase (217 aa); 13, methyltransferase, type 11 (234 aa); 14, PEP mutase 
(288 aa); 15, phosphonopyruvate decarboxylase (376 aa); 16, methylcrotonyl-CoA carboxylase 
biotin-containing subunit (414 aa); 17, 2-ketoglutarate dependent dioxygenase (297 aa); 18, 
hypothetical protein (74 aa); 19, hypothetical protein (297 aa); 20, hypothetical protein (760 aa); 
21, mycolysin precursor (520 aa); 22, hypothetical protein (291 aa); 23, hypothetical protein (281 
aa). 
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Figure 2.27. Organization of the Saccharothrix sp. NRRLB-16348 phosphonate biosynthetic gene 
cluster. 1, D-3-phosphoglycerate dehydrogenase (328 aa); 2, putative N-acetyl-glutamate 
semialdehyde dehydrogenase (372 aa); 3, phosphoglycerate kinase (387 aa); 4, iron-containing 
alcohol dehydrogenase (376 aa); 5, hypothetical protein (343 aa); 6, hypothetical protein (854 aa); 
7, epoxidase (229 aa); 8, PEP mutase (287 aa); 9, TetR family transcriptional regulator (189 aa); 
10, conserved hypothetical protein (165 aa); 11, hypothetical protein (235 aa); 12, hypothetical 
protein (205 aa); 13, hypothetical protein (146 aa); 14, multidrug efflux MFS permease (484 aa); 
15, pectate lyase (503 aa); 16, GntR family transcriptional regulator (131 aa); 17, ABC transporter 
ATP-binding protein (294 aa); 18, transmembrane transport protein (331 aa); 19, esterase/lipase 
(380 aa). 
Several large groups of nearly identical gene clusters were observed that appear to be 
involved in synthesis of phosphonolipids or phosphonoglycans (Figures 2.28A and 2.29). The 
largest of these, comprised of 93 gene clusters found mostly in Burkholderia, consists of a seven-
gene putative operon that we propose may be responsible for synthesis of phosphonolipids with 
1-hydroxy-2-aminoethylphosphonate as the head group (Figures 2.28A, group 1 and 2.29), 
similar to lipids previously characterized in Bdellovibrio stolpii (45). A second large group is found 
solely in Burkholderia species, most of which also encode the group 1 gene cluster (Figure 2.28A, 
group 2). We predict that these genes are responsible for synthesis of 2-hydroxy-
phosphonoacetate, which may be used as an alternative phosphonolipid headgroup in these 
strains (Figure 2.29). A third group including 27 gene clusters, mainly from Bacteroides and 
Treponema, includes a locus previously implicated in the synthesis of capsular polysaccharide B 
by B. fragilis, which contains AEP in an ester linkage to a hydroxyl group of the carbohydrate (3) 
(Figure 2.28A, group 3). Interestingly, the nearly identical cluster found in B. eggerthii DSM 20697 
has replaced the gene needed to make AEP from phosphonoacetaldehyde (PnAA) with a gene 
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that produces hydroxyethylphosphonate (HEP) from the same substrate (41). Thus, we conclude 
that some Bacteroides strains produce a similar capsular polysaccharide decorated with HEP 
instead of AEP. Group 4 and several additional groups with a few members each also contain 
genes related to lipid biosynthesis and, thus, are probably involved in the synthesis of 
phosphonolipids (Figures 2.28A and 2.29). Collectively, these groups account for approximately 
half of the identified pepM gene clusters. The remaining pepM gene neighborhoods are highly 
diverse and include the genes for synthesis of the known bioactive phosphonates, as well as 
those from all of the actinomycetes sequenced in this study (Figures 2.28A, groups 9 &10 and 
2.29). We expect that the majority of these gene clusters will direct synthesis of low-molecular 
weight C-P compounds. Interestingly, 10% of sequenced genomes analyzed in our dataset lack 
the gene encoding Ppd, thus Ppd-independent phosphonate biosynthesis is common in nature.  
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Figure 2.28. Analysis of PepM and phosphonate gene clusters from microbial genomes. (A) 
Maximum-likelihood tree of PEP mutase sequences from NCBI and 25 actinomycete strains from 
this study. The tree was calculated with FastTree program (36) with default settings. The tree is 
rooted with 2-methylisocitrate lyase sequence (NP_286072). The branch is colored based on the 
source of pepM sequences: 25 actinomycete isolates from this study (red), NCBI archaeal 
genomes (purple), NCBI bacterial genomes (blue) and NCBI genomic fragments (green). 
Selected pepM groups are highlighted by color shading, with the number of sequences within a 
group shown in the bracket. Known phosphonate compounds are indicated and marked with 
asterisk. The phosphonate biosynthetic loci for 25 actinomycete strains from this chapter are  
shown in Figures 2.3-2.27. The phosphonate gene cluster for each organism is listed at http://file-
server.igb.illinois.edu/~xyu9/Dataset_S4._Phosphonate_gene_clusters.html, shown in the same 
order as in the tree. (B) Phosphonate gene cluster similarity as a function of PepM identity.  
 71 
Figure 2.28. (cont.) 
Phosphonate gene cluster similarity was calculated using the fraction of homologous genes 
shared by two gene clusters. PepM identity was calculated using pairwise deletion of missing 
sites across the whole PepM alignment. Gene cluster similarity measures were binned by PepM 
identity at intervals of 0.02 and plotted with a standard boxplot. The line shown is a linear 
regression over the PepM identity range 0.6-1.0, with equation ŷ=−0.86+1.6x, R-squared = 0.74. 
The correlation has p-value of 2.2 x 10
-16
. 
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Figure 2.29. Representative gene clusters and proposed biosynthetic pathways for abundant 
phosphonate cluster groups identified from microbial genomes. (A) Schematic overview of 
representative phosphonate gene clusters. (B) Proposed biosynthetic pathways based on gene 
contents in the phosphonate biosynthetic loci shown on (A). Abbreviations used: PepM, PEP  
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mutase; Ppd, phosphonopyruvate decarboxylase; AEPT, AEP transaminase; ALDH, aldehyde 
dehydrogenase; ADH, alcohol dehydrogenase; acetyl-CoA hydro/transf, acetyl-CoA 
hydrolase/transferase; CDP-OH_P_transf, CDP-alcohol phosphatidyltransferase; ADP-Glc PPase,  
ADP-glucose pyrophosphorylase; G1P-TT, Glucose-1-phosphate thymidylyltransferase; UndPP-
QuiNAC-P-transf, UndPP-QuiNAC-P-transferase. Group 1 is proposed to be involved in making 
phosphonolipids with 1-hydroxy-2-AEP as the head group since CDP-alcohol 
phosphatidyltransferase, which is in the same operon of phosphonate biosynthetic genes, is 
essential for synthesizing phosphatidylglycerol (16). Group 2 likely encodes 2-hydroxy-
phosphonoacetate, which may be used as an alternative head group in phosphonolipids. Group 3 
is involved in phosphonoglycan biosynthesis in that it includes a locus previously implicated in the 
biosynthesis of capsular polysaccharide B by B. fragilis (3). Group 4, due to the presence of 
multiple copies of choline sulfatase gene near the 2-AEP biosynthetic locus, may be related to the 
synthesis of phosphonolipids. Group 10 is proposed to be involved in the biosynthesis of small 
molecule phosphonates, Representative gene cluster is the biosynthetic locus for the anti-
malarial compound FR-900098 (14). The biosynthetic pathway is adapted from (20). 
PEP mutase sequence similarity is strongly correlated with similarity of pepM gene 
neighborhoods. Due to the strongly conserved gene neighborhoods seen in many closely 
related strains, we were interested in whether PepM phylogeny was a reflection of the organismal 
phylogeny. To test this idea, we constructed a PepM phylogenetic tree using the sequences 
obtained from sequenced microbial genomes and from the 25 actinomycete gene clusters 
sequenced in this study (Figure 2.28A). For this analysis, neighborhoods defined to encompass 
six genes upstream and downstream of pepM (thirteen genes in total). The results show scant 
correlation between the PEP mutase phylogeny and organismal phylogenies. This is strikingly 
illustrated by the group 1 and group 2 gene neighborhoods, which encode distantly related PEP 
mutase sequences, but which are often found in the same organism. Many other related PepM 
proteins are also found in unrelated organisms (e.g. the group 3 gene cluster PepM found in 
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Treponema and Bacteroides and the group 1 gene cluster PepM found in Burkholderia and 
Cupriavidus).  
In contrast, there is a strong correlation between PEP mutase phylogeny and pepM gene 
neighborhood. Including those discussed above, we found twelve groups of nearly identical gene 
neighborhoods found in at least three different organisms (Figure 2.28A). All of the PEP mutase 
sequences from each group are monophyletic, suggesting that similarity of PEP mutase is a good 
predictor of the other genes in phosphonate biosynthetic pathway. To test this idea in a more 
rigorous fashion we plotted the similarity of 342 pepM gene neighborhoods against the similarity 
of PEP mutase amino acid sequences in all pairwise combinations (58,311 comparisons). The 
data reveal a highly significant, linear correlation for PEP mutase pairs having greater than 60% 
identity, with essentially no similarity in pepM gene neighborhood at lower values (Figure 2.28B).  
Numerous undiscovered phosphonate natural products are likely to exist. The 
preceding analysis shows that when two organisms have similar PepM sequences, they are 
much more likely to encode similar (if not identical) phosphonate metabolic pathways and 
therefore produce similar phosphonate molecules. The converse is also likely to be true. 
Therefore, we can estimate the diversity of phosphonate biosynthetic pathways in nature by 
examining the number of different PepM sequences in various datasets. To do this, we estimated 
the number of different PepM sequences in the microbial genomes, GOS metagenomes and 
IMG/M metagenomes using rarefaction analysis (19, 38). We also constructed and sequenced a 
large library of pepM PCR amplicons using DNA isolated directly from local soils to provide a 
greater depth of coverage specific to the pepM gene. 
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Based on the resulting collector’s curves, it is clear that the diversity of PepM sequences in 
nature is very large (Figure 2.30). Among the datasets examined, only the soil PCR library was 
sampled at sufficient depth to approach saturation. Using an 84% PepM identity level, which 
represents conservation of roughly half of the genes in the cluster, we observe 135, 248, 213 and 
60 PepM groups in the microbial genomes, GOS metagenomes, IMG/M metagenomes and soil 
clone libraries, respectively (Table 2.3). Significantly, there is little overlap between the PepM 
groups found from different environments (e.g. distinct PepM sequences found in aquatic 
ecosystems, terrestrial ecosystems or animal-associated microbiota) (Figure 2.31). Thus, a 
realistic estimate of phosphonate diversity in nature would be closer to the sum of the four 
richness estimates.  
 
Figure 2.30. Rarefaction analysis of amino acid sequences of pepM identified from IMG microbial 
genomes, IMG/M microbiomes, GOS metagenomes and soil pepM clone libraries. Rarefaction 
curves are shown for OTUs with differences not exceeding 16%. 
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Figure 2.31. Maximum-likelihood tree of PEP mutase sequences (total no.: 2166) from IMG 
cultured isolates, GOS and IMG/M metagenomes, soil clone libraries and 25 actinomycete strains 
from this study. The tree was calculated with FastTree program (39) with the following settings 
(JTT+CAT model, -pseudo, -mlacc 2 -slownni) based on amino acid sequences of the PEP 
mutase. The tree is rooted with 2-methylisocitrate lyase sequence (NP_286072). The branch is 
colored based on the source of pepM sequences: GOS and IMG/M aquatic metagenomes (red), 
local soil clone libraries (green), IMG bacterial genomes (cyan), IMG eukaryotic genomes (yellow), 
IMG archaeal genomes (purple), IMG genomic fragments (lime), 25 actinomycetes from this 
study (blue), IMG/M plant microbiomes (violet), IMG/M terrestrial microbiomes (teal), IMG/M solid 
waste microbiomes (saddle brown), IMG/M porifera microbiomes (turquoise), IMG/M mollusca 
microbiomes (orange), IMG/M mammal microbiomes (dark green), IMG/M human microbiomes 
(magenta), IMG/M bird microbiomes (dark red), IMG/M biotransformation microbiomes (grey), 
IMG/M arthropoda microbiomes (silver) and IMG/M wastewater microbiomes (coral). Known 
phosphonate compounds are indicated. 
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Table 2.3. Diversity analyses of PEP mutase sequences from different datasets  
Dataset  Observed pepMs Observed OTUs  Chao 1 ACE 
IMG microbial genomes  289 135 392 421 
IMG/M microbiomes 1229 213 328 459 
GOS metagenomes 392 248 536 630 
Soil clone libraries 595 60 85 99 
2.4 Discussion 
PEP mutase initiates C-P bond formation in almost all known naturally occurring 
phosphonates. Our results show that ~5% of phylogenetically distinct microorganisms throughout 
different ecosystems encode putative pepM genes. Therefore, the biosynthetic capacity for 
phosphonates is common, widespread and diverse. Also, our analyses may underestimate the 
prevalence of phosphonate biosynthesis because eukaryotes that are known to produce 
phosphonate-containing macromolecules (see Chapter 1) are not well represented in public 
databases.  
We also show that despite some exceptions of high PepM similarity with low phosphonate 
gene cluster similarity and vice versa, PepM phylogeny is strongly correlated with pepM gene 
neighborhoods, which allows inferring the diversity of phosphonate biosynthetic pathways by 
studying a population of PepM sequences. By extrapolation, hundreds of distinct phosphonate 
gene clusters and hence distinct phosphonate molecules await discovery.  
Interestingly, most of the actinomycete strains examined in this study have unique pepM 
gene neighborhoods or ones that are similar to known phosphonate antibiotic gene clusters, 
suggesting that this group may represent a valuable source of novel phosphonate natural 
products (Figure 2.28A, red branches).  
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 CHAPTER 3: PURIFICATION AND CHARACTERIZATION OF PHOSPHONOGLYCANS 
FROM GLYCOMYCES SP. NRRL B-16210 AND STACKEBRANDTIA  
NASSAUENSIS NRRL B-16338
2
 
 
3.1 Introduction 
Recently, our lab conducted a large-scale, gene-based screen to identify novel phosphonate-
containing natural products from actinomycetes. As part of a team effort, I screened 973 strains 
from the USDA-ARS actinomycete collection using PCR with pepM degenerate primers. Forty of 
those strains contained pepM. Subsequent culturing of all pepM
+
 strains under a single culture 
condition identified six potential phosphonate producers, two of which were Glycomyces sp. 
NRRL B-16210 and Stackebrandtia nassauensis NRRL B-16338. Both strains showed production 
of significant amounts of phosphonates (with the highest yields of phosphonates seen in lab so 
far) in 
31
P NMR, which prompted me to explore them further. In this chapter, I show that both 
organisms produce novel phosphonoglycans containing unusual methylated sugars and both 
glycerol- and hexose-linked 2-HEP in place of 2-AEP.  
3.2 Materials and Methods 
Bacterial strains, plasmids and culture conditions. Strains and plasmids used in this 
study are listed in Table 3.1. Streptomyces strains were grown at 30°C on ISP2 or ISP4 agar 
(Difco, Sparks, MD). Glycomyces and Stackebrandtia strains were grown at 30°C on ATCC 
medium 172 agar (8) or ISP4 agar. To probe the source of the methoxy group of O-
methylgalactose, which is part of the phosphonoglycans, 0.4 mg/ml of L-[
13
C-methyl]-methionine 
and L-[
2
H3-methyl]-methionine were supplemented to ISP4 agar plates, respectively, for the 
growth of Glycomyces and Stackebrandtia. Escherichia coli strains were grown at 37°C on Luria-
Bertani agar or broth supplemented with antibiotics where appropriate. Antibiotics were used at 
the following concentrations for plasmid maintenance: chloramphenicol 12.5 µg/ml, ampicillin 100 
                                                          
2
 See published manuscript (Yu X, Price NP, Evans BS and Metcalf WW. 2013. Purification and characterization of 
phosphonoglycans from Glycomyces sp. strain NRRL B-16210 and Stackebrandtia nassauensis NRRL B-16338. J 
Bacteriol. 196(9): 1768-1779.). X Yu performed the major part of the experiments described herein. NP Price performed 
the analyses of sugar linkages and sugar components. BS Evans performed LC-MS analyses of phosphonates.  
 
 83 
µg/ml and apramycin 50 µg/ml. Diaminopimelic acid (1 mM) was added to the media for the 
growth of E. coli WM6029.  
DNA isolation and manipulation. All DNA manipulations were performed by established 
protocols (24). Endonuclease and T4 DNA ligase were purchased from Invitrogen (Carlsbad, CA) 
and New England Biolabs (Ipswich, MA). The oligonucleotide PCR primers were obtained from 
Integrated DNA Technologies (Coralville, IA), listed in Table 3.1. Plasmids and fosmids were 
isolated using Qiagen (Valencia, CA) Miniprep or Maxiprep kits. The genomic DNA from 
Glycomyces and Stackebrandtia strains, extracted using UltraClean Microbial DNA Isolation Kit 
(MO BIO Laboratories, Carlsbad, CA), was used as the template for PCR amplification of a 406-
bp pepM fragment with degenerate primers as described previously (9). PCR amplifications were 
performed with GoTaq Green Master Mix (Promega). Correct amplifications of the pepM gene 
were confirmed by DNA sequencing. 
Construction of Glycomyces and Stackebrandtia genomic libraries, library screening, 
fosmid sequencing and sequence annotations. Construction of genomic libraries of 
Glycomyces and Stackebrandtia were as previously described (9), except that E. coli WM4489 
was used as the cloning host. Fosmid clones carrying the phosphonate biosynthetic gene clusters 
from both strains were isolated as described in (9). Eight pepM
+
 fosmids from Glycomyces were 
pooled and sequenced on a Roche 454 GS FLX system on a quarter of a full 454 plate after 
tagging and library construction using Nextera Kits (EPICENTRE Biotechnologies, Madison, WI). 
Sequence assembly of 454 reads was accomplished using Newbler (18). Additional sequence-
specific primers were designed to fill in remaining gaps, as needed, by traditional Sanger 
sequencing by the Applied Biosystems 3730xl DNA Analyzer. All sequencing was performed at 
the Roy J. Carver Biotechnology Center at the University of Illinois at Urbana-Champaign. 
Potential open reading frames were initially identified using RAST (2) and Blast analysis (1). Start 
sites and additional ORFs were corrected after visual inspection of the translated sequence.  
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Table 3.1. Bacterial strains, plasmids and oligonucleotides 
Strain  Relevant characteristics Source/Reference 
E. coli WM4489 E. coli DH10B derivative; mcrA Δ(mrr-hsdRMS-
mcrBC) 80(ΔlacM15) ΔlacX74 endA1 recA1 
deoR Δ(ara leu)7697araD139 galU galK nupG 
rpsLλattB::pAE12(PrhaB::trfA33 ΔoriR6K-cat::frt5) 
(6) 
E. coli WM6029 dam-3, dcm -9, metB1, galK2, galT27, lacY1, tsx-
78, supE44, thi, mel-1, tonA31,  Δ2 (mcrC-mrr)::frt 
Δ(endA)::frt attλ::pAE12-Δ1(oriR6K-cat::frt5), 
Δ5816(dapA)::frt, uidA(ΔMluI)::pir(wt),   
attHK::pJK1006:: Δ1/2(Δ oriR6K-cat, trfA) 
 This chapter  
Glycomyces sp. 
NRRL B-16210 
Phosphonoglycan producer  ARS Culture 
Collection 
Stackebrandtia 
nassauensis  NRRL 
B-16215 
Phosphonoglycan producer ARS Culture 
Collection 
S. lividans TK24 Heterologous host for phosphonate production (15) 
S. lividans MMG559  Derivative of S. lividans TK24 containing putative 
phosphonoglycan gene cluster from Glycomyces 
integrated at C31 attB site; Apr
R
 
This chapter  
S. lividans  MMG598 Derivative of S. lividans TK24 containing putative 
phosphonoglycan gene cluster from 
Stackebrandtia integrated at C31 attB site; Apr
R
 
This chapter  
Plasmid Relevant characteristics Source/Reference 
pJK050 Double-cos fosmid vector; oriV, λattB, loxP, FRT, 
Cm
R
 
(9) 
pAE4 OriT, Apr
R
, λattP, C31 int, C31attP (9) 
Fosmid 4-7G Glycomyces genomic DNA cloned into pJK050; 
contains putative phosphonoglycan gene cluster 
This chapter  
Fosmid 4-10A Stackebrandtia  genomic DNA cloned into 
pJK050; contains putative phosphonoglycan gene 
cluster 
This chapter  
Primer Sequence (5'-3') 
pepMF-for 5'-CGCCGGCGTCTGCNTNGARGAYAA-3' (9) 
pepMR-rev 5'-GGCGCGCATCATGTGRTTNGCVYA-3' (9) 
Heterologous expression of phosphonate gene clusters in Streptomyces lividans. To 
add functions necessary for transfer and integration into S. lividans, pepM
+
 fosmids from 
Glycomyces and Stackebrandtia were in vitro recombined with plasmid pAE4 (9), using Gateway 
BP Clonase II enzyme mix (Invitrogen) following the manufacturer’s instructions. Conjugal 
transfer of fosmids from E. coli donor strain WM6029 to S. lividans TK24 was conducted using 
the standard protocol (9). Exconjugants were purified by repeated single-colony isolations on 
ISP4-apramycin plates. Correct integration of the fosmids into the genome of S. lividans TK24 
were verified by PCR amplification of the pepM fragment from the purified genomic DNA. To test 
phosphonate production, exconjugants were first inoculated to 3 mL MYG (1% malt, 0.4% yeast 
extract and 1% glucose) broth and incubated at 30°C for 3 days on a roller drum. This seed 
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culture was then plated to ISP4 agar plates (Difco) (50 μL per plate) and incubated at 30°C for 
additional 10 days. The liquid fraction containing phosphonates, released from the agar as 
described in the following section, was concentrated 40-fold by lyophilization, resuspended in 
water and filtered through a 0.2 micron filter to remove insoluble particles.  
Isolation and purification of phosphonoglycans from Glycomyces. For isolation of the 
phosphonoglycans, 20 mL of ATCC 172 broth (8) was inoculated with 200 μL of the starter 
culture of Glycomyces sp. NRRL B-16210 and agitated on a rotary shaker at 200 rpm for 5 days 
at 30°C. The culture was then plated to 10 L of ISP4 agar plates (Difco) and incubated at 30°C for 
additional 10 days. The plates were frozen at -80°C, followed by subsequent thawing and 
squeezing, which allowed liquids to be liberated from agar. Squeezed agar was soaked with 70% 
methanol for 2 hours at room temperature, and then subjected to a second squeezing. Liquids 
from two extractions were combined and concentrated 40-fold by evaporation. Hydrophobic 
contaminants were removed from the concentrated liquids by successive extractions with 
dichloromethane, ethyl acetate and hexane, while the phosphonoglycans were retained in the 
aqueous phase, as determined by 
31
P NMR. The aqueous phase was then treated with 60% (v/v) 
methanol and incubated on ice for 30 min. Following centrifugation at 4925 g for 30 min, the 
supernatant fluid was collected and the precipitates were removed. Subsequent addition of 
methanol to a final concentration of 80% (v/v) precipitated the phosphonoglycans, which were 
collected by centrifugation at 4925 g for 30 min, air-dried and redissolved in water. The final 
purification step involved ultrafiltration using an Amicon Ultra-15 membrane (MWCO=50K) 
(Millipore; Billerica, MA). After 10 cycles of concentration and dilution, the phosphonoglycan in the 
retentate was recovered and lyophilized. The total yield of the phosphonoglycan was 120 mg per 
L culture.  
Isolation and purification of phosphonoglycans from Stackebrandtia. The 
Stackebrandtia phosphonoglycans were purified in the same manner, except that a 30K Amicon 
Ultra-15 membrane (Millipore) was used for ultrafiltration. The total yield of the phosphonoglycan 
was 40 mg per L culture.  
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Compositional and linkage analysis by GC-MS. Phosphonoglycans from both strains were 
treated with 200 mM ice-cold trifluoroacetic acid (TFA). The resulting supernatant, after high-
speed centrifugation to remove precipitates, was hydrolyzed by 2 M TFA for 1 h at 110°C. The 
monosaccharides thus obtained were derivatized using either aldononitrile acetate or alditol 
acetate as described elsewhere (13, 23). Permethylation linkage analysis was performed by 
established methods (7). Mono-O-methylated galactose standards were synthesized by treatment 
of galactose with methyl iodide in aqueous acetone and were purified on a mixed bed column of 
Celite/activated charcoal. GC-MS analysis was undertaken as previously reported (23).  
Partial acid hydrolysis and isolation of phosphonate-containing oligosaccharides from 
Glycomyces and Stackebrandtia. Partial hydrolysis of 800 mg of purified Glycomyces 
phosphonoglycan was performed at 100°C in 6 M HCl under reflux for 3 h. The hydrolysate was 
adjusted to pH 7.0 by adding 5 M NH4OH and incubated with 70 g of activated charcoal (Sigma). 
The aqueous supernatant was removed after centrifugation. Charcoal-bound phosphonylated 
oligosaccharides were eluted stepwise with increasing concentrations of methanol (25%, 50%, 
75%, 90%) and lyophilized. The resultant solid was dissolved in water, passed through an Oasis 
HLB extraction cartridge (Waters) and eluted with water. The water eluant was concentrated, 
treated with Fe
3+
-charged Chelex 100 resin (Sigma) and eluted with NH4HCO3 gradient (10-500 
mM) and 2% NH4OH, followed by lyophilization. The major phosphonate-containing fraction was 
further chromatographed on Bio-Gel P-2 (100 x 1.5 cm) (Bio-Rad). Late phosphonate-containing 
fractions eluted from P-2 column (5 mL per tube) were pooled, concentrated and dialyzed against 
water using a Micro Float-A-Lyzer dialysis device (MWCO= 0.5-1.0K, Spectra/Por). The filtrate 
was concentrated and fractionated on a Sephadex LH-20 column (100 x 3 cm) (GE Healthcare). 
Collected phosphonate-containing fractions (5 mL per tube) were concentrated for further NMR, 
GC-MS and LC-MS analyses. Partial acid hydrolysis of Stackebrandtia phosphonoglycans and 
isolation of phosphonate-containing fractions were performed in a similar manner.  
NMR spectroscopy. All NMR experiments except Diffusion Ordered Spectroscopy (DOSY 
NMR) were performed at room temperature on a Varian Inova 600 spectrometer equipped with a 
5-mm Varian 600DB AutoX probe tuned for proton at 600 MHz and phosphorus at 242.83 MHz at 
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the University of Illinois, Urbana-Champaign. 
1
H DOSY spectra were acquired on a Bruker 
Avance spectrometer (Bruker BioSpin Corp., Billerica, MA) operating at 500.11 MHz using a 
standard 5-mm z-gradient BBI probe at 27°C. The deuterated solvents used in this study were 
from Cambridge Isotope Laboratories (Andover, MA). Spectra were collected in water 
supplemented with 25% - 90% D2O as a lock solvent. Chemical shifts are reported in δ (ppm), 
referenced to tetramethylsilane for 
1
H and 
13
C or 85% H3PO4 as an external standard for 
31
P 
chemical shifts. 
Sample preparation and analysis by LC-MS. Phosphonates were analyzed by LC-MS as 
previously described (10). Briefly, phosphonates in crude culture extracts were partially purified 
using Fe
3+
-charged IMAC, dried in a SpeedVac (Thermo Scientifc) and then reconstituted in 90% 
acetonitrile containing 10 mM ammonium bicarbonate. LC-MS analysis was performed on a 
custom 11T linear ion-trap Fourier-transform mass spectrometer (LTQ-FT, Thermo Fisher 
Scientific) equipped with a 1200 HPLC system (Agilent). Samples were separated on a Zic 
pHILIC column (2.1 mm x 150 mm, SeQuant) using 90% acetonitrile containing 10 mM 
ammonium bicarbonate (B) and 10 mM ammonium bicarbonate (A) as mobile phases. The 
elution was performed at 0.2 mL/min flow rate with the following gradient condition: 0-5 min, 100% 
B; 5-15 min, from 100% to 40% B; 15-20 min, from 40% to 100% B; 20-35 min, 100% B. The 
mass spectral analysis consisted of a full scan at resolution 100,000 (m/z 100-1000), a source 
fragmentation scan (85V, m/z 50-110) detected in the ion trap and a targeted CID MS2 scan with 
FT detection to obtain tandem mass spectra of target compounds. The data were analyzed 
manually using the Qualbrowser application of Xcalibur software (Thermo Fisher Scientific).  
Elemental analysis. CHN (carbon, hydrogen and nitrogen) analysis was performed with 
CE440 Elemental Analyzer (Exeter Analytical Inc.) and P (phosphorus) analysis was performed 
with OES Optima 2000 DV (Perkin Elmer) at the Microanalytical Lab of the University of Illinois, 
Urbana-Champaign. Both measurements were performed in duplicates.  
Nucleotide sequence accession number. The sequence for the putative phosphonoglycan 
biosynthetic locus from Glycomyces sp. NRRL B-16210 has been deposited in GenBank under 
accession number KJ125437. 
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3.3 Results 
Production of phosphonoglycans by Glycomyces sp. NRRL B-16210 and S. 
nassauensis NRRL B-16338. We recently screened a large collection of actinomycetes for the 
presence of the pepM gene to identify novel phosphonate producers (19). Among the pepM-
positive organisms we identified were two members of the family Glycomycetaceae (16, 17): 
Glycomyces sp. NRRL B-16210 and S. nassauensis NRRL B-16338.   
Spent media obtained after growth of both organisms contained substantial amounts of P-
containing compounds that had chemical shifts consistent with C-P linkages in 
31
P NMR analyses 
(Figure 3.1A and B). 
31
P NMR spectra from washed cells of Glycomyces also indicated the 
presence of phosphonates (Figure 3.1C). Treatment of Glycomyces cells with lysozyme released 
significant amounts of the phosphonate into the supernatant (Figure 3.1D), suggesting that the 
molecule was attached to the cell surface. Initial analyses of the phosphonates present in spent 
media showed that the molecules could be precipitated by 80% methanol and that they were 
retained during ultra-filtration using high molecular weight-cutoff filters. Taken together, these 
analyses suggested that the two organisms were producing phosphonate-modified 
exopolysaccharides.  
 
Figure 3.1. 
31
P NMR spectra of phosphonates from Glycomyces and Stackebrandtia. (A) 
Concentrated culture extract of Glycomyces shows the presence of phosphonates. (B) 
Concentrated culture extract of Stackebrandtia shows the presence of phosphonates. (C) 
Washed cells of Glycomyces contain a small amount of phosphonates. (D) Lysozyme treatment  
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Figure 3.1. (cont.) 
of the sample in (C) releases cell-bound phosphonates. Concentrated culture extracts were 
supplemented with 20% D2O for 
31
P NMR analyses, as shown in (A) and (B). Glycomyces cells 
(750 mg wet weight) were harvested and washed three times with 10 mM Tris buffer (pH=7.0). 
Washed buffers were combined, dried and redissolved in D2O for 
31
P NMR analysis, as shown in 
(C). Washed cells were resuspended in 10 mM Tris buffer (pH=7.0) and treated with DNase, 
RNase and proteinase K. Enzymes were inactivated by successive extractions with 
phenol:chloroform:isoamyl (25:24:1) and chloroform:isoamyl (24:1) and centrifugations. The 
aqueous phase collected was filtered using a 10 kDa Amicon filter. The retentate on the filter was 
washed 10 times with water, lyophilized, resuspended in 20% D2O for 
31
P NMR analysis, as 
shown in (D). P peaks with chemical shifts between 5 and 40 ppm are usually indicative of 
phosphonates and phosphinates whereas P peaks between +5 to -20 ppm range are usually 
phosphate monomers, esters and pyrophosphates.  
Purification of phosphonoglycans and molecular weight determination. To obtain 
detailed structural and compositional data, we purified the phosphonoglycans from both 
organisms as described in the methods. In 
31
P NMR spectra, three to five peaks with close 
chemical shifts between 23-25 ppm were observed for both strains, suggesting that they may 
produce phosphonoglycans with a variety of linkages in the vicinity of the phosphonate moiety 
(Figure 3.2A and B). Failure to separate those phosphonoglycans through steps of purification, 
along with the fact that they had very similar phosphorus chemical shifts, indicated that the 
structures may be very closely related. The 
1
H NMR spectrum of purified phosphonoglycans from 
Glycomyces resembled that from Stackebrandtia; at least four signals were found in the anomeric 
proton region (δH 4.4-5.3 ppm, excluding the water peak). However, line broadening caused by 
sample viscosity precluded anomeric signal integrations. Other major signals shown in the 
1
H 
NMR spectra included the CH2P groups at δH 1.78 and 1.86 ppm for Glycomyces (and δH 1.81 
and 1.94 ppm for Stackebrandtia) and other sugar ring protons in the region of δH 3.2-4.4 ppm 
(Figure 3.2C and D). The proton chemical shifts of CH2P groups were determined from 
1
H-
31
P 
HMBC experiments (Figure 3.3).  
DOSY NMR, which resolves different compounds based on their differing diffusion rates, 
provides a relatively convenient method to estimate molecular size (20, 26). Based on 
1
H DOSY 
NMR experiments and comparison with known pullulan standards, predicted sizes of 
phosphonoglycans of Glycomyces and Stackebrandtia purified from spent media were ~40-50 
kDa (Figure 3.4A and B) whereas sizes of cell-bound phosphonoglycans from Glycomyces 
approximated to be 5-6 times larger (Figure 3.4C). Elemental analysis (wt.%) of the 
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phosphonoglycans found the following for Glycomyces: C, 31.60 (±0.26); H, 4.31 (±0.13); P, 1.24 
(±0.05); for Stackebrandtia: C, 36.12 (±0.07); H, 5.22 (±0.04); P, 0.26 (±0.03).   
 
Figure 3.2. NMR spectra of purified phosphonoglycans. (A) 
31
P NMR spectrum of purified 
phosphonoglycans from Glycomyces. (B) 
31
P NMR spectrum of purified phosphonoglycans from 
Stackebrandtia. (C) 
1
H NMR spectrum of purified phosphonoglycans from Glycomyces. (D) 
1
H 
NMR spectrum of purified phosphonoglycans from Stackebrandtia. 
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Figure 3.3. 
1
H-
31
P HMBC spectra of purified phosphonoglycans from Glycomyces (A) and 
Stackebrandtia (B). In the 
1
H-
31
P HMBC spectrum of purified phosphonoglycans from 
Glycomyces (A), the major 
31
P signal at 24.03 ppm had cross-peaks with three proton signals at 
1.78, 3.59 and 3.80 ppm. The proton signals at 1.78 and 3.59 ppm were assigned to CH2P and 
CH2OH of a phosphonate head group, respectively, by 
1
H-
1
H COSY correlations of H-1 with H-2. 
The proton signal at 3.80 ppm may originate from a phosphonate ester. There were two minor 
31
P 
signals at 22.89 and 22.99 ppm. One of them (or both) had cross-peaks with three proton signals 
at 1.86 (assigned to CH2P of a phosphonate), 3.81 and 4.07 ppm. 
31
P signal overlapping in this 
region prevented assignments of other proton signals. In the 
1
H-
31
P HMBC spectrum of purified 
phosphonoglycans from Stackebrandtia (B), the 
31
P signal at 23.71 ppm had cross-peaks with 
three protons signals at 1.81, 3.64 and 3.78 ppm. The proton signals at 1.81 and 3.64 ppm were 
assigned to CH2P and CH2OH of a phosphonate head group, respectively, by 
1
H-
1
H COSY 
correlations of H-1 with H-2. The proton signal at 3.78 ppm may originate from a phosphonate 
ester. The 
31
P signal at 23.45 ppm had a cross-peak with proton signal at 1.94 ppm (assigned to 
CH2P of a phosphonate) and possibly also had cross-peaks with proton signals at 3.81 and 4.11 
ppm. The proton signals at 3.81 and 4.11 ppm could not be confidently assigned due to low 
signal intensities.  
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Figure 3.4. 
1
H DOSY NMR spectra of phosphonoglycans from Glycomyces and Stackebrandtia. 
(A) 
1
H DOSY NMR spectrum of Glycomyces phosphonoglycans purified from the culture extract. 
(B) 
1
H DOSY NMR spectrum of Stackebrandtia phosphonoglycans purified from the culture 
extract. (C) 
1
H DOSY NMR spectrum of Glycomyces cell-bound phosphonoglycans. (D) A 
standard curve to plot log MW v.s. log D of a series of Shodex pullulan standards (in the range of 
5.8 and 1660 kDa) in D2O. The x axis in the 
1
H DOSY NMR spectrum shows proton chemical 
shifts whereas the y axis shows the diffusion coefficiencies (log D) of compounds. The standard 
curve can be used to determine the approximate molecular weights of phosphonoglycans. The 
proton signal at 4.6 ppm in (A), (B) and (C) originated from water.  
Compositional and per-deutero-methylation linkage analysis. To determine the sugar 
composition, phosphonoglycans from the two strains were hydrolyzed, derivatized and then 
analyzed by GC-MS. The major phosphonoglycan from Glycomyces was composed of galactose 
(70.7%), various mono-methoxygalactoses (21.0%), xylose (6.4%) and 2,3-di-O-methylgalactose 
(1.9%) (Table 3.2). GC-MS monosaccharide compositional analysis of the phosphonoglycan is 
exemplified in Figure 3.5. The predominant monosaccharides from Stackebrandtia 
phosphonoglycans were glucose (73.2%) and galactose (18.2%), with different varieties of mono-
methoxygalactoses and xylose present as minor components (Table 3.2).   
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Figure 3.5. Overlaid GC chromatographs of aldononitrile acetate derivatives of the component 
monosaccharides from the major phosphonoglycan of Glycomyces. Top is from the acid 
hydrolysate of the phosphonoglycan. Lower, inverted, are a series of monosaccharide standards: 
Rha, rhamnose; Rib, ribose; Ara, arabinose; Xyl, xylose; Man, mannose; Glc, glucose; Gal, 
galactose; Ino, inositol. Peaks dues to the five partially O-methylated monosaccharides are 
indicated.  
Table 3.2. Glycomyces and Stackebrandtia phosphonoglycan compositional analysis by GC-MS 
of sugar aldononitrile acetate derivatives 
 
Sugar 
% of total 
Glycomyces Stackebrandtia 
galactose 70.7 18.2 
glucose - 73.2 
2-O-methylgalactose 7.4 3.9 
3-O-methylgalactose 1.8 <1 
4-O-methylgalactose 3.9 <1 
6-O-methylgalactose 7.9 4.7 
2,3-di-O-methylgalactose 1.9 - 
xylose 6.4 <1 
Because of the presence of the various naturally-occurring methoxygalactose residues in the 
phosphonoglycan backbone of Glycomyces, we decided to undertake permethylation linkage 
analysis using isotopically-labeled deuterated [CD3]-methyl iodide. In this case, the more 
standard usage of dimethylsulfoxide as solvent was precluded by the low solubility of the 
phosphonated polysaccharide and because the use of aqueous acetone plus sodium hydroxide 
base catalyst was found to be more effective. Partially methylated galactose standards were 
prepared from methyl galactoside under the same reaction conditions. Following 
perdeuteromethylation and hydrolysis, aldononitrile acetate derivatives were prepared for 
analysis by GC-MS.  
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The results for the linkage analysis are summarized in Table 3.3. Permethylation analysis 
gave rise to several di-methoxygalactose residues that had one non-deuterated and one 
deuterated methyl group. These arose from mono-deuteromethylation of the various naturally-
occurring mono-methoxygalactose residues. The location of the deutero-methyl groups, and 
hence of potential linkage sites, was determined from the EI-MS fragmentation analysis. 
Fragmentation of O-methylated aldononitrile acetates tends to occur adjacent to methoxy groups, 
due to the addition stability of [R-O-Me]
+
 ions (5). Hence, hexose aldononitrile acetates that are 
substituted by a methyl group at the 6-hydroxy position are characterized by an m/z 45 fragment 
ion, which arises from cleavage of the hexosyl C5-C6 carbon-carbon bond. Replacement of this 
methyl group by a deutero-methyl (CD3) increases the mass of this ion to m/z 48 and this was 
observed for the GC peaks at retention times 11.95, 12.34, and 12.59 min. These primary 
fragment ions are degraded further by loss of ketene (-42 Da), acetic acid (-60 Da), or acetic 
anhydride (- 102 Da). Thus, 3,6D3-diMeGal was characterized by m/z 48 plus the two ion series 
192 → 132 → 90 and 236 → 176 → 116, clearly showing that the methyl group at O-3 was non-
deuterated. However, both of the methyl groups on the 2,6-diMeGal and 4,6-diMeGal derivatives 
were deuterated, showing that these arose from the non-methylated galactosyl residues in the 
polysaccharide. 
These per-deutero-methylation data indicated that four of the galactosyl residues in the 
polysaccharide backbone were 3,4-linked Gal; 2,4-linked 3-MeGal; 2,3-linked Gal; and 3,6-linked 
2-MeGal. This suggested that these residues are either at branch points in the polysaccharide 
backbone, or that another acid-labile substituent is present on these residues, other than the 
single methoxy group. It also showed that these residues are likely to be a part of the 
polysaccharide backbone, rather than terminating branch-point sugars. Moreover, from the lack of 
deutero-methylation at the 5-position it is reasonable to assume that these residues are 
predominantly present as pyranoses. Interestingly, we observed linkage types for 2-MeGal and 3-
MeGal, but we did not observe a deutero-methylated derivative arising from the 4-MeGal or 6-
MeGal residues. This suggested that the 4-MeGal and 6-MeGal residues present may be at a 
trisecting branch-point, which is unusual, or that they are more heavily substituted than the 2-, or 
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3-MeGal residues. In addition, a peak was observed with a retention time of 13.33 min, due to 
non-deuterated 2,3-diMeGal. This showed that the small amount of 2,3-dimethoxy-galactose in 
the polysaccharide backbone is 4,6-linked or, alternatively, substituted by acid-labile substituents 
at these positions. 
Table 3.3. Per-deutero-methylation linkage analysis for phosphonoglycans from Glycomyces  
Derivative Retention time (min) % of total
a
 Inferred linkage 
2D3,6D3-diMeGal 11.95 53.7 3,4-linked Gal 
3,6D3-diMeGal 12.34 2.2 2,4-linked 3-MeGal 
4D3,6D3-diMeGal 12.59 16.0 2,3-linked Gal 
2,3-diMeGal  13.33 8.2 4,6-linked 2,3-diMeGal 
2,4D3-diMeGal 13.65 17.4 3,6-linked 2-MeGal 
a
fractional % of total dimethylated residues detected. 
GC-MS analysis of O-methylgalactose component of phosphonoglycan isolated from 
Stackebrandtia cultured with isotopically enriched L-methionine. Various mono-O-
methylated galactose residues were shown to be a component of both the Glycomyces and the 
Stackebrandtia phosphonoglycans. The biosynthetic origin of the O-methyl groups was 
investigated by culturing two strains with L-[
13
C-methyl] methionine or L-[
2
H3-methyl] 
methionine. Following culturing and extraction of the phosphonoglycans, the component 
monosaccharides were recovered, acid hydrolyzed and analyzed by GC-MS as peracetylated 
aldononitrile (PAAN) derivatives. For phosphonoglycans from Glycomyces, the sensitivity of the 
isotopic enrichment was too low to allow for the unambiguous assignments of peaks, probably 
due to poor uptake. However, phosphonoglycans from Stackebrandtia grown in the presence of 
L-[
13
C-methyl] methionine gave rise a GC peak at 15.2 min due to 2-O-methylgalactose PAAN 
and was seen to have incorporated 
13
C-label with about 50% enrichment. As is typical for PAAN 
derivatives no molecular ion was observed, but characteristic fragment ions were 
apparent. Electron impact mass spectrometry generated fragment ions across the C2-C3, C4-C5 
and C5-C6 bonds of the sugar derivative. The ions arising from C2-C3 (m/z 289 and the daughter 
ion m/z 187) and C4-C5 (m/z 145) were not isotopically enriched and were derived from the non-
methylated part of the 2-O-methylgalactose PAAN (Figure 3.6). However, the C5-C6 cleavage 
generated a series of fragments ions (m/z 287, 245 and 185) that were 1 Da greater than the 
equivalent fragments of the control (Figure 3.6). These mass differences were due to the 
incorporation of 
13
C from L-[
13
C-methyl] methionine into these ions. A small enrichment was also 
 96 
observed when the same strain was grown on L-[
2
H3-methyl]-methionine, with the control ion at 
m/z 286 being increased by 3 mass units due to the incorporation of the deuterated methyl group 
(data not shown). The isotopic enrichment of L-methionine suggested that the O-methyl groups 
on the monomethylated galactose residues arose via S-adenosylmethionine, the classic pathway 
for the biological formation of methyl ethers.   
 
Figure 3.6. Electron impact mass spectra of 2-O-methylgalactose PAAN derived from 
phosphonoglycans of Stackebrandtia, grown in the presence of L-[
13
C-methyl]-methionine (A) or 
in the presence of L-methionine (control) (B). Structures and fragmentation patterns of the 
compound are indicated in the insets.  
Partial hydrolysis of phosphonoglycans and isolation of phosphonate-containing 
oligosaccharides. To study the linkage of the phosphonate to the polysaccharide, partial acid 
hydrolysis (6 M HCl, 3 h) of Glycomyces phosphonoglycans was performed at 100°C. This 
resulted in the release of various polymeric fragments containing 2-HEP bound oligosaccharides 
and 2-HEP (Figure 3.7). The hydrolysate was purified as described in Materials and Methods. 
Analysis of one sample after partial acid hydrolysis excluded the possibility of an ether linkage 
between 2-HEP and oligosaccharides, as in the 
1
H-
13
C HMBC spectrum, H-2 of 2-HEP had only 
one cross-peak with C-1 of 2-HEP but not with any other carbons from sugar rings (Figure 3.8). 
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Therefore, we believe 2-HEP is most likely bound to oligosaccharides through an ester linkage. 
Dialysis of the hydrolysate against water with a Micro Float-A-Lyzer dialysis device (MWCO= 0.5-
1.0K, Spectra/Por) followed by fractionation of the filtrate on a Sephadex LH-20 column (GE 
Healthcare) provided a fraction, which contained a mixture of two unknown phosphonates and 2-
HEP (Figure 3.9A). In addition to 2-HEP, high resolution LC-MS analysis of this fraction identified 
the presence of the ion at m/z 287.0538, corresponding to 2-HEP linked to one hexose (Figure 
3.9B). Further MS
2
 investigation indicated that 2-HEP is possibly ester-linked to hexose at either 
the O-5 or O-6 position, by virtue of the fragment ions at m/z 251.0324, 227.0322, 197.0219, 
167.0115 and 125.0009 (Figure 3.9B and C). Based on the sugar component analysis, the only 
hexose present in the phosphonoglycans is galactose and it is the major component (accounting 
70.7% of total); we therefore assigned the hexose as galactose. Unfortunately, attempts to use 
GC-MS to determine the 2-HEP and galactose linkage following sodium borohydride reduction, 
peracetylation and derivatization were not successful. Nonetheless, galactose more often occurs 
in bacterial polysaccharides in the form of pyranose. If this was the case in the Glycomyces 
phosphonoglycan, which was supported by the lack of deutero-methylation at the 5-position of 
galactose (or O-methylgalactose) as noted above (thereby implying the pyranose configuration), 
the O-5 of galactose would be part of the sugar ring, and hence not available for substitution. 
Therefore, the most likely attachment to 2-HEP is through an ester bond to O-6 of galactose.  
 
Figure 3.7. Partial acid hydrolysis of Glycomyces phosphonoglycans produced various polymeric 
fragments containing different amounts of 2-HEP bound oligosaccharides and unbound 2-HEP. 
Fractions #11 to #16 were phosphonate-containing fractions eluted from Bio-Gel P2 column (Bio- 
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Figure 3.7. (cont.) 
Rad). The identity of the peak with the chemical shift of 21.2 ppm was confirmed to be 2-HEP by 
spiking the sample with an authentic 2-HEP standard. Fractions #14 to #16 were pooled for 
subsequent purification and characterization. 
 
Figure 3.8. 2D NMR analyses of retentate (MWCO= 0.5-1.0K) after partial acid hydrolysis of 
Glycomyces phosphonoglycans. (A) 
1
H-
31
P HMBC spectrum. (B)
 1
H-
13
C HSQC spectrum. (C) 
1
H-
13
C HMBC spectrum. In the 
1
H-
31
P HMBC spectrum, the proton signal at 1.86 ppm had a cross-
peak with one of the 
31
P signals (or both) at 24.14 and 24.20 ppm. This was assigned to H-1 of 
the 2-HEP moiety, which is likely bound to oligosaccharides. C-1 (30.1 ppm) of the 2-HEP moiety, 
determined by the 
1
H-
13
C HSQC NMR experiment, had only one correlation with a proton signal 
at 3.67 ppm in the 
1
H-
13
C HMBC spectrum. This proton was assigned to H-2 of the 2-HEP moiety, 
which also showed the correlation with the 
31
P signal at 24.14 (or 24.20) ppm in the 
1
H-
31
P HMBC 
spectrum. H-2 of 2-HEP only had one correlation with C-1 of 2-HEP but not with any other 
carbons in the 
1
H-
13
C HMBC spectrum, excluding the possibility of an ether linkage between 2-
HEP and sugars.  
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Figure 3.9. Characterization of 2-HEP linked hexose after partial acid hydrolysis of Glycomyces 
phosphonoglycans. (A) 
31
P NMR spectrum of one fraction eluted from Sephadex LH-20, which 
contained two unknown phosphonates and 2-HEP. (B) High resolution LC-MS analysis of the 
sample shown in (A). The precursor ion at m/z 287.0538 indicated HEP-linked hexose. This ion 
was selected for MS
2
. (C) Proposed structures based on fragment ions generated by MS
2
.  
The Stackebrandtia phosphonoglycans were also subjected to 6 M HCl hydrolysis at 100°C 
for 3 h. The hydrolysate was desalted by size-exclusion chromatography on Sephadex G-25, 
treated with Fe
3+
-charged Chelex 100 resin and dialyzed against water using a Micro Float-A-
Lyzer dialysis membrane (MWCO= 0.5-1.0K, Spectra/Por). The filtrate was further fractionated on 
Sephadex LH-20. One fraction from Sephadex LH-20 exhibited a major peak at 24.5 ppm in 
31
P 
NMR (Figure 3.10A). Using the combination of NMR and LC-MS analyses, this phosphonate was 
determined to be 2-HEP mono(2,3-dihydroxypropyl) ester (Figures 3.10 and 3.11). Assignment of 
most of the 
1
H and 
13
C signals to 2-HEP mono(2,3-dihydroxypropyl) ester is summarized in Table 
3.4. High resolution LC-MS analysis of the same sample in the negative mode detected the 
precursor ion at m/z 199.0382 and its fragment ions at m/z 181.0275, 169.0274 and 125.0010, 
suggesting the presence of 2-HEP mono(2,3-dihydroxypropyl) ester, in good agreement with 
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NMR results (Figure 3.12). Interestingly, the same fragment ion was also detected from the above 
partially acid-hydrolyzed Glycomyces phosphonoglycan sample, albeit in lower abundance 
(Figure 3.13). Presumably, 2-HEP in this sample is also attached to glycerol via an ester linkage.  
 
Figure 3.10. 1D and 2D NMR analyses of 2-HEP mono(2,3-dihydroxypropyl) ester after partial 
acid hydrolysis of Stackebrandtia phosphonoglycans. (A) 
31
P NMR spectrum. (B) 
1
H NMR 
spectrum. (C) 
1
H-
31
P HMBC spectrum. (D) 
1
H-
1
H COSY NMR spectrum. (E) 
1
H-
1
H TOCSY NMR 
spectrum. (F) 
1
H-
13
C HMBC spectrum. (G)
 1
H-
13
C HSQC spectrum. In the 
1
H-
31
P HMBC spectrum, 
four proton signals at 1.85, 3.67, 3.72 and 3.78 ppm, had cross-peaks with the 
31
P signal at 24.5 
ppm. The proton signals at 1.85 and 3.67 ppm were assigned to CH2P and CH2OH of the 2-HEP 
moiety, respectively, by 
1
H-
1
H COSY and 
1
H-
1
H TOCSY correlations of H-1 with H-2 and 
1
H-
13
C 
HMBC correlations of H-1 with C-2. Proton signals at 3.72 and 3.78 ppm are both from C-1′, as 
evident from 
1
H-
13
C HMBC correlations of H-1′ with C-2′ but not with C-1 or C-2. Additionally, two 
cross-peaks were found between the proton signal at 3.47 ppm and the carbon signals at 64.8 
(C-1′) and 70.7 (C-2′) ppm. This proton signal was assigned to H-3′, consistent with 
1
H-
1
H TOCSY 
correlations of H-2′ with H-3′. Together, these data allow to assign the structure as 2-HEP 
mono(2,3-dihydroxypropyl) ester.
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Figure 3.11. Structure of 2-HEP mono(2,3-dihydroxypropyl) ester 
 
Figure 3.12. High resolution LC-MS analysis of 2-HEP mono(2,3-dihydroxypropyl) ester after 
partial acid hydrolysis of Stackebrandtia phosphonoglycans. The precursor ion at m/z 199.0382 
indicated HEP-linked glycerol, namely, 2-HEP mono(2,3-dihydroxypropyl) ester. This ion was 
selected for MS
2
. Proposed ion structures were shown at the bottom.  
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Figure 3.13. High resolution LC-MS analysis of 2-HEP mono(2,3-dihydroxypropyl) ester after 
partial acid hydrolysis of Glycomyces phosphonoglycans. The precursor ion at m/z 199.0376 
indicated HEP-linked glycerol, namely, 2-HEP mono(2,3-dihydroxypropyl) ester. This ion was 
selected for MS
2
. Proposed ion structures were shown at the bottom.  
Table 3.4. 
1
H (600 MHz) and 
13
C (150 MHz) spectroscopic data for 2-HEP mono(2,3-
dihydroxypropyl) ester in D2O  
No. δC δH, mult (J in Hz) 
1
H-
1
H COSY 
1
H-
1
H TOCSY 
1
H-
13
C HMBC 
1 29.3 1.85, m H-2 H-2 C-2 
2 56.8 3.67, m H-1 H-1 - 
1′ 64.8 3.72,m, 3.78, m - - C-2′ 
2′ 70.7 3.74, m - H-3′ - 
3′ 62.0 3.47, dd (11.8, 5.9), 
3.53, dd (11.8, 5.9) 
H-2′ H-2′ C-1′,2′ 
Cloning, sequencing and bioinformatic analyses of phosphonoglycan biosynthetic 
gene clusters. Since genes encoding phosphonate biosynthetic pathways are usually clustered 
with the pepM gene (19, 27), PCR screening with pepM degenerate primers enabled the 
identification of plasmid clones carrying the phosphonoglycan biosynthetic gene clusters from two 
strains. Fosmid libraries of both strains were constructed and screened with pepM primers as 
described previously (9). Out of 3072 fosmid clones screened, eight and seven fosmid clones 
(containing overlapping fragments from the same gene locus) from Glycomyces and 
Stackebrandtia strains, respectively, were shown to be pepM positive. The fosmids from 
Glycomyces were pooled, sequenced, annotated and compared with the phosphonoglycan 
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biosynthetic locus from Stackebrandtia (genome sequence available under GenBank accession 
number NC_013947) (Figure 3.14; Tables 3.5 and 3.6).  
 
Figure 3.14. Putative phosphonoglycan biosynthetic loci of Glycomyces sp. NRRL B-16210 and 
S. nassauensis NRRL B-16338. Red lines indicate gene homologs shared by two clusters. ORFs 
colored in green encode genes possibly involved in polysaccharide biosynthesis whereas ORFs 
colored in blue encode genes possibly involved in teichoic acid biosynthesis. Black arrows 
indicate the borders of fosmids, which were used for heterologous expression in S. lividans TK24. 
Annotations of ORFs from Glycomyces and Stackebrandtia putative phosphonoglycan clusters 
are shown in Tables 3.5 and 3.6.  
Table 3.5. Summary of ORFs in putative phosphonoglycan biosynthetic locus of Glycomyces 
ORF No. of amino 
acids 
Protein Homology
a
 Amino acid 
identity (%) 
1 579 Stackebrandtia nassauensis hypothetical 
protein (YP_003514486) 
159/473 (34%) 
2 307 Stackebrandtia nassauensis proline 
dehydrogenase (YP_003514483) 
210/305 (69%) 
3 441 Salinispora hypothetical protein 
(WP_018799539) 
250/434 (58%) 
4 404 Actinomadura madurae hypothetical protein 
(WP_021595829) 
204/389 (52%) 
5 496 Streptomyces globisporus group 1 glycosyl 
transferase (ZP_11382042) 
287/495 (58%) 
6 187 Streptomyces griseus putative acetyltransferase 
(ZP_08238656) 
134/187 (72%) 
7 391 Streptomyces fulvissimus UDP-N-
acetylglucosamine 2-epimerase 
(YP_007931007) 
256/361 (71%) 
8 527 Streptomyces globisporus group 1 glycosyl 
transferase (ZP_11382042) 
299/522 (57%) 
9 428 Streptomyces sp. nucleotide sugar 
dehydrogenase (WP_020127806) 
355/427 (83%) 
10 337 Streptomyces somaliensis dehydrogenase 
(WP_010470231) 
230/332 (69%) 
11 368 Micromonospora aurantiaca glutamine-scyllo-
inositol transaminase (YP_003835206)  
263/358 (73%) 
12 263 Actinoplanes sp. xylose isomerase domain-
containing protein (YP_007955649) 
165/257 (64%) 
13 272 Stackebrandtia nassauensis hypothetical 
protein Snas_5757 (YP_003514480) 
166/267 (62%) 
14 273 Actinoplanes sp. hypothetical protein 
(YP_007955491)  
131/261 (50%) 
15 572 Stackebrandtia nassauensis hypothetical 
protein Snas_5667 (YP_003514390)  
240/512 (47%) 
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Table 3.5. (cont.) 
16 429 Stackebrandtia nassauensis PEP mutase 
(YP_003514388) 
354/427 (83%) 
17 375 Stackebrandtia nassauensis 
phosphonopyruvate decarboxylase 
(YP_003514387) 
277/371 (75%) 
18 387 Stackebrandtia nassauensis iron-containing 
alcohol dehydrogenase (YP_003514386) 
239/377 (63%) 
19 648 Stackebrandtia nassauensis LicD family protein 
(YP_003509551) 
182/500 (36%) 
20 654 Stackebrandtia nassauensis LicD family protein 
(YP_003509551) 
190/496 (38%) 
21 1113 Salinispora pacifica hypothetical protein 
(WP_018254297) 
492/1156 
(43%) 
22 180 Stackebrandtia nassauensis UDP-N-
acetylglucosamine pyrophosphorylase-like 
protein (YP_003509695) 
135/178 (76%) 
23 245 Streptomyces sp. putative bifunctional ribulose 
5-phosphate reductase/CDP-ribitol 
pyrophosphorylase (ZP_09401011) 
116/238 (49%) 
24 522 Stackebrandtia nassauensis hypothetical 
protein Snas_5667 (YP_003514390) 
216/504 (43%) 
25 180 Stackebrandtia nassauensis UDP-N-
acetylglucosamine pyrophosphorylase-like 
protein (YP_003509695) 
135/178 (76%) 
26 389 Stackebrandtia nassauensis glycosyl 
transferase group 1 (YP_003509810) 
163/388 (42%) 
27 915 Stackebrandtia nassauensis DNA 
topoisomerase I (YP_003509305) 
646/856 (75%) 
28 775 Verrucosispora maris membrane-bound proton-
translocating pyrophosphatase 
(YP_004402993) 
547/777 (70%) 
29 173 Stackebrandtia nassauensis hypothetical 
protein Snas_0500 (YP_003509308) 
74/150 (49%) 
30 120 Stackebrandtia nassauensis anti-sigma-factor 
antagonist (YP_003509309) 
55/107 (51%) 
a
 Results were generated by BLASTP analysis (performed on 11.10.2013) of deduced amino 
acids of each ORF and accession numbers were shown in parentheses.  
Table 3.6. Summary of ORFs in putative phosphonoglycan biosynthetic locus of Stackebrandtia 
ORF No. of amino acids Predicted function (GenBank accession) 
1′ 116 ABC transporter (YP_003514402) 
2′ 474 nucleotide sugar dehydrogenase  (YP_003514401) 
3′ 310 endonuclease/exonuclease/phosphatase (YP_003514400) 
4′ 193 hypothetical protein Snas_5676 (YP_003514399) 
5′ 704 LmbE family protein (YP_003514398) 
6′ 762 glycosyl transferase group 1 (YP_003514397) 
7′ 549 N-acetylglucosamine phosphotransferase (YP_003514396) 
8′ 593 N-acetylglucosamine phosphotransferase (YP_003514395) 
9′ 685 CDP-alcohol phosphatidyltransferase (YP_003514394) 
10′ 253 ABC transporter related protein (YP_003514393) 
11′ 291 CDP-alcohol phosphatidyltransferase (YP_003514392) 
12′ 239 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 
(YP_003514391) 
13′ 551 hypothetical protein Snas_5667 (YP_003514390) 
14′ 569 hypothetical protein Snas_5666 (YP_003514389) 
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Table 3.6. (cont.) 
15′ 437 PEP mutase (YP_003514388) 
16′ 373 phosphonopyruvate decarboxylase (YP_003514387) 
17′ 386 iron-containing alcohol dehydrogenase  (YP_003514386) 
18′ 238 hypothetical protein Snas_5662 (YP_003514385) 
19′ 138 hypothetical protein Snas_5661 (YP_003514384) 
20′ 106 hypothetical protein Snas_5660 (YP_003514383) 
21′ 237 hypothetical protein Snas_5659 (YP_003514382) 
22′ 196 hypothetical protein Snas_5658 (YP_003514381) 
23′ 102 hypothetical protein Snas_5657 (YP_003514380) 
24′ 662 major facilitator superfamily protein  (YP_003514379) 
25′ 239 flavoprotein (YP_003514378) 
26′ 449 radical SAM protein  (YP_003514377) 
27′ 222 NAD-dependent epimerase/dehydratase (YP_003514376) 
28′ 143 glyoxalase/bleomycin resistance protein/dioxygenase 
(YP_003514375) 
29′ 219 GntR family transcriptional regulator (YP_003514374) 
Comparative analyses of two phosphonoglycan gene clusters revealed significant similarities 
surrounding pepM. Four genes were shared in common between two clusters: ORF 15 
(hypothetical protein), ORF 16 (PEP mutase), ORF 17 (PnPy decarboxylase) and ORF 18 (iron-
dependent alcohol dehydrogenase) (Figure 3.14). The latter three genes encode enzymes with 
high homology to ones involved in the synthesis of 2-HEP, which is a common intermediate in 
characterized phosphonate biosynthetic pathways including dehydrophos, fosfomycin and 
phosphinothricin (25). Hence, presence of these three genes in clusters provided molecular 
evidence for the biosynthesis of HEP-containing phosphonoglycans. ORF 15 shares 47% and 48% 
sequence identity, respectively, with ORF 13′ (hypothetical protein Snas_5667) and ORF 14′ 
(hypothetical protein Snas_5666) from S. nassauensis (Figure 3.14). Homologous proteins in 
other bacterial genomes have been annotated as CDP-glycerol:poly(glycerophosphate) 
glycerophosphotransferase. For example, tagF-encoded glycerophosphotransferase catalyzes 
extension of the teichoic acid main chain through sequential transfer of glycerol-phosphate units 
from CDP-glycerol to the linkage unit lipid in both Bacillus subtilis 168 and Staphylococcus 
epidermidis ATCC 14990 (11, 21). Homologs in phosphonoglycan gene clusters may perform a 
similar function. In addition, there are some genes involved in sugar metabolism (e.g. 
glycosyltransferase) and teichoic acid biosynthesis in two clusters (Tables 3.5 and 3.6). Whether 
and how those genes are involved in phosphonoglycan biosynthesis remains to be identified. The 
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gene responsible for O-methylation of galactose is absent in both clusters; it may be encoded 
elsewhere in the genomes. 
Heterologous production in S. lividans. To determine genes necessary for 
phosphonoglycan production, we transferred pepM-containing fosmids (Figure 3.14) to S. lividans 
TK24, which is not known to produce any phosphonates. The culture extract from one 
recombinant strain, S. lividans MMG559, which harbored the putative phosphonoglycan gene 
cluster from Glycomyces, exhibited a peak in the 
31
P NMR spectrum with a chemical shift of 17.7 
ppm (Figure 3.15A). Addition of an authentic 2-HEP standard increased the intensity of the peak 
at 17.7 ppm. No new peaks were observed, indicating that the phosphonate species from this 
recombinant strain is 2-HEP (Figure 3.15A). The production of 2-HEP by S. lividans MMG559 
was further confirmed by high resolution LC-MS (Figure 3.15B). Similarly, recombinant strain S. 
lividans MMG598, which was integrated with the putative phosphonoglycan gene cluster from 
Stackebrandtia, also produced 2-HEP. This was again confirmed by both spiking the sample with 
an authentic 2-HEP standard and high-resolution LC-MS analysis (Figure 3.15C and D).  
 
Figure 3.15. Heterologous expression of putative phosphonoglycan gene clusters from 
Glycomyces and Stackebrandtia in S. lividans. (A) 
31
P NMR spectrum demonstrating 
heterologous expression of 2-HEP when transferring the phosphonoglycan gene cluster from 
Glycomyces to S. lividans. (top) Concentrated culture extract from S. lividans MMG559; (bottom)  
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Figure 3.15. (cont.) 
Concentrated culture extract from S. lividans MMG559 spiked with an authentic 2-HEP standard. 
(B) LC-FTMS analysis showing the presence of 2-HEP from S. lividans MMG559 culture extract. 
(C) 
31
P NMR spectrum demonstrating heterologous expression of 2-HEP when transferring the 
phosphonoglycan gene cluster from Stackebrandtia to S. lividans. (top) Concentrated culture 
extract from S. lividans MMG598; (bottom) Concentrated culture extract from S. lividans MMG598 
spiked with an authentic 2-HEP standard. (D) LC-FTMS analysis showing the presence of 2-HEP 
from S. lividans MMG598 culture extract.  
3.4 Discussion 
Phosphonate biosynthesis is both widespread and diverse in nature with more than 5% of 
sampled microbial cells encoding putative pepM gene (27). Gene neighborhood analyses have 
shown that most phosphonate biosynthetic pathways from sequenced microbial genomes are 
involved in the synthesis of phosphonate-containing structural components with 2-AEP as 
common constituents in lipids or glycans (27). 2-HEP may be an alternative head group in some 
phosphonate-containing macromolecules. For example, B. eggerthii DSM 20697 has the nearly 
identical phosphonate biosynthetic locus as B. fragilis polysaccharide B complex (3) but has 
replaced AEP biosynthetic genes with HEP biosynthetic genes; thus, it has been predicted to  
produce a HEP-decorated capsular polysaccharide, though direct experimental evidence is 
lacking (27). The occurrence of 2-HEP head group in a macromolecule has only been 
demonstrated from a novel biosurfactant isolated from the waterblooms of Aphanizomenon flos-
aquae (14). To the best of our knowledge, the structures described in the current study represent 
the first example of phosphonoglycans containing 2-HEP.  
Currently it is difficult to determine whether 2-HEP occurs randomly along the polysaccharide 
chain or whether 2-HEP is attached to certain sugars in some orderly arrangement. Detection of 
glycerol-HEP and HEP-hexose both by ester-linkages from the same sample after partial acid 
hydrolysis of phosphonoglycans from Glycomyces suggests that these two molecules may be 
part of a more complex structure. In fact, this is reminiscent of poly (glycerol-phosphate) teichoic 
acids present in the cell wall of some Gram-positive bacteria (4). Three species of Glycomyces, G. 
tenuis, G. rutgersensis and G. harbinensis were reported to produce species-specific cell wall 
teichoic acids with different structures (22). Given that phosphonoglycans from Glycomyces are 
also cell-bound, it is possible that they may be part of novel teichoic acid-like molecules with 2-
HEP as the side chain. If true, occurrence of a phosphonate head group in teichoic acids would 
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be unprecedented. No experiments have been conducted to directly test the physiological 
functions of phosphonate-containing macromolecules in any organism. It has been speculated 
that C-P bond, in place of C-O-P bond, in macromolecules, enhances the stability to hydrolysis by 
hydrolases, such as phosphatases, phospholipases and phosphodiesterases (12). Presumably, 
occurrence of 2-HEP in the cell membrane may have a similar function.  
The presence of various partially O-methylated galactosyl residues within a single 
polysaccharide structure is also highly unusual. Candidates for O-methylation of galactose are 
not found in either of the phosphonoglycan gene clusters. This may explain why heterologous 
expression of putative phosphonoglycan gene clusters in S. lividans only produced free 2-HEP. 
Furthermore, for the biosynthesis of a polysaccharide of such complexity, the machinery involved 
in polysaccharide assembly, export and regulation may be specific only to the native producer. 
Nevertheless, given that there is only one pepM homolog and hence only one phosphonate 
biosynthetic locus in each genome of Glycomyces and Stackebrandtia, demonstration of 2-HEP 
expression in S. lividans still provides evidence to link the gene clusters with the biosynthesis of 
phosphonoglycans.            
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CHAPTER 4: INDUCTION OF CRYPTIC PHOSPHONATE PATHWAYS IN ACTINOMYCETES 
 
4.1 Introduction 
Recent advances in next-generation sequencing technologies have greatly facilitated the 
genomics-guided approach for natural product discovery. Accumulating evidence has shown that 
for many microorganisms (especially those with large genomes), the metabolic capacities for 
secondary metabolites far exceed the known isolated compounds (4, 11, 22, 26). Many of those 
clusters are dormant or expressed at very low levels under standard laboratory culture conditions; 
hence they are usually referred to as “cryptic” or “silent” pathways (12, 13). Since they represent 
a valuable reservoir for novel chemical identities and bioactive constituents, it is of particular 
interest to induce the expression of cryptic pathways. In this regard, many successful strategies 
have been developed toward activating silent biosynthetic gene clusters, including optimizing 
culture conditions (media composition, pH, temperature, aeration, UV mutagenesis and heat 
shock) (6, 10, 16), co-culturing with other microorganisms (19, 26, 28, 29), introducing ribosomal 
mutations (also called “ribosome engineering”) (14, 31, 33), adding small-molecule elicitors (1, 3, 
27) and genetic engineering (heterologous expression, overexpression of positive regulatory 
genes and disruption of negative regulatory genes) (2, 5, 15, 23).  
Like many other classes of natural products, the predominance of cryptic pathways was also 
observed in phosphonates. Out of 346 pepM
+
 actinomycete strains identified from our collection, 
~85% failed to produce detectable levels of phosphonates under a single growth condition, 
although phosphonate production could be elicited in a small fraction of strains by simply varying 
the culture conditions or by adding small-molecule elicitors (e.g. N-acetyl-glucosamine). In this 
chapter, I describe attempts to induce cryptic phosphonate pathways in pepM
+ 
actinomycetes by 
co-culturing with other microbes and by introducing drug-resistant mutations. In this initial test, I 
focused on a set of 43 actinomycete isolates, comprising mostly Streptomyces, which are 
predicted to produce similar phosphonate products based on  80% sequence similarities of their 
respective PEP mutases.  
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4.2 Materials and Methods 
Strains, media and culture conditions. Strains used in this study are listed in Table 4.1. E. 
coli and Sinorhizobium meliloti were grown at 37°C in Luria-Bertani broth. Pseudomonas putida 
and Bacillus subtilis were grown at 30°C in Luria-Bertani broth. Actinomycete strains were grown 
at 30°C in ATCC 172 medium (9). Saccharomyces cerevisiae was grown at 30°C in Yeast 
Extract-Peptone-Dextrose (YPD) broth (Difco). Required supplements were added as follows if 
necessary to the minimal media: tryptophan (final concentration of 20 μg/mL for B. subtilis 168), 
methionine (final concentration of 50 μg/mL for S. melitoti) and biotin (final concentration of 1 
μg/mL for S. melitoti).  
Table 4.1. Microbial strains 
Strain  Relevant characteristics Source/Reference 
E. coli WM4489 Co-culturing strain; E. coli 
DH10B derivative 
(8) 
Bacillus subtilis 168 Co-culturing strain; trpC2 BGSC 
Sinorhizobium meliloti 1021  Co-culturing strain Dr. Stephen Farrand 
Streptomyces coelicolor A(3)2 Co-culturing strain ARS Culture Collection 
S. lividans TK24 Co-culturing strain (17) 
Pseudomonas putida PRS2000 Co-culturing strain (24) 
Saccharomyces cerevisiae Co-culturing strain Dr. Bradley Evans 
Streptomyces sp. MMG1662
a
 pepM
+
 strain (34) 
S. griseoluteus NRRL ISP-5360 pepM
+
 strain ARS Culture Collection 
S. varsoviensis NRRL B-3589 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3904 pepM
+
 strain ARS Culture Collection 
Streptomyces sp. NRRL WC-3704 pepM
+
 strain ARS Culture Collection 
S. albus NRRL F-4371
a
 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3899 pepM
+
 strain ARS Culture Collection 
S. lavendulae NRRL B-2775
a
 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3900 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3880 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3558 pepM
+
 strain ARS Culture Collection 
S. chartreusis NRRL WC-3882 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3925 pepM
+
 strain ARS Culture Collection 
Streptomyces sp. NRRL WC-3701 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL B-2626 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3930 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3898 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL B-8076 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3877 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL F-5621
a
 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3873
a
 pepM
+ 
strain ARS Culture Collection 
S. rimosus NRRL WC-3560 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3927 pepM
+
 strain  ARS Culture Collection 
S. rimosus NRRL B-2659 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3869 pepM
+
 strain ARS Culture Collection 
Streptomyces sp. NRRL WC-3703 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3875 pepM
+
 strain ARS Culture Collection 
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Table 4.1. (cont.)   
S. lavendulae NRRL WC-3532 pepM
+
 strain ARS Culture Collection 
S. aureofaciens NRRL B-2658
a
 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL B-2660 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3874 pepM
+
 strain ARS Culture Collection 
Streptomyces sp. NRRL B-3253
a
 pepM
+
 strain ARS Culture Collection 
Streptomyces sp. NRRL WC-3702 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3876 pepM
+
 strain ARS Culture Collection 
S. peucetius NRRL WC-3868 pepM
+
 strain ARS Culture Collection 
S. violaceusniger NRRL F-8817
a
 pepM
+
 strain ARS Culture Collection 
S. griseoflavus  NRRL B-1830
a
 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL B-3698 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3897 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL ISP-5260 pepM
+
 strain ARS Culture Collection 
S. rimosus NRRL WC-3896
a
 pepM
+
 strain ARS Culture Collection 
Streptosporangium roseum NRRL B-
2638 
pepM
+
 strain ARS Culture Collection 
Goodfellowiella coeruleoviolacea 
NRRL B-24058 
pepM
+
 strain ARS Culture Collection 
a 
These strains were used for preparations of drug-resistant mutants.  
Preparation of inocula and co-culturing methods. All co-culturing experiments were 
performed on solid media. Initially, co-culturing of pepM
+
 actinomycete strains (four selected 
strains) with a bacterial inducing strain (S. lividans, B. subtilis, E. coli, S. meliloti or P. putida) was 
done on ISP4+R2A plates, prepared by mixing media components of ISP4 (Difco) and 
Reasoner’s 2A (R2A) (32) in 1:1 ratio. Co-culturing of pepM
+
 actinomycete strains (the same four 
strains) with S. cerevisiae was done on ISP4+YMM plates, prepared by mixing media 
components of ISP4 (Difco) and yeast minimal medium (YMM) (0.67% yeast nitrogen base 
without amino acids (Difco), 2% glucose) in 1:1 ratio. Subsequently, a chemically defined solid 
medium (herein called “modular component medium”) (27.5 mM glycerol, 17.1 mM NaCl, 1.97 
mM MgCl2, 0.15 mM CaCl2, 6.71 mM KCl, 10 mM NH4HCl, 1 mM Na2SO4, 5 mM Na2HPO4, 0.1% 
trace element solution, 16% bacto agar) was used for co-cultivations of pepM
+
 strains (all 43 
strains) with either S. coelicolor or B. subtilis.  
To prepare starter cultures, pepM
+
 actinomycete strains and S. coelicolor were inoculated 
into glass culture tubes containing 5 mL of ATCC 172 medium and incubated at 30°C on a roller 
drum rotating (80 rpm) for 4-5 days, yielding condensed cultures. Starter cultures for S. melitoti 
were grown in the same manner except that it was inoculated to Luria-Bertani broth and agitated 
at 37°C. One day before actinomycete starter cultures were ready, B. subtilis, P. putida, E. coli 
and S. cerevisiae were inoculated, respectively, into glass culture tubes containing 5 mL of Luria-
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Bertani broth (YPD broth for S. cerevisiae) and agitated at 30°C (37°C for E. coli) overnight. Cells 
were harvested by centrifugation (10 min at 4925 g), washed once with R2A (YMM for S. 
cerevisiae) and resuspended in the same volume of R2A (YMM for S. cerevisiae). Cell 
suspensions of E. coli, B. subtilis and P. putida were diluted 10-fold in R2A broth whereas cell 
suspensions of S. cerevisiae were diluted 1000-fold in YMM broth. To a sterile Eppendorf tube, 
cell suspensions of a pepM
+ 
strain and an inducing strain (after dilution if indicated) were mixed in 
1:1 ratio, plated to the above mentioned co-culture plates (100 μL/plate, 3 plates/sample) and 
incubated at 30°C for additional 10 days. For a subset of 7 pepM
+ 
strains, the effect of plating 
different ratios of mixed cells on phosphonate induction was tested on the aforementioned 
modular component medium. Both monocultures of the pepM
+ 
strains and the inducing strains 
were grown in corresponding media as controls. All samples were processed and analyzed by 
31
P 
NMR for phosphonate production as described below.  
Preparation of drug-resistant mutants. Strains used to prepare spontaneous drug-
resistant mutants were listed in Table 4.1. Strains were inoculated to MS (2% soy flour, 2% 
mannitol, 2% agar) plates and incubated at 30°C for 7-10 days for sporulation. Spores were 
scraped off plates, washed once with Tryptic Soy Broth (also called TSB;Difco) and resuspended 
in TSB.  
To select for Str
R
 mutants, spore suspensions (>10
10
 spores), after heat activation (55°C, 15 
min), were spread to the yeast extract malt extract agar (ISP2 medium, Difco) plates with various 
concentrations of streptomycin (50, 100 and 200 μg/mL). To select for Rif
R
 mutants, heat-
activated spore suspensions (>10
10
 spores) were spread to ISP2 plates with various 
concentrations of rifampicin (50, 100 and 200 μg/mL). Plates were incubated at 30°C for 7-14 
days. Colonies that developed on the plates were purified by single-colony isolation. Pure 
colonies were inoculated to 5 mL of ATCC 172 medium with 50 μg/mL of streptomycin (or 
rifampicin). The cultures were grown at 30°C on a roller drum rotating (80 rpm) for 4 days and 
used as a seed culture. One hundred μL of the seed culture was spread to ISP4 agar plates (3 
plates/sample) and incubated at 30°C for 7 days. All samples were processed and analyzed by 
31
P NMR for phosphonate production as described below. 
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Sample analyses by NMR. Plates were frozen at -80°C, followed by subsequent thawing 
and squeezing, which allowed liquids to be liberated from agar. Liquids were concentrated 40-fold 
by rotary evaporation, filtered and resuspended in 20% D2O for NMR analyses. All NMR 
experiments were performed at room temperature on a Varian Inova 600 spectrometer equipped 
with a 5-mm Varian 600DB AutoX probe tuned for proton at 600 MHz and phosphorus at 242.83 
MHz at the University of Illinois, Urbana-Champaign. Chemical shifts are reported in δ (ppm), 
referenced to tetramethylsilane for 
1
H or 85% H3PO4 as an external standard for 
31
P chemical 
shifts. 
4.3 Results 
Phosphonate production was not induced by co-culturing. Mixed fermentations of 
microorganisms have been demonstrated to be a viable method to induce the production of novel 
metabolites or increase the yields of known metabolites (26). To examine the impact of microbial 
interactions on the biosynthesis of phosphonates, pepM
+
 actinomycete isolates were co-cultured 
with a collection of Gram-positive and Gram-negative bacterial strains as well as the yeast on 
different culture media. As exemplified in Figures 4.1 and 4.2, pigment production was induced in 
some co-cultures, which were absent in the monoculture controls, indicating induced gene 
expressions of certain secondary metabolites in co-cultures.  
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Figure 4.1. Co-culturing of pepM
+
 actinomycete isolates with bacterial inducing strains on 
ISP4+R2A plates. Co-culturing experiments were performed as described in “Materials and 
Methods”.  
 
Figure 4.2. Co-culturing of pepM
+
 actinomycete isolates with S. coelicolor or B. subtilis on the 
modular component medium. Co-culturing experiments were performed as described in  
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Figure 4.2. (cont.) 
“Materials and Methods”. To test the effect of plating different cell ratios of a pepM
+ 
strain and an 
inducing strain on phosphonate production, cells of a pepM
+ 
strain were mixed at 10:1 and 100:1 
ratios, respectively, with cells of B. subtilis. The ratios of cells plated for a pepM
+ 
strain and S. 
coelicolor were 1:1, 5:1 and 1:5, respectively.  
Metabolites from co-cultures as well as from individual strains were examined by 
31
P NMR 
for the presence of phosphonates. In the 
31
P NMR spectra, most C-P molecules tend to have a 
chemical shift between 5-40 ppm as opposed to the -20-5 ppm range observed for phosphate 
esters and anhydrides; however, notable exceptions exist where some phosphate esters also 
have a chemical shift in the phosphonate range (7, 25). Most co-culture samples from this study 
did not give a signal between 5-40 ppm in the 
31
P NMR spectra. Moreover, varying the cell ratios 
of a pepM
+
 strain and an inducing strain did not affect phosphonate production. Interestingly, four 
pepM
+
 strains, when cultured with other strains, produced tiny P peaks within the phosphonate 
range (Figure 4.3). However, combined treatments by alkaline phosphatase and 
phosphodiesterase eliminated these peaks in all but one of the samples, indicating that those 
signals probably originate from phosphate esters (Figure 4.3). Subsequent analyses of the one 
remaining sample, from S. griseoluteus NRRL ISP-5360 co-cultured with S. coelicolor, by strong 
acid hydrolysis and 2D NMR experiments indicated that this P signal also arises from a 
phosphate ester, despite its resistance to enzymatic treatments (Figure 4.4). Therefore, none of 
the co-culture experiments (131 combinations in total) reported induced phosphonate production 
within the limits of our detection methods.  
 118 
 
Figure 4.3. 
31
P NMR spectra of concentrated culture extracts of pepM
+
 actinomycetes co-cultured 
with other strains on the modular component medium. (A) 
31
P NMR spectra of concentrated 
monoculture and co-cultures of S. griseoluteus NRRL ISP-5360. Inducing strains were S. 
coelicolor or B. subtilis as indicated. (B) 
31
P NMR spectra of concentrated co-cultures of S. 
violaceusniger NRRL F-8817 with S. coelicolor. (C) 
31
P NMR spectra of concentrated co-cultures 
of S. rimosus NRRL B-8076 with S. coelicolor. (D)
 31
P NMR spectra of concentrated co-cultures of 
S. rimosus NRRL WC-3927 with S. coelicolor. NMR spectra were shown for samples before and 
after enzymatic treatments using alkaline phosphatase and phosphodiesterase. P peaks of 
interest were labeled with arrows.  
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Figure 4.4. The P peak produced by co-cultures of S. griseoluteus with S. coelicolor was 
probably not due to the presence of a phosphonate. (A) 
31
P NMR spectra of concentrated co-
cultures of S. griseoluteus with S. coelicolor before and after strong acid hydrolysis. Acid 
hydrolysis was performed using 3 M HCl under reflux (100
o
C, 3 h). The P peak with a chemical 
shift at 17.9 ppm (labeled with an arrow) was acid labile. (B) 
1
H-
31
P HMBC spectrum of the above 
concentrated co-cultured sample. The P peak at 17.9 ppm had cross-peaks with two proton 
signals at 4.08 and 4.60 ppm, resembling the typical coupling patterns of a phosphate ester. It 
showed no correlations with protons between 1-2 ppm, where the protons from CH2P should shift. 
Taken together, the P peak at 17.9 ppm was unlikely to arise from a phosphonate.   
Phosphonate production was not induced by introducing drug-resistant mutations. 
Modulating ribosomal proteins or rRNA by introducing drug-resistant mutations has also been 
shown to elicit bacterial secondary metabolism (20). Mutants resistant to streptomycin (or other 
drugs such as gentamicin, spectinomycin and kanamycin which target the ribosome) or rifampicin 
(which targets the RNA polymerase), in many examples, enhanced or activated antibiotic 
production by various actinomycetes (20, 30). To test whether the acquisition of streptomycin or 
rifampicin resistance could induce silent phosphonate biosynthetic gene clusters, spores of 
eleven pepM
+
 actinomycete isolates (Table 4.1) were plated to ISP2 agar plates containing 
different concentrations of streptomycin (or rifampicin) to select for spontaneous drug-resistant 
mutants, accompanied by 
31
P NMR screening for phosphonate production. Out of 50 mutants 
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screened, 
31
P NMR spectra of two samples showed P peaks in the phosphonate range; however, 
careful analyses by enzymatic treatments, strong acid hydrolysis or 2D NMR experiments 
indicated that those P peaks were unlikely to come from phosphonates (Figures 4.5 and 4.6).  
 
Figure 4.5. 
31
P NMR spectra of concentrated culture extracts of a rifampicin-resistant mutant of S. 
rimosus NRRL WC-3873 before and after enzymatic treatments. This mutant arose from an ISP2 
agar plate supplemented with 50 μg/mL of rifampicin. Enzymatic treatments were performed 
using alkaline phosphatase and phosphodiesterase, which digested the P peaks of interest 
(labeled with an arrow), indicating that they may come from phosphate esters.  
 
Figure 4.6. The P peak produced by a streptomycin-resistant mutant of Streptomyces sp. NRRL 
B-3253 was probably not due to the presence of a phosphonate. This mutant arose from an ISP2 
agar plate supplemented with 100 μg/mL of streptomycin. (A) 
31
P NMR spectra of concentrated 
culture extracts of a streptomycin-resistant mutant of Streptomyces sp. NRRL B-3253 before and 
after strong acid hydrolysis. Acid hydrolysis was performed using 3 M HCl under reflux (100
o
C, 3  
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Figure 4.6. (cont.) 
h). The P peak with a chemical shift at 18.1 ppm (labeled with an arrow) was acid labile. (B) 
1
H-
31
P HMBC spectrum of the above streptomycin-resistant mutant. The P peak at 18.1 ppm had 
cross-peaks with three proton signals at 3.97, 4.22 and 4.56 ppm, resembling the typical coupling 
patterns of a phosphate ester. It showed no correlations with protons between 1-2 ppm, where 
the protons from CH2P should shift. Taken together, the P peak at 18.1 ppm was unlikely to come 
from a phosphonate.   
4.4 Discussion 
Though still in its infancy, the application of co-culturing techniques have led to the discovery 
of at least nine new compounds with different biological activities (26). In reported examples, 
inducing conditions varied dramatically for different compounds, some requiring diffusible 
signaling molecules, some relying on direct cell-cell interactions while others depending on 
mechanisms yet to be identified. For example, the marine fungus Libertella sp., when cultured 
with an unidentified marine bacterium, produced four new diterpenoids, libertellenones A-D, 
which were not detected in pure cultures of the fungus or the bacterium (21). The induced 
production of these compounds appeared to be mediated by direct physical contacts of the two 
microorganisms, as neither the dead bacterial cells nor the cell-free supernatant could result in 
diterpene biosynthesis (21). In another example, co-culturing of Rhodococcus fascians with S. 
padanus led to the detections of two aminoglycoside antibiotics rhodostreptomycins A and B, 
which were not detected in pure cultures of individual strains; interestingly, there was a 
correlation between production of these two antibiotics and horizontal gene transfer from S. 
padanus to R. fascians (18). However, one should note the differences in those experiments and 
the experiment reported here. In other co-culture experiments, they may activate multiple gene 
clusters within a microorganism and look for induced product(s) from any of those clusters, 
whereas in our case, we specifically focus on a single pepM
+ 
locus to elicit phosphonate 
production from that particular locus. Apparently, the former potentially has higher possibilites of 
finding induced production of compounds than the latter.  
Microbial competition for limited space and nutrients is believed to the major selective force 
driving the production of bioactive secondary metabolites (21). In this regard, it is interesting to 
note that the syntheses of many bioactive molecules were enhanced or induced by microbes from 
highly competitive environments (e.g. plant or animal surfaces) (26). Actinomycetes are a group 
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of soil-dwelling microorganisms capable of producing a variety of natural products. By choosing 
Bacillus, Pseudomonas, Sinorhizobium and other actinomycetes as inducing strains, which are 
also commonly found in soils and are more likely to interact with actinomycetes, we tried to mimic 
the natural environments of actinomycetes in order to induce the silent phosphonate biosynthetic 
pathways in this group of microorganisms. Although initial experiments were not successful to 
detect induced production of phosphonates from tested microbe combinations, several factors 
could be considered to improve future experiments: (1) testing more microbe combinations; (2) 
testing timing of inoculation of the inducing strains and (3) testing different co-culture media. 
Regardless of which steps considered for optimization, it should be noted that the method of co-
culturing to induce a cryptic pathway is fortuitous in nature and usually the mechanism involved in 
triggering biosynthesis is less clear; therefore, screening a large amount of samples in various 
conditions is necessary to find a positive result. With that said, more efficient ways to prepare and 
analyze co-culture samples for phosphonate production are required.  
Selection of drug-resistant mutants is another method to turn on natural product synthesis. 
Examples included, but were not limited to, marked activations of cryptic secondary metabolite 
gene clusters in rifampicin- or streptomycin-resistant mutants of various actinomycetes (30, 31). 
The effect could be accumulated by sequentially selecting for multiple drug resistant mutants. For 
example, septuple and octuple mutants of S. coelicolor A(3)2, with resistance to seven or eight 
drugs, produced the polyketide antibiotic actinorhodin 180-fold higher than the wild type whereas 
introduction of a single drug-resistant mutation increased the yield of the same molecule only by 
10-fold (33). Unfortunately, we failed to detect phosphonate production from any rifampicin- or 
streptomycin-resistant mutants of pepM
+ 
actinomycetes. However, since selections for 
streptomycin-resistant mutants mediate the translational machinery (the ribosome) and selections 
of rifampicin-resistant mutants mediate the transcriptional machinery (the RNA polymerase), 
modulation of these two processes may act cooperatively to increase antibiotic production (20) . 
Therefore, it is worthwhile to select for multiple drug resistant mutants and examine how they 
affect phosphonate production. Furthermore, as mentioned above, more robust and sensitive 
methods other than 
31
P NMR spectroscopy are required to facilitate high throughput screening to 
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identify phosphonate producers as NMR techniques are not sensitive enough to detect molecules 
produced in low abundance.  
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CHAPTER 5: TESTING CORYNEBACTERIUM GLUTAMICUM AS A HETEROLOGOUS HOST 
FOR PHOSPHONATE PRODUCTION 
 
5.1 Introduction 
As described in Chapter 4, most pepM
+
 actinomycetes cultured under standard laboratory 
screening conditions
 
failed to
 
produce
 
phosphonates detectable by
 31
P NMR spectroscopy. 
Therefore, to facilitate rapid identification and evaluation of novel compounds, it is important to 
develop a suite of heterologous hosts for high-level expression of phosphonates. Traditionally, 
heterologous production of secondary metabolites from actinomycetes was performed in S. 
lividans, S. coelicolor or E. coli, because extensive tools are available for genetic manipulation in 
those organisms (1, 21). Streptomyces were also the heterologous hosts of choice when it came 
to expressing different phosphonate biosynthetic pathways (2-4, 22). However, evidence has 
shown that different heterologous hosts may have marked differences in compound yields, even 
when very closely related strains are tested, indicating the necessity of testing a wide range of 
expression hosts (1, 15).  
In this chapter, I describe a synthetic biology approach used for heterologous expression of 
2-HEP in Corynebacterium glutamicum, the industrial workhorse for large-scale production of 
amino acids, vitamins, nucleotides and numerous organic acids (8, 10). This microorganism was 
chosen due to its ease of cultivation, rapid growth rates and the availability of convenient genetic 
tools.  
5.2 Materials and Methods 
Strains, plasmids and culture conditions. Strains and plasmids used in this study are 
listed in Table 5.1. E. coli strains were grown at 37°C on Luria-Bertani agar or broth 
supplemented with antibiotics where appropriate. C. glutamicum strains were grown at 30°C, 
either in Luria-Bertani medium or in BMCG chemically defined medium (11) containing 50 mM 
glucose, succinate or pyruvate. Antibiotics were used for plasmid maintenance at the following 
concentrations: ampicillin 100 µg/ml and kanamycin 50 µg/ml (25 µg/ml for C. glutamicum). 
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Table 5.1. Bacterial strains, plasmids and oligonucleotides 
Strain  Relevant characteristics Source/Reference 
E. coli DH5pir Cloning host for 2-HEP synthetic constructs (9) 
E. coli MMG602 E. coli DH5pir transformed with plasmid pXY002 This chapter 
E. coli XY003 E. coli DH5pir transformed with plasmid pXY003 This chapter 
E. coli XY052 E. coli DH5pir transformed with plasmid pXY004 This chapter 
C. glutamicum 
Res
-
 AS019-E12 
Expression host for 2-HEP synthetic constructs (7) 
C. glutamicum 
NRRL B-2874 
Expression host for 2-HEP synthetic constructs ARS Culture Collection 
C. glutamicum 
XY068 
C. glutamicum Res
-
 AS019-E12 transformed with 
plasmid pXY002 
This chapter 
C. glutamicum 
XY042 
C. glutamicum Res
-
 AS019-E12 transformed with 
plasmid pXY003 
This chapter 
C. glutamicum 
XY056 
C. glutamicum Res
-
 AS019-E12 transformed with 
plasmid pXY004 
This chapter 
C. glutamicum 
XY062 
C. glutamicum NRRL B-2874 transformed with 
plasmid pXY002 
This chapter 
C. glutamicum 
XY060 
C. glutamicum NRRL B-2874 transformed with 
plasmid pXY003 
This chapter 
C. glutamicum 
XY063 
C. glutamicum NRRL B-2874 transformed with 
plasmid pXY004 
This chapter 
Plasmid Relevant characteristics Source/Reference 
pKSJ283 E. coli-C. glutamicum shuttle vector; Kan
R
 Dr. Kou-San Ju 
pXY002 Derivative of pKSJ283; two BbsI sites were 
introduced to the MCS site 
This chapter 
pBMH-2-HEP-1 A partial fragment of the original 2-HEP synthetic 
construct cloned into pBMH vector; Amp
R
 
This chapter 
pBMH-2-HEP-2 A partial fragment of the original 2-HEP synthetic 
construct cloned into pBMH vector; Amp
R
 
This chapter 
pBMH-2-HEP-3 A partial fragment of the original 2-HEP synthetic 
construct cloned into pBMH vector; Amp
R
 
This chapter 
pBMH-revised-2-
HEP-1 
A partial fragment of the revised 2-HEP synthetic 
construct cloned into pBMH vector; Amp
R
 
This chapter 
pBMH-revised-2-
HEP-2 
A partial fragment of the revised 2-HEP synthetic 
construct cloned into pBMH vector; Amp
R
 
This chapter 
pBMH-revised-2-
HEP-3 
A partial fragment of the revised 2-HEP synthetic 
construct cloned into pBMH vector; Amp
R
 
This chapter 
pXY003 Original 2-HEP synthetic construct assembled and 
cloned into pXY002 by Golden Gate assembly; 
Kan
R
 
This chapter 
pXY004 Revised 2-HEP synthetic construct assembled and 
cloned into pXY002 by Golden Gate assembly; 
Kan
R
 
This chapter 
Primer Sequence (5'-3') 
BbsI-oligosF 5'-
CTCACCGAATTCTACATCGTCTTCGAAGACGAGATATCGTGCACGTGAG
CTCCTAGGC-3' 
BbsI-oligosR 5'-
GCCTAGGAGCTCACGTGCACGATATCTCGTCTTCGAAGACGATGTAGA
ATTCGGTGAG-3' 
CGpepMF 5'-GCCTGATCGACGCAAAGCCA-3' 
CGpepMR 5'-TGCGGTGAACGAAGTCCTCG-3' 
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Table 5.1. (cont.) 
CGppdF 5'-GCACTGATCGCAGCAGCAGA-3' 
CGppdR 5'-CAGTGCCTTTGCTGCTGCTG-3' 
CGadhF 5'-TGGTTGAGCGCTTCGACCCA-3' 
CGadhR 5'-CCTCGATTGCTGGAACCAGC-3' 
Reagents. BbsI and T4 DNA ligase were purchased from Invitrogen (Carlsbad, CA) and New 
England Biolabs (Ipswich, MA). The oligonucleotide PCR primers were obtained from Integrated 
DNA Technologies (Coralville, IA), listed in Table 5.1. HisProbe-HRP (Thermo Scientific), which 
was used to detect His-tagged proteins, was a gift from Dr. John Gerlt, University of Illinois at 
Urbana-Champaign. Horseradish peroxidase (HRP)-conjugated goat-anti-rabbit immunoglobulin 
G (IgG) was provided by Dr. Wilfred van der Donk, University of Illinois at Urbana-Champaign. 
DNA isolation and manipulation. All DNA manipulations were performed using established 
protocols (19). Plasmids isolated using the Qiagen (Valencia, CA) Miniprep kit were used as the 
template for PCR amplifications of pepM, ppd and adh gene fragments with primers listed in 
Table 5.1. PCR amplifications were performed with GoTaq Green Master Mix (Promega). 
Plasmid construction. The Golden Gate receiver plasmid, pXY002, was modified from an E. 
coli-C. glutamicum shuttle vector pKSJ283 by introducing two BbsI sites into the MCS. Briefly, 
two 58-mer reverse-complemented oligonucleotides (Table 5.1) containing two BbsI sites were 
synthesized and annealed to generate a cassette with EcoRI and SacI restriction enzyme 
overhangs. Plasmid pKSJ283 was digested with EcoRI and SacI and purified by gel 
electrophoresis. The annealed cassette was ligated to the double-digested pKSJ283 vector with 
T4 DNA ligase and the reaction was carried out at 4°C overnight. The ligation product was 
transformed to chemically competent cells of E. coli DH5pir and selected on a LB agar 
supplemented with kanamycin (50 µg/ml). Plasmids were isolated and the nucleotide sequence 
was verified by automated DNA sequencing at the Roy J. Carver Biotechnology Center at the 
University of Illinois at Urbana-Champaign. 
2-HEP construct design and synthesis. Genes encoding PEP mutase (PepM), PnPy 
decarboxylase (Ppd) and alcohol dehydrogenase (Adh) were chosen from the biosynthetic locus 
involved in the synthesis of 2-HEP containing phosphonoglycans of Glycomyces sp. NRRL B-
16802 (Chapter 3). These three genes were codon optimized using Optimizer (17) by referring to 
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the codon usage of predicted highly expressed genes (HEG) of C. glutamicum ATCC 13032 
Kitasato with One AA-one codon as the method. Each of the three genes was originally designed 
to be flanked by a different set of synthetic promoters (24) and terminators (12, 13, 23) known to 
have high activities in C. glutamicum. For gene syntheses, the construct was divided into three 
partial fragments. One BbsI site and unique 4 bp recombination sites (tags 1 to 4) were added to 
both 5' and 3' ends of partial fragments, allowing for Golden Gate assembly (5) of these 
fragments in a specified order with the receiver plasmid pXY002 (Figure 5.1A). The construct was 
subsequently revised to replace all synthetic promoters with natural promoters previously shown 
to have high activities in C. glutamicum (16) (Figure 5.1B); an epitope tag (FLAG tag, His tag or 
Strep tag II) was added at the 5' terminus of each gene to facilitate detection of protein 
expression by Western blotting. Partial fragments for both constructs were synthesized and 
cloned into the cloning vector pBMH (Amp
R
) by Biomatik (Wilmington, Delaware).  
 
Figure 5.1. Schematic representations of synthetic gene fragments designed to reconstruct the 2-
HEP biosynthetic pathway in C. glutamicum. (A) Synthetic DNA fragments with synthetic 
promoters. (B) Revised synthetic DNA fragments with natural promoters and N-terminal epitope 
tags. Differences in construct design between (A) and (B) were highlighted in red. Construct 
designs were described in “Materials and Methods” and gene fragments were synthesized by 
Biomatik (Wilmington, Delaware).  
Golden Gate assembly and transformation. Golden Gate assembly of 2-HEP synthetic 
fragments with plasmid pXY002 was performed as described (6) (Figure 5.2). Transformations of 
E. coli and C. glutamicum cells were carried out using standard protocols (19, 20).  
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Figure 5.2. The strategy for plasmid construction. Plasmid pXY004 was constructed through 
Golden Gate assembly of three plasmids cloned with partial 2-HEP synthetic fragments and E. 
coli-C. glutamicum shuttle vector pXY002. By carefully choosing the 4 bp overhang (tags 1 to 4) 
created by BbsI, the 2-HEP pathway was assembled in a specified manner. BbsI recognition sites 
were highlighted in red. Tags shadowed in the same color were designed to be complementary 
after BbsI digestion. Tags have 4 nucleotides with following sequences: tag1, TACA; tag2, ATCT; 
tag3, GCTT; tag4, GATA. The same strategy was used to construct plasmid pXY003.  
Checking 2-HEP production by recombinant C. glutamicum strains. Recombinant C. 
glutamicum strains transformed with pXY002 (empty vector), pXY003 (original 2-HEP synthetic 
construct cloned into pXY002) or pXY004 (revised 2-HEP synthetic construct cloned into pXY002) 
were cultivated as follows. Strains were first inoculated into 5 mL of Luria-Bertani broth 
supplemented with kanamycin (25 µg/ml) and incubated at 30°C on a roller drum overnight. Next, 
1 mL of starter cultures were used to inoculate 100 mL of either Luria-Bertani, BMCG (containing 
50 mM glucose, pyruvate or succinate, respectively) or R2AS (per L: 10.8 g sodium succinate 
hexahydrate, 0.5 g yeast extract, 0.5 g peptone, 0.5 g casamino acids, 0.5 g glucose, 0.5 g potato 
starch, 0.3 g sodium pyruvate, 0.3 g monobasic potassium phosphate and 0.05 g magnesium 
sulfate heptahydrate) broth supplemented with kanamycin (25 µg/ml) in 500 mL flasks. Flasks 
were incubated at 30°C on a rotary shaker at 200 rpm for 3 days.  
Culture supernatants were concentrated 40-fold by rotary evaporation and treated with 70% 
methanol. After centrifugation (4925 g, 10 min) to remove precipitates, supernatants were 
concentrated again by rotary evaporation to remove methanol and lyophilized. Samples were 
redissolved in 20% D2O for NMR analyses. All NMR experiments were performed at room 
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temperature on a Varian Inova 600 spectrometer equipped with a 5-mm Varian 600DB AutoX 
probe tuned for proton at 600 MHz and phosphorus at 242.83 MHz at the University of Illinois, 
Urbana-Champaign. Chemical shifts are reported in δ (ppm), referenced to tetramethylsilane for 
1
H or 85% H3PO4 as an external standard for 
31
P chemical shifts. 
Protein analyses. Cells from the aforementioned 100 mL cultures were harvested by 
centrifugation, washed once with 10 mM Tris-HCl buffer (pH 7.5) and resuspended in 5 mL of the 
same buffer for sonication. Cell suspensions were disrupted on ice for 10 25 sec cycles, with 60 
sec pauses between each cycle using a Microson Ultrasonic Cell Disruptor (Misonix, Farmingdale, 
NY) at power level 7. The suspension was centrifuged at 4925 g for 10 min at 4
 
°C to pellet cell 
debris. Cell lysates were analyzed for protein concentration by the Bradford assay, using 
reagents from Thermo Scientific. Both cell lysates and cell debris were analyzed by SDS-PAGE 
(12% acrylamide gel in Tris-glycine buffer). Duplicate gels were made and run, one for Western 
blotting and the other for visualization by Coomassie blue staining. Following electrophoresis, 
proteins were transferred to a nitrocellulose membrane (Bio-Rad). Membranes were washed with 
deionized water for 1 min, followed by incubation in TBS buffer containing 0.1% Tween-20 (TBST) 
and 5% non-fat milk for 1 h. Membranes were then washed once with deionized water and 
incubated at 4
 
°C with gentle shaking overnight in diluted primary antibodies or HisProbe-HRP. 
The following primary antibodies or probes were used to probe for epitope-tagged proteins: rabbit 
monoclonal anti-FLAG antibody (1:5000; Sigma), mouse monoclonal anti-StrepMAB-classic-HRP 
(1:4000; IBA) and HisProbe-HRP (1:5000; Thermo Scientific). Following three additional washes 
with TBST buffer, the membrane initially incubated with rabbit monoclonal anti-FLAG antibody 
was incubated in StartingBlock Blocking Buffers (Thermo Scientific) containing HRP-conjugated 
goat-anti-rabbit IgG (1: 5000; Cell Signaling). Immunoblots were developed using ECL 2 Western 
Blotting Substrate (Pierce) following the manufacturer’s directions. For chemifluorescence 
detection, bands were visualized with a Molecular Dynamics Typhoon 9410 Molecular Imager 
(Amersham Biosciences) using a 457 nm blue laser and a 520 BP 40 emission filter. 
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5.3 Results 
Plasmid design. A 2-HEP production plasmid was designed to express the genes encoding 
PepM, Ppd and Adh from three sets of promoters and terminators. Plasmids pXY003 (original 2-
HEP synthetic construct cloned into pXY002) and pXY004 (revised 2-HEP synthetic construct 
cloned into pXY002) were both assembled by four genetic fragments with the assembly scheme 
illustrated in Figure 5.2. In the original construct, promoters selected for pepM, ppd and adh are 
synthetic promoters H36, H3 and H28 previously described (24), whereas terminators for the 
three genes are thrB terminator, trp attenuator and lysA terminator. In the revised construct, 
synthetic promoters for pepM, ppd and adh were replaced with three natural promoters, leuA 
promoter, Phom promoter and Pper promoter. After transforming plasmids to E. coli and verifying 
that the constructs were correct by restriction digestions (data not shown), plasmids were 
electroporated to two C. glutamicum strains: a wildtype strain and a Res
- 
strain. Successful 
uptakes of plasmids by C. glutamicum strains were demonstrated by PCR amplifications of gene 
fragments of pepM, ppd and adh (Figure 5.3).  
 
Figure 5.3. PCR amplifications of pepM, ppd and adh gene fragments from plasmids isolated 
from recombinant C. glutamicum strains. Lane M, 2-Log DNA ladder (NEB); lane 1, the PCR 
product amplified with primers CGpepMF/CGpepMR (expected: 414 bp); lane 2, the PCR product 
amplified with primers CGppdF/CGppdR (expected: 375 bp), lane 3, the PCR product amplified  
 133 
Figure 5.3. (cont.) 
with primers CGadhF/CGadhR (expected: 441 bp). (A) pepM, ppd and adh gene fragments 
amplified from pXY003 isolated from recombinant C. glutamicum Res
-
 AS019-E12. (B) pepM, ppd 
and adh gene fragments amplified from pXY003 isolated from recombinant C. glutamicum NRRL 
B-2874. (C) pepM, ppd and adh gene fragments amplified from pXY004 isolated from 
recombinant C. glutamicum Res
-
 AS019-E12. (D) pepM, ppd and adh gene fragments amplified 
from pXY004 isolated from recombinant C. glutamicum NRRL B-2874.  
Screening of 2-HEP production by 
31
P NMR. To determine whether the synthetic 2-HEP 
pathway was functional, C. glutamicum strains (both the wildtype and the Res
-
 strains) 
transformed with pXY003 or pXY004 were grown in different culture media and the concentrated 
supernatants were analyzed by 
31
P NMR for 2-HEP. Only the wildtype C. glutamicum strain 
transformed with pXY004 produced a P signal consistent with 2-HEP production (Figure 5.4A). 
The production of 2-HEP was confirmed by spiking the sample with authentic 2-HEP, strong acid 
hydrolysis and 
1
H-
31
P HMBC NMR (Figure 5.4). Unfortunately, this positive result could not be 
reproduced. Although growing the same clone or other clones (all verified to have pXY004 
successfully transformed into cells of the wildtype C. glutamicum) later in the same medium or 
other culture media could reproducibly produce a P peak in the phosphonate range (albeit with 
slight differences in the chemical shift compared with the positive result) (Figure 5.5), those P 
peaks were susceptible to strong acid hydrolysis, indicating that they were unlikely to be 2-HEP. 
Part of the reasons may be attributed to plasmid instability. When plating the overnight culture of 
the recombinant C. glutamicum NRRL B-2874 (transformed with pXY004) on LB agar with and 
without kanamycin, about half of the clones lost the plasmid without kanamycin selection (Table 
5.2). Whether this was the cause of the irreproducibility of 2-HEP production needs to be further 
investigated.  
Table 5.2. Evaluations of pXY004 stability in C. glutamicum NRRL B-2874 
Dilution of overnight 
culture  
No. of colonies on LB 
plate on day 3 
No. of colonies on LB/Kan25 
plate on day 3 
10
-6
 112 86 
10
-7
 11 6 
10
-8
 2 1 
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Figure 5.4. C. glutamicum NRRL B-2874 when transformed with plasmid pXY004 (revised 2-HEP 
construct cloned into pXY002) produced 2-HEP. (A) 
31
P NMR spectra of C. glutamicum NRRL B-
2874 transformed with pXY002 (empty vector) (top) or pXY004 (middle). The culture medium was 
chemically defined BMCG broth supplemented with 1% glucose. Spiking the 2-HEP standard into 
the sample that produced a P peak at 21.6 ppm (bottom) did not result in the formation of a new 
peak while the intensity of the peak at 21.6 ppm increased indicating that this peak is 2-HEP. (B) 
31
P NMR spectra of recombinant C. glutamicum NRRL B-2874 (transformed with pXY004) before 
and after acid hydrolysis. Acid hydrolysis was undertaken using 6 M HCl under reflux (100 
o 
C, 3 
h). The peak at 21.6 ppm was acid-stable. The differences in chemical shifts before and after acid 
hydrolysis were due to pH. (C) 
1
H-
13
C HMBC spectrum of recombinant C. glutamicum NRRL B-
2874 (transformed with plasmid pXY004) grown in BMCG broth supplemented with 1% glucose. 
This sample was first treated with 70% methanol. After centrifugation to remove precipitates, the 
liquid portion was completely dried by rotary evaporation and resuspended in water. Next, it was 
applied to activated charcoals and eluted with 70% methanol. The eluent was then completely 
dried again by rotary evaporation and resuspended in 20% D2O for NMR analyses. The P peak of 
interest (labeled in red) at 21.1 ppm had correlations with two H signals at 1.81 and 3.66 ppm, in 
accord with the expected coupling patterns for 2-HEP. The identity of the P peak at 22.9 ppm was 
unknown.  
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Figure 5.5. 
31
P NMR spectra of recombinant C. glutamicum NRRL B-2874 (transformed with 
pXY004) grown in different culture media. All produced a P peak (note: there were multiple P 
peaks in the R2AS medium) in the range of 19-20 ppm, slightly different from the chemical shift of 
the original P peak (21 ppm) observed in the positive result. These P peaks were all susceptible 
to strong acid hydrolysis, a second trait distinct from the positive result shown in Figure 5.4.  
Analyses of protein expression. To analyze whether PEP mutase, PnPy decarboxylase 
and alcohol dehydrogenase were expressed, total cellular proteins of recombinant C. glutamicum 
strains (transformed with pXY003 or pXY004) were resolved by SDS-PAGE. No protein bands 
corresponding to the predicted sizes of these three enzymes were observed compared to 
negative controls (data not shown). Therefore, it was decided to use Western blotting to detect 
the expression of PepM, Ppd and Adh bearing a N-terminal epitope tag. Results were shown in 
Figure 5.6. Due to the presence of a high background, it was difficult to conclude whether all 
three enzymes were expressed although FLAG-tagged PepM and His-tagged PnPy appeared to 
be expressed and detected in the insoluble protein fraction. The protocol for Western blotting 
needs to be optimized in future experiments to get cleaner results.  
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Figure 5.6. Western blot to detect expression of PepM, PnPy decarboxylase and alcohol 
dehydrogenase from C. glutamicum NRRL B-2874 transformed with pXY004. Methods for sample 
preparations and Western blot were described in “Materials and Methods”. Cell extracts prepared 
from C. glutamicum NRRL B-2874 transformed with pXY002 cultured in the same condition were 
used as negative controls. M, Precision Plus Protein Dual Color standard (Bio-Rad); S, soluble 
proteins; P, cell pellets after sonication; PC, a N-terminal His-tagged protein (26 kDa). (A) 
Western blot using Anti-FLAG mAb to detect N-terminal FLAG-tagged PepM mutase (expected 
size: 48.19 kDa). (B) Western blot using Anti-His mAb to detect N-terminal His-tagged PnPy 
decarboxylase (expected size: 42.25 kDa). (C) Western blot using Anti-Strep mAb to detect N-
terminal Strep-tagged alcohol dehydrogenase (expected size: 43.57 kDa). Potential protein bands 
of interest were highlighted in red. Due to high background, it was difficult to tell whether the three 
enzymes were expressed. 
5.4 Discussion 
In this chapter, I present a synthetic biology approach to manipulate C. glutamicum to 
produce phosphonates, which can serve as a starting point for further metabolic engineering in 
order to improve the compound yield. 2-HEP production was confirmed from a recombinant C. 
glutamicum strain harboring the plasmid encoding genes required for 2-HEP biosynthesis. 
However, reproducibility of 2-HEP production became an issue later on, partially attributed to 
plasmid instability or insufficient enzyme expression due to the low copy number of the plasmid.  
To yield the final compound in a heterologous host, not only enzymes in the pathway should 
be expressed and functional, but also their activities should be coordinated. This can be achieved 
by tuning gene expression at the transcriptional (e.g. using promoters of different strengths for 
different enzymes) or the translational level (e.g. using RBSs with different strengths for different 
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enzymes) or both (14, 18). Unfortunately, even fine-tuning gene expression by using different 
promoters or RBSs may not always guarantee the success of heterologous expression. For 
example, the metabolic fluxes may not be tuned properly to provide all necessary precursors or 
cofactors in sufficient quantities. Alternatively, biosynthetic enzymes may be susceptible to 
proteolytic degradations. Whether any of these is the cause of inconsistent results in our 
experiment merits further inspection.  
In a good construct design, as in the first synthetic biology framework for genetic engineering 
of C. glutamicum presented by Ravasi and his coworkers (18), all plasmid-based components 
influencing gene expression (e.g. transcriptional regulator, promoter and RBS) should be easily 
exchangeable to facilitate rapid testing to find out the right combination of different regulatory 
elements. For this purpose, it is essential to have a toolbox with a collection of promoters and 
RBSs which can provide different levels of gene expression (18). Building a synthetic biology 
platform like this will be of tremendous value to designing versatile heterologous host strains and 
enabling efficient phosphonate screening and production.  
5.5 References 
1. Baltz, R. H. 2010. Streptomyces and Saccharopolyspora hosts for heterologous 
expression of secondary metabolite gene clusters. Journal of Industrial Microbiology & 
Biotechnology 37:759-772. 
2. Blodgett, J. A. V., J. K. Zhang, and W. W. Metcalf. 2005. Molecular cloning, sequence 
analysis, and heterologous expression of the phosphinothricin tripeptide biosynthetic 
gene cluster from Streptomyces viridochromogenes DSM 40736. Antimicrobial Agents 
and Chemotherapy 49:230-240. 
3. Circello, B. T., A. C. Eliot, J. H. Lee, W. A. van der Donk, and W. W. Metcalf. 2010. 
Molecular cloning and heterologous expression of the dehydrophos biosynthetic gene 
cluster. Chemistry & Biology 17:402-411. 
4. Eliot, A. C., B. M. Griffin, P. M. Thomas, T. W. Johannes, N. L. Kelleher, H. M. Zhao, 
and W. W. Metcalf. 2008. Cloning, expression, and biochemical characterization of 
Streptomyces rubellomurinus genes required for biosynthesis of antimalarial compound 
FR900098. Chemistry & Biology 15:765-770. 
5. Engler, C., R. Kandzia, and S. Marillonnet. 2008. A one pot, one step, precision cloning 
method with high throughput capability. PLoS One 3:e3647. 
6. Engler, C., and S. Marillonnet. 2013. Combinatorial DNA assembly using Golden Gate 
cloning, p. 141-156. In K. M. Polizzi and C. Kontoravdi (ed.), Synthetic Biology, vol. 1073. 
Humana Press Inc, Totowa. 
 138 
7. Follettie, M. T., and A. J. Sinskey. 1986. Recombinant DNA technology for 
Corynebacterium glutamicum. Food Technology 40:88-94. 
8. Hermann, T. 2003. Industrial production of amino acids by coryneform bacteria. Journal 
of Biotechnology 104:155-172. 
9. Kolter, R., M. Inuzuka, and D. R. Helinski. 1978. Trans-complementation-dependent 
replication of a low molecular weight origin fragment from plasmid R6K. Cell 15:1199-
1208. 
10. Leuchtenberger, W., K. Huthmacher, and K. Drauz. 2005. Biotechnological production 
of amino acids and derivatives: current status and prospects. Applied Microbiology and 
Biotechnology 69:1-8. 
11. Liebl, W., R. Klamer, and K. H. Schleifer. 1989. Requirement of chelating compounds 
for the growth of Corynebacterium glutamicum in synthetic media. Applied Microbiology 
and Biotechnology 32:205-210. 
12. Mateos, L. M., A. Pisabarro, M. Patek, M. Malumbres, C. Guerrero, B. J. Eikmanns, 
H. Sahm, and J. F. Martin. 1994. Transcriptional analysis and regulatory signals of the 
hom-thrb cluster of Brevibacterium lactofermentum. Journal of Bacteriology 176:7362-
7371. 
13. Matsui, K., K. Miwa, and K. Sano. 1987. Two single-base-pair substitutions causing 
desensitization to tryptophan feedback inhibition of anthranilate synthase and enhanced 
expression of tryptophan genes of Brevibacterium lactofermentum. Journal of 
Bacteriology 169:5330-5332. 
14. Medema, M. H., R. Breitling, R. Bovenberg, and E. Takano. 2011. Exploiting plug-and-
play synthetic biology for drug discovery and production in microorganisms. Nature 
Reviews Microbiology 9:131-137. 
15. Ongley, S. E., X. Y. Bian, B. A. Neilan, and R. Muller. 2013. Recent advances in the 
heterologous expression of microbial natural product biosynthetic pathways. Natural 
Product Reports 30:1121-1138. 
16. Patek, M., G. Muth, and W. Wohlleben. 2003. Function of Corynebacterium glutamicum 
promoters in Escherichia coli, Streptomyces lividans, and Bacillus subtilis. Journal of 
Biotechnology 104:325-334. 
17. Puigbo, P., E. Guzman, A. Romeu, and S. Garcia-Vallve. 2007. OPTIMIZER: a web 
server for optimizing the codon usage of DNA sequences. Nucleic Acids Research 
35:W126-131. 
18. Ravasi, P., S. Peiru, H. Gramajo, and H. G. Menzella. 2012. Design and testing of a 
synthetic biology framework for genetic engineering of Corynebacterium glutamicum. 
Microbial Cell Factories 11:147-157. 
19. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory 
Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Woodbury, NY. 
20. van der Rest, M. E., C. Lange, and D. Molenaar. 1999. A heat shock following 
electroporation induces highly efficient transformation of Corynebacterium glutamicum 
with xenogeneic plasmid DNA. Applied Microbiology and Biotechnology 52:541-545. 
 139 
21. Winter, J. M., and Y. Tang. 2012. Synthetic biological approaches to natural product 
biosynthesis. Current Opinion in Biotechnology 23:736-743. 
22. Woodyer, R. D., Z. Y. Shao, P. M. Thomas, N. L. Kelleher, J. A. V. Blodgett, W. W. 
Metcalf, W. A. Van der Donk, and H. M. Zhao. 2006. Heterologous production of 
fosfomycin and identification of the minimal biosynthetic gene cluster. Chemistry & 
Biology 13:1171-1182. 
23. Yeh, P., A. M. Sicard, and A. J. Sinskey. 1988. Nucleotide sequence of the IysA gene 
of Corynebacterium glutamicum and possible mechanisms for modulation of its 
expression. Molecular & General Genetics 212:112-119. 
24. Yim, S. S., S. J. An, M. Kang, J. Lee, and K. J. Jeong. 2013. Isolation of fully synthetic 
promoters for high-level gene expression in Corynebacterium glutamicum. Biotechnology 
and Bioengineering 1:2959-2969. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 140 
CHAPTER 6: CONCLUSIONS  
 
6.1 Summary and Narrative of Findings 
6.1.1 Phosphonate biosynthetic pathways are prevalent and diverse (Chapter 2) 
Recent renewed interest in phosphonates and phosphinates stems from the observation that 
they could potentially target a wide array of cellular pathways involving phosphate esters and 
carboxylates. Known phosphonate (or phosphinate)-containing natural products have 
demonstrated an impressive range of biological activities including antibacterial, antifungal, 
antimalarial, herbicidal and antihypertensive properties. The Metcalf lab has great interest in 
identifying new phosphonate-producing microorganisms and discovering novel phosphonate-
containing natural products with therapeutic and biotechnological potential. Two questions central 
to this effort are: how common is phosphonate biosynthesis, and how diverse are phosphonate 
biosynthetic pathways in nature?  
To address the first question, I analyzed the occurrence of pepM homologs, which is used as 
a molecular marker for phosphonate biosynthetic capacity, in sequenced microbial genomes, 
GOS marine metagenomes as well as IMG/M microbiome datasets. I found that phosphonate 
biosynthesis is common in microbes as ~5% of sequenced microbial genomes and 7% of 
genome equivalents in metagenomic datasets carried pepM homologs. Using PhymmBL, a 
bioinformatics tool for phylogenetic classification of metagenomic reads, I showed that the 
biosynthetic potential for phosphonates is widely distributed in diverse microbial taxa. In addition, 
with the assistance of other lab members, we screened 2,622 actinomycete isolates (from local 
soils and USDA-ARS actinobacteria collection) with degenerate pepM PCR primers and found 
4.6% of those strains encoded pepM.  
The research effort of the Metcalf lab is focused on actinomycetes due to our interest in 
bioactive phosphonates. Towards this end, with the assistance of other lab members, I cloned 
and sequenced phosphonate biosynthetic gene clusters from 25 actinomycete isolates. To 
address the second question about the diversity of phosphonate biosynthetic pathways, these 25 
clusters were analyzed and compared with those found in sequenced microbial genomes. 
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Together with Dr. James Doroghazi, we showed that phosphonate biosynthetic pathways are 
highly diverse. In particular, most of the actinomycete strains examined in this study have unique 
pepM gene neighborhoods or are similar to those from known phosphonate antibiotic producers, 
supporting the idea that actinomycetes represent a valuable source for bioactive phosphonates. 
Furthermore, we found that there is a direct and linear correlation between PepM sequence 
conservation and conservation of nearby genes, suggesting the diversity of the phosphonate 
biosynthetic pathways could be inferred by studying PepM diversity. To estimate the range of 
phosphonate biosynthetic pathways, I performed rarefaction analyses of pepM genes from 
different datasets, which predicted that hundreds of unique phosphonate biosynthetic pathways 
remain to be discovered in nature.  
6.1.2 Identification and structural characterization of phosphonoglycans from Glycomyces 
and Stackebrandtia (Chapter 3) 
During the course of screening a large collection of actinomycetes for phosphonates, I 
identified two novel phosphonate producers: Glycomyces sp. NRRL B-16210 and Stackebrandtia 
nassauensis NRRL B-16338. Both produced high amounts of phosphonate-containing molecules, 
which were identified to be phosphonate-containing polysaccharides (also called 
phosphonoglycans). Purification protocols for these molecules were developed that involved 
successive organic solvent extractions, methanol precipitation and ultrafiltration. To elucidate the 
polysaccharide structures, I collaborated with Dr. Neil Price from the USDA-ARS lab, who was 
able to determine sugar components and sugar linkages for both phosphonoglycans. 
Interestingly, phosphonoglycans from Glycomyces and Stackebrandtia both contain a variety of 
O-methylated galactose residues unprecedented in known bacterial polysaccharides. Using 
isotopic labeling studies, we showed that O-methyl groups on the monomethylated galactose 
residues derive from S-adenosylmethionine. However, the gene responsible for O-methylation of 
galactose was not identified.  
The phosphonate moiety in both phosphonoglycans was shown to be 2-HEP following strong 
acid hydrolysis. These are the first examples of glycans substituted with 2-HEP, as opposed to 2-
AEP. To elucidate the linkage of 2-HEP to polysaccharides, I unsuccessfully attempted enzymatic 
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hydrolysis with different sugar hydrolases with the purpose of breaking down the molecules (40-
50 kDa in size). Subsequently, I turned to partial acid hydrolysis. Due to the random nature of 
chemical hydrolysis, this resulted in a mixture of polymeric HEP-bound oligosaccharides as well 
as unbound HEP in Glycomyces, from which I purified the smallest possible phosphonylated 
sugars for structural analyses. By NMR and LC-MS (performed by Dr. Bradley Evans) 
characterizations, we showed that 2-HEP from Glycomyces was linked to a hexose (presumably 
galactose), in ester linkage at the O-5 or O-6 position. We also detected 2-HEP mono(2,3-
dihydroxypropyl) ester. Partial acid hydrolysis of Stackebrandtia phosphonoglycans revealed an 
identical 2-HEP mono(2,3-dihydroxypropyl) ester. 
In order to provide genetic evidence to link the gene cluster with the compound, heterologous 
expression of putative phosphonoglycan gene clusters from Glycomyces and Stackebrandtia was 
attempted in S. lividans, which is not known to produce any phosphonates. In both cases, free 2-
HEP, as opposed to HEP-decorated glycans, was produced in S. lividans. However, this is not too 
surprising because gene candidates for O-methylation of galactose were not found in the 
phosphonoglycan gene clusters. Moreover, the molecular apparatus required for polysaccharide 
assembly, export and regulation may be specific only to the native producer. Nevertheless, 
showing that 2-HEP, the expected intermediate in the phosphonoglycan biosynthetic pathway, 
was produced in the heterologous host, still provides evidence to link the gene clusters with the 
biosynthesis of phosphonoglycans.  
Unfortunately, the complexity of these two phosphonoglycans precluded a full structure 
elucidation. We speculate that the structures presented here may be part of novel teichoic acid-
like molecules. If true, teichoic acids with a phosphonate head group would be highly unusual.  
6.1.3 Inducing cryptic phosphonate gene clusters through co-culturing or ribosome 
engineering (Chapter 4) 
To test whether we could turn on silent phosphonate gene clusters by co-culturing them with 
other microorganisms, a subset of 43 pepM
+
 actinomycete isolates (expected to produce similar 
phosphonate compounds based on PepM phylogeny) were chosen to be co-cultured with a panel 
of strains from different phylogenetic groups on solid media. I examined the concentrated co-
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metabolites by 
31
P NMR for induced phosphonate production. Although some co-culture samples 
gave a P signal in the expected phosphonate range of the 
31
P NMR spectra, thorough chemical 
analyses indicated that they were most likely phosphate esters, rather than phosphonates. 
Further, varying the ratios of cells of a pepM
+
 strain and an inducing strain plated for co-culturing 
did not affect phosphonate production.  
To investigate whether introducing streptomycin or rifampicin-resistance could induce 
phosphonate production, I analyzed 50 spontaneous mutants arising from ISP2 plates 
supplemented with various concentrations of streptomycin or rifampicin. Culturing those mutants 
on ISP4 plates resulted in production of a P peak in the expected phosphonate range of the 
31
P 
NMR spectra for only two samples. Again, further chemical analyses indicated that they were 
likely to be phosphate esters.  
6.1.4 Testing C. glutamicum as a heterologous host for phosphonate production (Chapter 
5) 
The goal of this project was to develop a platform for heterologous expression of 
phosphonates in C. glutamicum. To this end, I modified an E. coli-C. glutamicum shuttle vector 
(courtesy of Dr. Kou-San Ju) so that it could be used for pathway reconstruction using the Golden 
Gate assembly. In the initial test, I decided to focus on 2-HEP, the simplest phosphonate 
molecule. Genes required for the biosynthesis of 2-HEP, namely, pepM, ppd and adh, which were 
selected from the biosynthetic locus of HEP-containing phosphonoglycans of Glycomyces 
(Chapter 3), were codon-optimized to the codon usage of predicted highly expressed genes of C. 
glutamicum. The HEP biosynthetic construct was designed in such a way that each gene was 
flanked by a different set of promoters and terminators. Two constructs were designed, one with 
synthetic promoters and the other with natural promoters. The latter design also incorporated an 
N-terminal epitope tag to each gene to facilitate detection of protein expression. Gene fragments 
for two constructs were synthesized by Biomatik (Wilmington, Delaware). Only the C. glutamicum 
wildtype strains transformed with the construct containing natural promoters could produce 2-
HEP. However, the result was not readily reproducible, probably due to plasmid instability and low 
protein yields.  
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6.2 Possible Future Work 
6.2.1 Activating cryptic phosphonate biosynthetic pathways by selecting for multidrug 
resistant mutants 
A logical extension of the study presented in Chapter 4 would be to select for spontaneous 
mutants which are resistant to several different antibiotics and then assay those mutants for 
phosphonate production. Rifampicin- or streptomycin-resistant mutants generated in Chapter 4 
could be used as starter strains for subsequent rounds of selection. The following antibiotics, all 
of which target ribosomal components could be employed, including paromomycin, geneticin, 
fusidic acid, thiostrepton and lincomycin (11). Detailed protocols for generating multiple drug-
resistant mutants of Streptomyces have been described by the Ochi research group (10). Unlike 
actinorhodin (blue color) or undecylprodigiosin (red color), enhanced production of which could be 
measured by colorimetric assays, a simple method is lacking to tell which mutant produces 
phosphonates and which does not directly from a culture plate. Therefore, it is important to 
screen many mutants after each round of selection. If possible, mutations should be mapped by 
DNA sequencing. Some types of mutations occur in much higher frequencies than others in 
antibiotic-overproducing strains (6). For example, K88E or K88R single point mutation in the rpsL 
gene, which encodes ribosomal protein S12, has been frequently found to be associated with 
overproduction of actinorhodin and other antibiotics by enhancing protein biosynthesis during late 
growth phase (5, 8). It would be desirable to prioritize similar mutants for selection with additional 
antibiotics.  
6.2.2 Activating cryptic phosphonate biosynthetic pathways by chemical elicitation 
Many chemical additives, including oligosaccharides, enzyme inhibitors, solvents and heavy 
metals, when supplemented to the culture media, have been shown to elicit the production of 
bioactive secondary metabolites (7, 9). Although in many cases the precise mechanism for 
induction is not clear, effects are dramatic. For example, addition of ethanol could elicit the 
synthesis of pestalone, a new antibiotic by the marine fungus Pestalotia (1) and increase 
synthesis of antibiotic jadomycin B in S. venezuelae (2) and carotenoid in Phaffia rhodozyma (4). 
Likewise, the presence of sodium butyrate, an enzyme inhibitor for histone deacetylase, 
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enhanced actinorhodin production in S. coelicolor A(3)2 and induced the antifungal activity of a 
Streptomyces isolate against the human pathogen Candida albicans (7). Due to their inexpensive 
nature and ease of use, testing these chemicals in eliciting phosphonate production is more 
feasible and less labor intensive than varying cultivation parameters or co-culturing.   
6.2.3 Construction of phosphonate high-producing C. glutamicum strains  
C. glutamicum, as a result of its fast-growing rate, metabolic versatility and well-developed 
genetic tools, in my opinion, is an ideal choice for heterologous expression of phosphonates. 
Unfortunately, C. glutamicum transformed with the synthetic 2-HEP pathway (as described in 
Chapter 5) failed to reproducibly produce 2-HEP. The E. coli-C. glutamicum shuttle vector 
pXY002 employed in the study is a derivative of plasmid pEP2. Plasmid pEP2 has been reported 
to have a much lower copy number in corynebacteria than in E. coli (12), consistent with my 
findings that the copy number of pXY002 is about 10 times less in C. glutamicum than in E. coli. 
This may potentially affect enzyme concentrations and hence 2-HEP yield. Further, as mentioned 
previously, pXY002 is not stably maintained within the cells of C. glutamicum. The next plan is to 
find an alternative E. coli-C. glutamicum shuttle vector, which may have medium to high copy 
numbers (e.g. pJC1, pSRK21 or pEBM2) (3) and assemble it with our existing 2-HEP constructs 
to examine whether the 2-HEP pathway could be reconstituted in C. glutamicum. If it works, 
strategies such as varying culture media components and gene knock-outs to increase the supply 
of precursors for phosphonate biosynthesis, will be utilized to increase the yield of 2-HEP. Since 
2-HEP is a common intermediate in many phosphonate pathways, successful reconstitution of 
the 2-HEP pathway in C. glutamicum will contribute to engineer C. glutamicum to produce other 
valuable phosphonate compounds.  
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